Document:

exv10w1

Exhibit 10.1

AMENDMENT NO. 5 TO

AMENDED AND RESTATED CREDIT AGREEMENT

     THIS AMENDMENT NO. 5 TO AMENDED AND RESTATED CREDIT AGREEMENT, dated as of December 22, 2009,
amends and supplements the Amended and Restated Credit Agreement dated as of June 9, 2008, as
amended (as so amended, the “Credit Agreement”) among ANCHOR BANCORP WISCONSIN INC., a Wisconsin
corporation (the “Borrower”), the financial institutions from time to time party thereto
(individually a “Lender” and collectively the “Lenders”) and U.S. BANK NATIONAL ASSOCIATION, a
national banking association, as administrative agent for the Lenders (in such capacity, the
“Agent”).

RECITALS

     The parties acknowledge the following (capitalized terms used in this Amendment No. 5 and not
defined herein have the meanings ascribed thereto in the Credit Agreement):

     A. The Borrower is indebted to the Agent and the Lenders under the Credit Agreement. As of
the date of this Amendment No. 5, the aggregate outstanding principal amount of such indebtedness
is $116,300,000.

     B. To secure the indebtedness and obligations of the Borrower to the Agent and the Lenders,
the Borrower granted to the Agent a security interest in (i) all of the issued and outstanding
stock of AnchorBank, fsb (the “Subsidiary Bank”) pursuant to the Pledge Agreement dated as of
June 9, 2008 (the “Bank Pledge Agreement”) from the Borrower to the Agent and (ii) all of the
issued and outstanding stock of Investment Directions, Inc. pursuant to the Pledge Agreement dated
as of May 29, 2009 from the Borrower to the Agent (the “IDI Pledge Agreement” and together with the
Bank Pledge Agreement, the “Pledge Agreements”).

     C. Events of Default have occurred and are continuing under the Credit Agreement by reason of
the Borrower failing to make a principal payment on the Notes required by the scheduled reduction
in the Total Revolving Loan Commitment on March 2, 2009 (“Principal Reduction Failure”); failing to
comply with the covenants set forth in Sections 4.15(a), 4.15(b) and 4.15(c) of the Credit
Agreement; and failure to provide reports required by Section 4.11(n) of the Credit Agreement
(collectively “Existing Defaults”).

     D. The Borrower has requested that the Agent and the Lenders forbear from exercising their
rights and remedies under the Credit Agreement and the Pledge Agreements arising from the Existing
Defaults. On the terms and subject

 

 

to the conditions set forth below, the Agent and the Lenders
are prepared to forbear from exercising such rights and remedies for a limited period of time as
set forth below.

AGREEMENTS

     In consideration of the promises and agreements set forth in the Credit Agreement, as amended
and supplemented hereby, the Borrower and the Lenders agree as follows:

     1. References to Credit Agreement. Upon the execution and delivery of this Amendment
No. 5 to Amended and Restated Credit Agreement (“Amendment No. 5”) by the Borrower, the Lenders and
the Agent and the satisfaction of the conditions listed in Section 5 below, each reference to the
Credit Agreement contained in the Credit Agreement, the Pledge Agreements and any other document,
instrument or agreement relating thereto means the Credit Agreement as amended by this Amendment
No. 5. This Amendment No. 5 is a Loan Document.

     2. Acknowledgements by the Borrower. The Borrower acknowledges, represents and agrees
that:

          (a) The Recitals are true and correct.

          (b) Neither any of the Existing Defaults nor any other Event of Default which has occurred and is
continuing has been waived by the Lenders.

          (c) The Borrower has disclosed to the Agent and the Lenders each Event of Default existing on the
date of this Amendment No. 5.

          (d) As a result of the Existing Defaults, the Majority Lenders would be entitled to direct the
Agent to accelerate the maturity of the Notes and demand immediate payment.

          (e) As a result of the Existing Defaults, the Lenders have no obligation to make or continue Loans
to the Borrower.

          (f) To the extent required by the Loan Documents and applicable law, the Borrower has received
adequate and proper notice of the Principal Reduction Failure and the other Existing Defaults and
the Borrower hereby waives its right, if any, to any further notice thereof.

          (g) Neither this Amendment No. 5 nor any course of dealing between or among any of the parties
hereto is intended to operate, nor shall they be construed, as a waiver of any of the Existing
Defaults or any other Event of 

2

 

Default, whether now existing or arising in the future, as to which
the Agent and the Lenders reserve all of their rights.

          (h) Except as expressly provided to the contrary herein, (i) all of the Agent’s and the Lenders’
rights and remedies available under the Loan Documents and at law and in equity remain unchanged
and available without restriction; (ii) the terms of the Loan Documents remain unchanged and in
full force and effect and have not been amended, modified, or changed other than pursuant to a
writing signed by the Agent, each Lender and the Borrower; and (iii) the obligations and duties of
the Borrower to the Agent and the Lenders are not released, impaired, diminished, or amended as a
result of the execution and delivery of this Amendment No. 5 or by any subsequent undertakings of
the parties.

          (i) The principal of and accrued interest on the Notes, all fees and all other obligations and
liabilities of the Borrower to the Agent and the Lenders under the Loan Documents are due and owing
without offsets, deductions, counterclaims, or defenses of any kind or character whatsoever.

          (j) The security interests of the Agent in the outstanding stock of each of the Subsidiary Bank
and Investment Directions, Inc. and in all of the personal property of Investment Directions, Inc.
constitute valid, enforceable and perfected security interests as to which neither the Borrower,
the Subsidiary Bank nor Investment Directions, Inc. has any offsets, deductions, counterclaims, or
defenses of any kind or character whatsoever.

          (k) The Loan Documents are valid, binding and enforceable against the Borrower in accordance with
their respective terms, and the Borrower hereby ratifies and reaffirms its obligations under each
of the Loan Documents.

          (l) The Agent and each Lender have: (i) fully and timely performed all of their respective
obligations and duties to the Borrower under the Loan Documents; (ii) no obligation to (nor has the
Agent or any Lender made any representation of any kind that it will) extend any financial
accommodations to the Borrower; (iii) not made any agreements, representations, or commitments,
other than those expressly set forth in the Loan Documents; and (iv) acted reasonably, in good
faith, and appropriately under the circumstances, and within the Agent’s and each Lender’s rights
under the Loan Documents and applicable law, in all actions taken by the Agent and each Lender with
respect to the Borrower.

          (m) The purpose of this Amendment No. 5 is to provide the Borrower an additional period of time to
obtain funds to pay in full all of the Obligations of the Borrower to the Agent and the Lenders.

3

 

          (n) The forbearance by the Agent and the Lenders provided herein was requested by the Borrower and
shall result in a direct and substantial benefit to the Borrower.

     3. Forbearance by the Agent and the Lenders.

          (a) The Agent and the Lenders agree to forbear from exercising their rights and remedies available
to them against the Borrower as a result of the Principal Reduction Failure and the other Existing
Defaults until the earliest to occur of the following: (i) the occurrence of any Event of Default
(other than the Principal Reduction Failure or other Existing Defaults), or (ii) the Maturity Date.
The period of time from the date hereof until the earlier to occur of (i) or (ii) above is
referred to as the “Forbearance Period.” The Forbearance Period shall terminate immediately and
automatically, as provided above, without notice to or action by any party.

          (b) Upon the termination of the Forbearance Period, any obligation of the Agent or the Lenders to
forbear from the exercise of its rights and remedies as provided in Section 3(a) shall terminate
automatically and immediately without notice or further action and the Agent and the Lenders shall
be free to exercise immediately against the Borrower any and all of their rights and remedies,
including, without limitation, any rights and remedies under the Loan Documents or applicable law,
or in equity.

          (c) Notwithstanding the agreement to forbear as set forth herein, the Agent may at any time, in
its sole discretion, take any action reasonably necessary to preserve or protect its interest in
the stock of the Subsidiary Bank, Investment Directions, Inc. or any other collateral securing any
of the Obligations against the actions of the Borrower or any third party (including any
executions, levies, injunctions, conversion, theft, commingling, waste, misuse, neglect,
misappropriation, fraud, or any of the like) without notice to or the consent of any party.

          (d) The Agent and the Lenders have no obligation to, have not agreed to, nor have they made any
representation that they will, and this Amendment No. 5 shall not constitute an agreement by or
require the Agent or the Lenders to, renew or extend the Forbearance Period, grant additional
forbearance periods, forbear from exercising remedies as a result of any other Event of Default,
extend the time for payment or make any Loans or otherwise extend credit to the Borrower.

4

 

     4. Amendments to Credit Agreement.

          (a) The following defined terms shall be added to the Credit Agreement in appropriate alphabetical
order:

“Badger
Transaction Documents” means that certain Stock Purchase Agreement
by and between Badger Anchor Holdings, LLC and the Borrower dated as of December 1,
2009 and that certain Loan Agreement by and between Badger Anchor Holdings, LLC and
the Borrower dated as of December 1, 2009.

“Tier
1 Leverage Ratio” means the “leverage ratio” as defined in, and
calculated in accordance with, 12 C.F.R. Part 567.

“Total
Risk Based Capital Ratio” means the “total risk-based capital ratio”
as defined in, and calculated in accordance with, 12 C.F.R. Part 567.

          (b) The
defined term “Base Rate” is amended in its entirety as follows:

“Base
Rate” means, (i) on the date hereof and at all times up to and
including December 31, 2009, a fixed rate of 8.0% per annum, and (ii) at all times
thereafter, a floating rate per annum equal to the prime rate announced by the
Agent from time to time, and the Base Rate shall change on each day on which such
prime rate changes.

     (c) The
defined term “Deferred Interest Rate” is amended in its entirety as follows:

“Deferred
Interest Rate” means (i) on the date hereof and at all times up
to and including December 31, 2009, a fixed rate of 4.0% per annum and (ii) at all
times thereafter, the difference at any time between 12.0% per annum and the Base
Rate.

     (d) The
defined term “Gross Loans” is amended in its entirety as follows:

“Gross
Loans” means, at any time, the aggregate principal amount of the
total gross loans of the Subsidiary Bank determined on a basis consistent with the
Federal Reserve System Thrift Financial Report (TFR) of the Consolidated Financial
Statements for Bank Holding Companies most recently filed by the Borrower with the
appropriate governmental authority.

5

 

          (e) Section 2.3(a) of the Credit Agreement is amended in its entirety to read as follows:

(a) Interest Rate. The entire unpaid principal balance of the Loans
outstanding from time to time shall bear interest at a rate equal to the Base Rate
plus the Deferred Interest Rate. The Agent’s internal records of applicable
interest rates shall be determinative in the absence of manifest error.

          (f) Section 2.3(b) of the Credit Agreement is amended in its entirety to read as follows:

(b) Interest Payments. Interest accruing on the Loans at the Base Rate is
due on the last day of each month and on the Maturity Date. Interest accruing on
the Loans at the Deferred Interest Rate is due on the earlier to occur of (i) the
date the Loans are paid in full or (ii) the Maturity Date.

          (g) Section 4.11(e) of the Credit Agreement is amended in its entirety to read as follows:

(e) Promptly, and in any event within two Business Days, after the Borrower has
knowledge thereof, a statement of the chief financial officer of the Borrower
describing: (i) any event which, either of itself or with the lapse of time or the
giving of notice or both, would constitute a Default hereunder or a default or
event of default under any other material agreement to which the Borrower or any
Subsidiary is a party, including but not limited to the Badger Transaction
Documents, together with a statement of the actions which the Borrower proposes to
take with respect thereto; and (ii) any pending or threatened litigation or
administrative proceeding of the type described in Section 4.3;

          (h) Section 4.11(n) of the Credit Agreement is amended in its entirety to read as follows:

(n) Within 15 days after the end of each calendar month, a certificate in the form
of Exhibit B attached hereto, duly executed by the President or Vice President of
the Borrower, indicating whether the Borrower is in compliance with the covenants
set forth in Section 4.15.

(i) Section 4.15 is amended in its entirety to read as follows:

6

 

          4.15. Financial Covenants.

          (a) The Subsidiary Bank shall maintain a Tier 1 Leverage Ratio of not less
than (i) 4.00% at all times during the period ending February 28, 2010 and
(ii) 4.25% at all times thereafter.

          (b) The Subsidiary Bank shall maintain a Total Risk Based Capital ratio of not
less than (i) 7.25% at all times during the period ending February 28, 2010 and
(ii) 7.50% at all times thereafter.

          (c) The ratio of Non-Performing Loans to Gross Loans shall not exceed
(i) 13.75% at all times during the period ending January 31, 2010 and (ii) 14.50% at
all times thereafter.

          (j) Section 4.20 of the Credit Agreement is amended in its entirety to read as follows:

4.20 Escrow Deposits. On the date hereof, the Borrower shall deposit an
amount equal to $1,240,000 into the escrow account (the “Escrow Account”) at the
Agent established pursuant to that certain Escrow Agreement between the Agent and
the Borrower dated as of March 31, 2009. In the event that the Base Rate increases
after January 1, 2010 and results in the amount on deposit in the Escrow Account
being less than the interest which will accrue on the Notes through April 30, 2010,
then the Borrower shall deposit the amount of such deficiency into the Escrow
Account within two Business Days after the date of such change in the Base Rate.
In addition, on or before April 15, 2010, the Borrower shall deposit into the
Escrow Account an amount equal to the greater of (i) $315,000 or (ii) the amount
necessary to pay the interest payment due on May 31, 2010 at the Base Rate. In the
event that the Base Rate increases after April 15, 2010 and results in the amount
on deposit in the Escrow Account being less than the interest which will accrue on
the Notes through May 31, 2010, then the Borrower shall deposit the amount of such
deficiency into the Escrow Account within two Business Days after the date of such
change in the Base Rate.

          (k) Section 4.26 of the Credit Agreement is amended in its entirety as follows:

4.26 Agent’s and Lenders’ Access. The Borrower shall permit any
representatives, agents, accountants, valuation professionals,

7

 

attorneys of the
Agent or any Lender or any person engaged by any of the foregoing (each a
“Representative”) access to the Borrower’s and each Subsidiary’s places of
business, books, records, documents, officers, directors, managers, employees and
any collateral securing any of the Obligations, including, without limitation, the
stock transfer records of the Subsidiary Bank, for the purpose of inspecting,
examining, verifying, appraising or valuing the same or providing an enterprise
valuation or appraisal for Borrower or any one or more of its Subsidiaries or
exercising any of the Agent’s or any Lender’s rights or remedies under any of the
Loan Documents (each, an “Inspection/Valuation”). The Representatives shall have
such access for an Inspection/Valuation at any reasonable time and as often as the
Agent or any Lender may reasonably desire, and, upon demand by the Agent, the
Borrower shall reimburse the Agent or any Lender, as the case may be, for the cost
of any such Inspection/Valuation. The Borrower acknowledges that the Agent and the
Lenders shall have no obligation whatsoever to disclose the results of any such
Inspection/Valuation to Borrower or any Affiliate of Borrower.

          (1) A new Section 6.1(i) is added to the Credit Agreement as follows:

(i) Termination or Default Under Badger Transaction Documents. There is a
termination of either or both of the Badger Transaction Documents, or a default or
event of default occurs under any of the Badger Transaction Documents or any
related document, instrument or agreement, whether or not such default or event of
default is subsequently cured.

          (m) Exhibit B to the Credit Agreement is hereby deleted and replaced in its entirety with
Exhibit B attached hereto.

     5. Closing Conditions. This Amendment No. 5 shall become effective upon the execution
and delivery of this Amendment No. 5 by the Borrower, the Lenders and the Agent, and the following:

          (a) the receipt by the Agent of copies, certified to be accurate and complete by the Secretary or
Assistant Secretary of the Borrower, of a resolution of the Board of Directors of the Borrower
authorizing the execution and delivery of this Amendment No. 5;

          (b) the receipt by the Agent of a certificate of the President or Vice President of the Borrower
to the effect that the representations and warranties

8

 

of the Borrower set forth in the Credit
Agreement and the other Loan Documents are accurate and complete in all material respects and that
no Default or Event of Default exists other than those as disclosed to the Lenders; and

          (c) the receipt by the Agent of such other documents and instruments relating hereto as the Agent
shall reasonably request.

     6. Amendment Fee. Borrower shall pay to the Agent, for the ratable account of the
Lenders, an amendment fee of $1,163,000 (as such amount may be reduced pursuant to the last
sentence of this Section, the “Amendment Fee”). The Amendment Fee shall be fully earned by the
Lenders upon execution of this Amendment No. 5 and shall be due and payable on the earlier to occur
of (i) the date on which the Loans are paid in full or (ii) the Maturity Date. The Amendment Fee
shall be in addition to any other amendment fee or other fee payable pursuant to any other
agreement or other Loan Document. Notwithstanding the foregoing, in the event the transactions
contemplated by the Badger Transaction Documents close prior to the Maturity Date, the Amendment
Fee shall be reduced by an amount equal to the number of days between the day after such closing
and December 31, 2010 divided by 365, multiplied by the Amendment Fee.

     7. Representations and Warranties; No Default.

          (a) The execution and delivery of this Amendment No. 5 has been duly authorized by all necessary
corporate action on the part of the Borrower and does not violate or result in a default under the
Borrower’s Articles of Incorporation or By-Laws, any applicable law or governmental regulation or
any material agreement to which the Borrower is a party or by which it is bound.

          (b) The representations and warranties of the Borrower in the Credit Agreement and the other Loan
Documents are true and correct in all material respects and, except for the Existing Defaults, no
Default or Event of Default exists.

     8. Waiver, Release of Claims, and Indemnification. The Borrower, for itself and each and
all of its officers, employees, agents, shareholders, members, directors, heirs, successors, and
assigns, does hereby fully, unconditionally, and irrevocably waive and release the Agent and the
Lenders and their respective officers, employees, agents, directors, shareholders, affiliates,
attorneys, successors, and assigns (each a “Released Party”), of and from any and all claims,
liabilities, obligations, causes of action, defenses, counterclaims, and setoffs, of any kind,
whether known or unknown and whether in contract, tort, statute, or under any other legal theory,
arising out of or relating to any act or omission by the Agent, any

9

 

Lender or any other Released
Party, on or before the date of this Amendment No. 5. The Borrower agrees to defend, indemnify,
and hold the Agent, each Lender and each other Released Party harmless from and against any and all
losses, costs, expenses, damages, or liabilities (including reasonable attorneys’ fees) incurred in
connection with any demand, claim, counterclaim, cause of action, or proceeding brought as a result
of, or arising out of, or in any way related to any of the Loan Documents, this Amendment No. 5,
any documents executed in connection with or related to any of the Loan Documents, the performance
by the Agent and each Lender under any of the Loan Documents or any documents executed in
connection with or related to this Amendment No. 5 or any of the other Loan Documents, or any
transaction financed or to be financed, in whole or in part, directly or indirectly, with the
proceeds of any Loans. Notwithstanding the foregoing, the Borrower shall not have any obligation
to defend, indemnify, or hold the Agent, any Lender or any other Released Party harmless with
respect to any loss, cost, expense, damage, or liability resulting solely from willful misconduct
on the part of the Agent, such Lender or such other Released Party.

     9. Governing Law. This Amendment No. 5 shall be governed by and construed in accordance
with the internal laws (without regard to the conflict of law provisions) of the State of
Wisconsin.

     10. Costs and Expenses. The Borrower agrees to pay to the Agent and each Lender all costs
and expenses (including reasonable attorneys’ fees) paid or incurred by the Agent or such Lender in
connection with the negotiation, execution and delivery of this Amendment No. 5.

     11. Full Force and Effect. The Credit Agreement, as amended by this Amendment No. 5,
remains in full force and effect.

     12. Relief from the Automatic Stay. As a material inducement to the Agent and the Lenders
to enter into this Amendment No. 5, the Borrower hereby stipulates and agrees that the Agent and
the Lenders shall be entitled to relief from the automatic stay imposed by 11 U.S.C. § 362 or any
similar stay or suspension of remedies under any other federal or state law in the event the
Borrower becomes subject to a bankruptcy or other insolvency proceeding, to allow the Agent and the
Lenders to exercise their rights and remedies under the Pledge Agreements.

     13. Counterparts. This Amendment No. 5 may be executed in any number of counterparts and
by different parties hereto in separate counterparts, each of which when so executed and delivered
shall be deemed an original, but all such counterparts together shall constitute but one and the
same instrument; signature pages may be detached from multiple separate counterparts and attached

10

 

to a single counterpart so that all signature pages are physically attached to the same document.

Signature Page Follows

11

 

     IN WITNESS WHEREOF, the undersigned have executed this Amendment No. 5 as of the date
first set forth above.

	 	 	 	 	 	 	 	 	 
	 	 	ANCHOR BANCORP WISCONSIN INC.
	 
	 	 	 	 	 	 	 	 
	 

	 	BY	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 

	 	 	 	Its	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	U.S. BANK NATIONAL
ASSOCIATION,
as the Agent and a Lender
	 
	 	 	 	 	 	 	 	 
	 

	 	BY	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 

	 	 	 	Its	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	ASSOCIATED BANK, NATIONAL
ASSOCIATION
	 
	 	 	 	 	 	 	 	 
	 

	 	BY	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 

	 	 	 	Its	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	BANK OF AMERICA, N.A.
	 
	 	 	 	 	 	 	 	 
	 

	 	BY	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 

	 	 	 	Its	 	 	 	 
	 

	 	 	 	 	 	 	 	 

Acknowledged and agreed:

INVESTMENT DIRECTIONS, INC.

	 	 	 	 	 
	BY
	 	 	 	 
	 	 	 
	 

	 	Its	 	 
	 

	 	 	 	 

Signature Page to Amendment No. 5

 

 

EXHIBIT B

FORM OF FINANCIAL COVENANT COMPLIANCE CERTIFICATE

U.S. Bank National Association

Special Assets Group

777 East Wisconsin Avenue

MK-WI-J5N

Milwaukee, Wisconsin 53202

Attn: Joseph Svehla, Vice President

Dear Mr. Svehla:

     Reference is made to that certain Amended and Restated Credit Agreement, dated as of June 9,
2008, as amended to date (as so amended, the “Credit Agreement”), by and between Anchor Bancorp
Wisconsin Inc. (the “Borrower”), the financial institutions from time to time party thereto (the
“Lenders”) and U.S. Bank National Association, as administrative agent for the Lenders (“Agent”).
Unless otherwise defined herein, capitalized terms used herein have the respective meanings
assigned to them in the Credit Agreement and section references herein are to the sections of the
Credit Agreement.

     This Certificate is provided pursuant to Section 4.11(n) of the Credit Agreement.

     The undersigned hereby certifies that:

     1. (He) (She) is the [President] [Vice President] of the Borrower.

     2. Financial Covenants:

          (a) Through                                         , 20___, the Subsidiary Bank has at all times maintained a Tier 1 Leverage
Ratio of ___. (Required by Section 4.15(a) of the Credit Agreement.)

          (b) Through                                         , 20___, the Subsidiary Bank has at all times maintained a Total Risk
Based Capital Ratio of ___(Required by Section 4.15(b) of the Credit Agreement.)

          (c) As of                                         , 20___, the ratio of Non-Performing Loans to Gross Loans is ___%.
(Required by Section 4.15(c) of the Credit Agreement).

 

 

     3. Attached hereto are detailed calculations supporting the statements made in Sections 2(a)
through 2(c) above. Such calculations were made in accordance with the applicable definitions in
the Credit Agreement and the statements made in 2(a) through 2(c) above are true and correct.

     Dated:                                                             , 20  
                  .

                                                            

                    , [President] [Vice President]exv4w2

Exhibit 4.2

EXECUTION COPY

RULES-BASED MEDICINE, INC.

INVESTORS’ RIGHTS AGREEMENT

October 12, 2007

 

 

TABLE OF CONTENTS

	 	 	 	 	 
	 	 	Page	 
	1. Definitions
	 	 	1	 
	 
	2. Registration Rights
	 	 	4	 
	 
	2.1 Demand Registration
	 	 	4	 
	 
	2.2 Company Registration
	 	 	5	 
	 
	2.3 Underwriting Requirements
	 	 	6	 
	 
	2.4 Obligations of the Company
	 	 	7	 
	 
	2.5 Furnish Information
	 	 	9	 
	 
	2.6 Expenses of Registration
	 	 	9	 
	 
	2.7 Delay of Registration
	 	 	9	 
	 
	2.8 Indemnification
	 	 	9	 
	 
	2.9 Reports Under Exchange Act
	 	 	11	 
	 
	2.10 Limitations on Subsequent Registration Rights
	 	 	12	 
	 
	2.11 “Market Stand off” Agreement
	 	 	12	 
	 
	2.12 Termination of Registration Rights
	 	 	13	 
	 
	3. Information and Observer Rights
	 	 	13	 
	 
	3.1 Delivery of Financial Statements
	 	 	13	 
	 
	3.2 Inspection
	 	 	15	 
	 
	3.3 Termination of Information Rights
	 	 	15	 
	 
	 
	4. Rights to Future Stock Issuances
	 	 	15	 
	 
	4.1 Right of First Offer
	 	 	15	 
	 
	4.2 Termination of Covenants
	 	 	17	 
	 
	5. Additional Covenants
	 	 	17	 
	 
	5.1 Insurance
	 	 	17	 
	 
	5.2 Employee Agreements
	 	 	17	 
	 
	5.3 Employee Stock
	 	 	17	 
	 
	5.4 Matters Requiring Board Approval
	 	 	17	 
	 
	5.5 Board Matters
	 	 	19	 
	 
	5.6 Successor Indemnification
	 	 	19	 
	 
	5.7 Termination of Covenants
	 	 	20	 
	 
	6. Voting Provisions
	 	 	20	 

-i-

 

TABLE OF CONTENTS

(continued)

	 	 	 	 	 
	 	 	Page	 
	6.1 Voting Provisions Regarding Board of Directors
	 	 	20	 
	 
	6.2 Vote to Increase Authorized Common Stock
	 	 	21	 
	 
	6.3 Drag Along Rights
	 	 	22	 
	 
	6.4 Remedies
	 	 	24	 
	 
	6.5 Termination of Covenants
	 	 	25	 
	 
	6.6 Additional Shares of Stock
	 	 	25	 
	 
	7. Agreement Among the Company, the Investors and the Common Holders
	 	 	25	 
	 
	7.1 Definitions
	 	 	25	 
	 
	7.2 Right of First Refusal
	 	 	27	 
	 
	7.3 Right of Co-Sale
	 	 	30	 
	 
	7.4 Effect of Failure to Comply
	 	 	32	 
	 
	7.5 Exempt Transfers
	 	 	33	 
	 
	7.6 Agreement to be Bound
	 	 	34	 
	 
	7.7 Stop Transfer Instructions
	 	 	34	 
	 
	7.8 Termination of Covenants
	 	 	34	 
	 
	7.9 Ownership
	 	 	34	 
	 
	8. Exercise of Guarantee for RBM Management Group, L.L.C
	 	 	34	 
	 
	9. Miscellaneous
	 	 	35	 
	 
	9.1 Legends
	 	 	35	 
	 
	9.2 Successors and Assigns
	 	 	35	 
	 
	9.3 Governing Law
	 	 	36	 
	 
	9.4 Counterparts; Facsimile
	 	 	36	 
	 
	9.5 Titles and Subtitles
	 	 	36	 
	 
	9.6 Notices
	 	 	36	 
	 
	9.7 Amendments and Waivers
	 	 	36	 
	 
	9.8 Severability
	 	 	37	 
	 
	9.9 Aggregation of Stock
	 	 	37	 
	 
	9.10 Entire Agreement
	 	 	37	 
	 
	9.11 Dispute Resolution
	 	 	37	 
	 
	9.12 Specific Performance
	 	 	37	 

-ii-

 

TABLE OF CONTENTS

(continued)

	 	 	 	 	 
	 	 	Page	 
	9.13 Delays or Omissions
	 	 	37	 
	 
	9.14 Acknowledgment
	 	 	37	 
	 
	9.15 Additional Parties
	 	 	38	 
	 
	9.16 Stock Split
	 	 	38	 
	 
	9.17 Liquidation Examples
	 	 	38	 

-iii-

 

INVESTORS’ RIGHTS AGREEMENT

     THIS INVESTORS’ RIGHTS AGREEMENT is made as of the 12th day of October, 2007, by and among
Rules-Based Medicine, Inc., a Delaware corporation (the “Company”), each of the investors listed on
Schedule A hereto (each an “Investor” and together the “Investors”), and each of the
holders of Common Stock of the Company listed on Schedule B hereto (each, a “Common
Holder”). The Investors and Common Holders shall collectively be referred to as the
"Stockholders.”

RECITALS

     WHEREAS, the Company and the Investors are parties to the Series A-1 Preferred Stock Purchase
Agreement of even date herewith (the “Purchase Agreement”); and

     WHEREAS, in order to induce the Investors to enter into the Purchase Agreement, the Investors
and the Company hereby agree that this Agreement shall govern the rights of the Investors to, among
other things, cause the Company to register shares of Common Stock issuable to the Investors,
receive certain information from the Company, participate in future equity offerings by the
Company, elect certain members of the board of directors of the Company, have certain rights of
first refusal and co-sale rights with respect to sales and transfers by certain Common Holders, and
shall govern certain other matters as set forth in this Agreement;

     NOW, THEREFORE, the parties hereby agree as follows:

     1. Definitions. For purposes of this Agreement:

          1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or
indirectly, controls, is controlled by, or is under common control with such Person, including
without limitation any general partner, managing member, officer or director of such Person or any
venture capital fund now or hereafter existing that is controlled by one or more general partners
or managing members of, or shares the same management company with, such Person.

          1.2 “Common Stock” means shares of the Company’s common stock, par value $0.001 per share.

          1.3 “Damages” means any loss, damage, or liability (joint or several) to which a party hereto
may become subject under the Securities Act, the Exchange Act, or other federal or state law,
insofar as such loss, damage, or liability (or any action in respect thereof) arises out of or is
based upon (i) any untrue statement or alleged untrue statement of a material fact contained in any
registration statement of the Company, including any preliminary prospectus or final prospectus
contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to
state therein a material fact required to be stated therein, or necessary to make the statements
therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or
any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law,
or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state
securities law.

-1-

 

          1.4 “Derivative Securities” means any securities or rights convertible into, or exercisable or
exchangeable for (in each case, directly or indirectly), Common Stock, including options and
warrants.

          1.5 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder.

          1.6 “Excluded Registration” means (i) a registration relating to the sale of securities to
employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar
plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form
that does not include substantially the same information as would be required to be included in a
registration statement covering the sale of the Registrable Securities; or (iv) a registration in
which the only Common Stock being registered is Common Stock issuable upon conversion of debt
securities that are also being registered.

          1.7 “Form S-1” means such form under the Securities Act as in effect on the date hereof or any
successor registration form under the Securities Act subsequently adopted by the SEC.

          1.8 “Form S-2” means such form under the Securities Act as in effect on the date hereof or any
successor registration form under the Securities Act subsequently adopted by the SEC.

          1.9 “Form S-3” means such form under the Securities Act as in effect on the date hereof or any
registration form under the Securities Act subsequently adopted by the SEC that permits
incorporation of substantial information by reference to other documents filed by the Company with
the SEC.

          1.10 “GAAP” means generally accepted accounting principles in the United States.

          1.11 “Holder” means any Investor or Common Holder holding Registrable Securities, or any
assignee of record of such Registrable Securities to whom the rights under this Agreement have been
duly assigned in accordance with this Agreement; provided, that for purposes of this
Agreement, a holder of shares of Series A-1 Preferred Stock shall be deemed to be the Holder of the
number of shares of Common Stock issuable upon conversion of such shares of Series A-1 Preferred
Stock; provided, further, that the Common Holders shall not be deemed Holders for
the purposes of Sections 2.1, 2.9 and 2.10. The Company shall not be
obligated to register shares of Series A-1 Preferred Stock, and Holders of Registrable Securities
shall not be required to convert their shares of Series A-1 Preferred Stock into Common Stock in
order to exercise the registration rights granted under this Agreement until immediately before,
and contingent upon, the closing of the offering to which the registration relates.

          1.12 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent,
grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law,
brother-in-law, or sister-in-law, including adoptive relationships, of a natural person referred to
herein.

-2-

 

          1.13 “IPO” means the Company’s first underwritten public offering of its Common Stock under
the Securities Act.

          1.14 “Key Employee” means any executive-level employee (including division director and vice
president-level positions) as well as any employee who, either alone or in concert with others,
develops, invents, programs, or designs any Company Intellectual Property (as defined in the
Purchase Agreement).

          1.15 “New Securities” means, collectively, equity securities of the Company, whether or not
currently authorized, as well as rights, options, or warrants to purchase such equity securities,
or securities of any type whatsoever that are, or may become, convertible or exchangeable into or
exercisable for such equity securities.

          1.16 “Person” means any individual, corporation, partnership, trust, limited liability
company, association or other entity.

          1.17 “Preferred Stock” means shares of the Company’s Series A-1 Preferred Stock.

          1.18 “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of
the Series A-1 Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable
(directly or indirectly) upon conversion and/or exercise of any other securities of the Company,
acquired by the Investors after the date hereof; (iii) the shares of Common Stock held by the
Common Holders set forth on Schedule B-1 attached hereto; provided, that such
shares of Common Stock shall not be deemed Registrable Securities and the Common Holders shall not
be deemed “Holders” for the purposes of Sections 2.1, 2.9 and 2.10 and (iv)
any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or
other security that is issued as) a dividend or other distribution with respect to, or in exchange
for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all
cases, however, any Registrable Securities sold by a Person in a transaction in which the
applicable rights under this Agreement are not assigned pursuant to Section 9.2, and
excluding for purposes of Section 2 any shares for which registration rights have
terminated pursuant to Section 2.12 of this Agreement.

          1.19 “Registrable Securities then outstanding” means the number of shares determined by adding
the number of shares of outstanding Common Stock that are Registrable Securities and the number of
shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or
convertible securities that are Registrable Securities.

          1.20 “SEC” means the Securities and Exchange Commission.

          1.21 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act.

          1.22 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act.

          1.23 “Securities Act” means the Securities Act of 1933, as amended, and the

-3-

 

rules and regulations promulgated thereunder.

          1.24 “Selling Expenses” means all underwriting discounts, selling commissions, and stock
transfer taxes applicable to the sale of Registrable Securities.

          1.25 “Series A-1 Director” means any director of the Company that the holders of record of the
Series A-1 Preferred Stock are entitled to elect pursuant to the Company’s Certificate of
Incorporation.

          1.26 “Series A-1 Preferred Stock” means shares of the Company’s Series A-1 Preferred Stock,
par value $0.001 per share.

     2. Registration Rights. The Company covenants and agrees as follows:

          2.1 Demand Registration.

               (a) Form S-1 Demand. If at any time after the earlier of (i) January 1, 2012 or (ii)
one hundred eighty (180) days after the effective date of the registration statement for the IPO,
the Company receives a request from Investors (the “Initiating Investors”) holding more than fifty
percent (50%) of the then-outstanding shares of Series A-1 Preferred Stock (a “Majority in
Interest”) that the Company file a Form S-1 registration statement with respect to at least thirty
percent (30%) of the Registrable Securities then outstanding (or a lesser percent if the
anticipated aggregate offering price, net of Selling Expenses, would exceed $15 million), then the
Company shall (i) within ten (10) days after the date such request is given, give notice thereof
(the “Demand Notice”) to all Investors other than the Initiating Investors, and (ii) as soon as
practicable, and in any event within sixty (60) days after the date such request is given by the
Initiating Investors, file a Form S-1 registration statement under the Securities Act covering all
Registrable Securities that the Initiating Investors requested to be registered and any additional
Registrable Securities requested to be included in such registration by any other Investors, as
specified by notice given by each such Investor to the Company within twenty (20) days of the date
of the Demand Notice is given, and in each case, subject to the limitations of
Section 2.1(c) and Section 2.3.

               (b) Form S-3 Demand. If at any time when it is eligible to use a Form S-3
registration statement, the Company receives a request from Initiating Investors representing a
Majority in Interest that the Company file a Form S-3 registration statement with respect to
outstanding Registrable Securities of such Investors having an anticipated aggregate offering
price, net of Selling Expenses, of at least $3 million, then the Company shall within ten (10) days
after the date such request is given, give a Demand Notice to all Investors other than the
Initiating Investors, and (ii) as soon as practicable, and in any event within forty-five (45) days
after the date such request is given by the Initiating Investors, file a Form S-3 registration
statement under the Securities Act covering all Registrable Securities requested to be included in
such registration by any other Investors, as specified by written notice given by each such
Investor to the Company within twenty (20) days of the date of the Demand Notice is given, and in
each case, subject to the limitations of Section 2.1(c) and Section 2.3.

               (c) Notwithstanding the foregoing obligations, if the Company furnishes to the Initiating
Investors a certificate signed by the Company’s chief executive officer

-4-

 

stating that in the good faith judgment of the Company’s Board of Directors it would be
materially detrimental to the Company and its stockholders for such registration statement to
either become effective or remain effective for as long as such registration statement otherwise
would be required to remain effective, because such action would (i) materially interfere with a
significant acquisition, corporate reorganization, or other similar transaction involving the
Company; (ii) require premature disclosure of material information that the Company has a bona fide
business purpose for preserving as confidential; or (iii) render the Company unable to comply with
requirements under the Securities Act or Exchange Act, then the Company shall have the right to
defer taking action with respect to such filing for a period of not more than seventy five (75)
days after the request of the Initiating Investors is given; provided, however,
that the Company may not invoke this right more than once in any twelve (12) month period; and
provided further that the Company shall not register any securities for its own
account or that of any other stockholder during such seventy five (75) day period other than
pursuant to a registration relating to the sale of securities to employees of the Company or a
subsidiary pursuant to a stock option, stock purchase, or similar plan; a registration on any form
that does not include substantially the same information as would be required to be included in a
registration statement covering the sale of the Registrable Securities; or a registration in which
the only Common Stock being registered is Common Stock issuable upon conversion of debt securities
that are also being registered.

               (d) The Company shall not be obligated to effect, or to take any action to effect, any
registration pursuant to Section 2.1(a) (i) during the period that is sixty (60) days
before the Company’s good faith estimate of the date of filing of, and ending on a date that is one
hundred eighty (180) days after the effective date of, a Company-initiated registration, provided,
that the Company is actively employing in good faith commercially reasonable efforts to cause such
registration statement to become effective; (ii) after the Company has effected two registrations
pursuant to Section 2.1(a); or (iii) if the Initiating Investors propose to dispose of
shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a
request made pursuant to Section 2.1(b). The Company shall not be obligated to effect, or
to take any action to effect, any registration pursuant to Section 2.1(b) (i) during the
period that is thirty (30) days before the Company’s good faith estimate of the date of filing of,
and ending on a date that is ninety (90) days after the effective date of, a Company-initiated
registration, provided, that the Company is actively employing in good faith commercially
reasonable efforts to cause such registration statement to become effective; or (ii) if the Company
has effected two registrations pursuant to Section 2.1(b) within the twelve (12) month
period immediately preceding the date of such request. A registration shall not be counted as
“effected” for purposes of this Section 2.1(d) until such time as the applicable
registration statement has been declared effective by the SEC, unless the Initiating Investors
withdraw their request for such registration, elect not to pay the registration expenses therefor,
and forfeit their right to one demand registration statement pursuant to Section 2.6, in
which case such withdrawn registration statement shall be counted as “effected” for purposes of
this Section 2.1(d).

               2.2 Company Registration. If the Company proposes to register (including, for this
purpose, a registration effected by the Company for stockholders other than the Investors, to the
extent permissible) any of its securities under the Securities Act in connection with the public
offering of such securities solely for cash (other than in an Excluded Registration), the Company
shall, at such time, promptly give each Holder notice of such registration. Upon the

-5-

 

request of each Holder given within twenty (20) days after such notice is given by the
Company, the Company shall, subject to the provisions of Section 2.3, cause to be
registered all of the Registrable Securities that each such Holder has requested to be included in
such registration. The Company shall have the right to terminate or withdraw any registration
initiated by it under this Section 2.2 before the effective date of such registration,
whether or not any Holder has elected to include Registrable Securities in such registration. The
expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company
in accordance with Section 2.6.

          2.3 Underwriting Requirements.

               (a) If, pursuant to Section 2.1, the Initiating Investors intend to distribute the
Registrable Securities covered by its request by means of an underwriting, they shall so advise the
Company as a part of their request made pursuant to Section 2.1, and the Company shall
include such information in the Demand Notice. The underwriter(s) will be selected by the
Initiating Investors, subject only to the approval of the Company (which shall not be unreasonably
withheld or delayed). In such event, the right of any Investor to include such Investor’s
Registrable Securities in such registration shall be conditioned upon such Investor’s participation
in such underwriting and the inclusion of such Investor’s Registrable Securities in the
underwriting. Each Investor, to the extent it proposes to distribute its securities through such
underwriting shall (together with the Company as provided in Section 2.4(e)) enter into an
underwriting agreement in customary form with the underwriter(s) selected for such underwriting.
Notwithstanding any other provision of this Section 2.3, if the managing underwriter(s)
advise(s) the Initiating Investors in writing that marketing factors require a limitation on the
number of shares to be underwritten, then the number of Registrable Securities that may be included
in the underwriting shall be allocated among all participating Investors in proportion (as nearly
as practicable) to the number of Registrable Securities owned by each Investor, or in such other
proportion as shall be mutually agreed by all such participating Investors; provided,
however, that the number of Registrable Securities held by the Investors to be included in such
underwriting shall not be reduced unless all other securities are first entirely excluded from the
underwriting.

               (b) In connection with any offering involving an underwriting of shares of the Company’s
capital stock pursuant to Section 2.2, the Company shall not be required to include any of
a Holder’s Registrable Securities in such underwriting unless such Holder accepts the terms of the
underwriting as agreed upon between the Company and its underwriters, and then only in such
quantity as the underwriters in their sole discretion determine will not jeopardize the success of
the offering by the Company. If the total number of securities, including Registrable Securities,
requested by stockholders to be included in such offering exceeds the number of securities to be
sold (other than by the Company) that the underwriters in their reasonable discretion determine is
compatible with the success of the offering, then the Company shall be required to include in the
offering only that number of such securities, including Registrable Securities, which the
underwriters and the Company in their sole discretion determine will not jeopardize the success of
the offering. If the underwriters determine that less than all of the Registrable Securities
requested to be registered can be included in such offering, then the Registrable Securities that
are included in such offering shall be allocated first among the Investors in proportion (as nearly
as practicable)to the number of Registrable Securities

-6-

 

owned by each such participating Investor, or in such other proportions as shall be mutually
agreed by all such participating Investors until all Registrable Securities requested to be
included in such offering by the Investors are included in such offering, and second to the Common
Holders pro rata among the Common Holders on the basis of the number of shares of Registrable
Securities requested to be included in such registration by each such Common Holder.
Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included
in the offering be reduced unless all other securities (other than securities to be sold by the
Company) are first entirely excluded from the offering, and (ii) the number of Registrable
Securities included in the offering be reduced below thirty percent (30%) of the total number of
securities included in such offering, unless such offering is the IPO, in which case the selling
Holders may be excluded further if the underwriters make the determination described above and no
other stockholder’s securities are included in such offering. For purposes of the provision in
this Section 2.3(b) concerning apportionment, for any selling Holder that is a partnership,
limited liability company, or corporation, the partners, members, retired partners, retired
members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members
of any such partners, retired partners, members, and retired members and any trusts for the benefit
of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata
reduction with respect to such “selling Holder” shall be based upon the aggregate number of
Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this
sentence.

               (c) For purposes of Section 2.1, a registration shall not be counted as “effected” if,
as a result of an exercise of the underwriter’s cutback provisions in Section 2.3(a), fewer
than seventy five percent (75%) of the total number of Registrable Securities that the Investors
had requested to be included in such registration statement are actually included.

          2.4 Obligations of the Company. Whenever required under this Section 2 to
effect the registration of any Registrable Securities, the Company shall, as expeditiously as
reasonably possible:

               (a) prepare and file with the SEC a registration statement with respect to such Registrable
Securities and use its commercially reasonable efforts to cause such registration statement to
become effective and, upon the request of the Investors (or, to the extent that no Registrable
Securities of such Investors are included in such registration statement, the Holders of a majority
of the Registrable Securities registered thereunder), keep such registration statement effective
for a period of up to one hundred twenty (120) days or, if earlier, until the distribution
contemplated in the registration statement has been completed; provided, however, that (i)
such one hundred twenty (120) day period shall be extended for a period of time equal to the period
such Holders refrain, at the request of an underwriter of Common Stock (or other securities) of the
Company, from selling any securities included in such registration, and (ii) in the case of any
registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous
or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120)
day period shall be extended, if necessary, until such time as all such Registrable Securities held
by such Holders are sold;

               (b) prepare and file with the SEC such amendments and supplements to such registration
statement, and the prospectus used in connection with such registration

-7-

 

statement, as may be necessary to comply with the Securities Act in order to enable the
disposition of all securities covered by such registration statement;

               (c) furnish to the Holders of Registrable Securities covered by such registration statement
such numbers of copies of a prospectus, including a preliminary prospectus, as required by the
Securities Act, and such other documents as such Holders may reasonably request in order to
facilitate their disposition of their Registrable Securities;

               (d) use its commercially reasonable efforts to register and qualify the securities covered by
such registration statement under such other securities or blue-sky laws of such jurisdictions as
shall be reasonably requested by the Holders of Registrable Securities covered by such registration
statement; provided that the Company shall not be required to qualify to do business or to file a
general consent to service of process in any such states or jurisdictions, unless the Company is
already subject to service in such jurisdiction and except as may be required by the Securities
Act;

               (e) in the event of any underwritten public offering, enter into and perform its obligations
under an underwriting agreement, in usual and customary form, with the underwriter(s) of such
offering;

               (f) use its commercially reasonable efforts to cause all such Registrable Securities covered
by such registration statement to be listed on a national securities exchange or trading system and
each securities exchange and trading system (if any) on which similar securities issued by the
Company are then listed;

               (g) provide a transfer agent and registrar for all Registrable Securities registered pursuant
to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not
later than the effective date of such registration;

               (h) promptly make available for inspection by the participating Investors, any underwriter(s)
participating in any disposition pursuant to such registration statement, and any attorney or
accountant or other agent retained by any such underwriter or selected by the participating
Investors, all financial and other records, pertinent corporate documents, and properties of the
Company, and cause the Company’s officers, directors, employees, and independent accountants to
supply all information reasonably requested by any such seller, underwriter, attorney, accountant,
or agent, in each case, as necessary or advisable to verify the accuracy of the information in such
registration statement and to conduct appropriate due diligence in connection therewith;

               (i) notify each Holder of Registrable Securities covered by such registration statement,
promptly after the Company receives notice thereof, of the time when such registration statement
has been declared effective or a supplement to any prospectus forming a part of such registration
statement has been filed; and

               (j) after such registration statement becomes effective, notify each Holder of Registrable
Securities covered by such registration statement of any request by the SEC that the Company amend
or supplement such registration statement or prospectus.

-8-

 

          2.5 Furnish Information. It shall be a condition precedent to the obligations of the
Company to take any action pursuant to this Section 2 with respect to the Registrable
Securities of each Holder that such Holder shall furnish to the Company such information regarding
itself, the Registrable Securities held by it, and the intended method of disposition of such
securities as is reasonably required to effect the registration of such Holder’s Registrable
Securities.

          2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in
connection with registrations, filings, or qualifications pursuant to Section 2, including
all registration, filing, and qualification fees; printers’ and accounting fees; fees and
disbursements of counsel for the Company; and the reasonable fees and disbursements of one counsel
for the Holders requesting registration who shall be designated by the a Majority in Interest of
the participating Investors in the event any of the Investors’ Registrable Securities are included
in such registration (“Investor Counsel”), shall be borne and paid by the Company;
provided, however, that the Company shall not be required to pay for any expenses
of any registration proceeding begun pursuant to Section 2.1 if the registration request is
subsequently withdrawn at the request of Investors holding a majority of the Registrable Securities
to be included in such registration (in which case all selling Holders shall bear such expenses pro
rata based upon the number of Registrable Securities that were to be included in the withdrawn
registration), unless a Majority in Interest of the Investors agrees to forfeit their right to one
registration pursuant to Section 2.1(a) or Section 2.1(b), as the case may be;
provided further that if, at the time of such withdrawal, the Investors have
learned of a material adverse change in the condition, business, or prospects of the Company from
that known to the Investors at the time of their request and have withdrawn the request with
reasonable promptness after learning of such information then the Investors shall not be required
to pay any of such expenses and shall not forfeit their right to one registration pursuant to
Section 2.1(a) or Section 2.1(b). A portion of the Selling Expenses relating to
Registrable Securities registered pursuant to this Section 2 shall be borne and paid by
each Holder pro rata on the basis of the number of Registrable Securities registered on such
Holder’s behalf.

          2.7 Delay of Registration. No Holder shall have any right to obtain or seek an
injunction restraining or otherwise delaying any registration pursuant to this Agreement as the
result of any controversy that might arise with respect to the interpretation or implementation of
this Section 2.

          2.8 Indemnification. If any Registrable Securities are included in a registration
statement under this Section 2:

               (a) To the extent permitted by law, the Company will indemnify and hold harmless the Holders,
and their partners, members, officers, directors, and stockholders, if applicable; legal counsel
and accountants for the Holders; any underwriter (as defined in the Securities Act) for the
Holders; and each Person, if any, who controls a Holder or underwriter within the meaning of the
Securities Act or the Exchange Act, against any Damages, and the Company will pay to the Holder,
underwriter, controlling Person, or other aforementioned Person any legal or other expenses
reasonably incurred thereby in connection with investigating or defending any claim or proceeding
from which Damages may result, as such expenses are incurred; provided, however, that the
indemnity agreement contained in this Section 2.8(a) shall

-9-

 

not apply to amounts paid in settlement of any such claim or proceeding if such settlement is
effected without the consent of the Company, which consent shall not be unreasonably withheld, nor
shall the Company be liable for any Damages to the extent that they arise out of or are based upon
actions or omissions made in reliance upon and in conformity with written information furnished by
or on behalf of the Holder, underwriter, controlling Person, or other aforementioned Person
expressly for use in connection with such registration.

               (b) To the extent permitted by law, each selling Holder, severally and not jointly, will
indemnify and hold harmless the Company, and each of its directors, each of its officers who has
signed the registration statement, each Person (if any), who controls the Company within the
meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as
defined in the Securities Act), and any other Holder selling securities in such registration
statement, and any controlling Person of any such underwriter or any other selling Holder, against
any Damages, in each case only to the extent that such Damages arise out of or are based upon
actions or omissions made in reliance upon and in conformity with written information furnished by
or on behalf of such selling Holder expressly for use in connection with such registration; and
each such selling Holder will pay to the Company and each other aforementioned Person any legal or
other expenses reasonably incurred thereby in connection with investigating or defending any claim
or proceeding from which Damages may result, as such expenses are incurred; provided,
however, that the indemnity agreement contained in this Section 2.8(b) shall not apply
to amounts paid in settlement of any such claim or proceeding if such settlement is effected
without the consent of such Holder, which consent shall not be unreasonably withheld; and
provided further that in no event shall the aggregate amounts payable by a Holder by way of
indemnity or contribution under Sections 2.8(b) and 2.8(d) exceed the proceeds from
the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in
the case of fraud or willful misconduct by such Holder.

               (c) Promptly after receipt by an indemnified party under this Section 2.8 of notice of
the commencement of any action (including any governmental action) for which a party may be
entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof
is to be made against any indemnifying party under this Section 2.8, give the indemnifying
party notice of the commencement thereof. The indemnifying party shall have the right to
participate in such action and, to the extent the indemnifying party so desires, participate
jointly with any other indemnifying party to which notice has been given, and to assume the defense
thereof with counsel mutually satisfactory to the parties; provided, however, that an
indemnified party (together with all other indemnified parties that may be represented without
conflict by one counsel) shall have the right to retain one separate counsel, with the fees and
expenses to be paid by the indemnifying party, if representation of such indemnified party by the
counsel retained by the indemnifying party would be inappropriate due to actual or potential
differing interests between such indemnified party and any other party represented by such counsel
in such action. The failure to give notice to the indemnifying party within a reasonable time of
the commencement of any such action shall relieve such indemnifying party of any liability to the
indemnified party under this Section 2.8, to the extent that such failure materially
prejudices the indemnifying party’s ability to defend such action. The failure to give notice to
the indemnifying party will not relieve it of any liability that it may have to any indemnified
party otherwise than under this Section 2.8.

-10-

 

               (d) To provide for just and equitable contribution to joint liability under the Securities Act
in any case in which either (i) any party otherwise entitled to indemnification hereunder makes a
claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by
the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of
time to appeal or the denial of the last right of appeal) that such indemnification may not be
enforced in such case, notwithstanding the fact that this Section 2.8 provides for
indemnification in such case, or (ii) contribution under the Securities Act may be required on the
part of any party hereto for which indemnification is provided under this Section 2.8,
then, and in each such case, such parties will contribute to the aggregate losses, claims, damages,
liabilities, or expenses to which they may be subject (after contribution from others) in such
proportion as is appropriate to reflect the relative fault of each of the indemnifying party and
the indemnified party in connection with the statements, omissions, or other actions that resulted
in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant
equitable considerations. The relative fault of the indemnifying party and of the indemnified
party shall be determined by reference to, among other things, whether the untrue or allegedly
untrue statement of a material fact, or the omission or alleged omission of a material fact,
relates to information supplied by the indemnifying party or by the indemnified party and the
parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent
such statement or omission; provided, however, that, in any such case, (x) a Holder will
not be required to contribute any amount in excess of the public offering price of all such
Registrable Securities offered and sold by such Holder pursuant to such registration statement, and
(y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the
Securities Act) will be entitled to contribution from any Person who was not guilty of such
fraudulent misrepresentation; and provided further that in no event shall a Holder’s
liability pursuant to this Section 2.8(d), when combined with the amounts paid or payable
by such Holder pursuant to Section 2.8(b), exceed the proceeds from the offering received
by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful
misconduct or fraud by such Holder.

               (e) Unless otherwise superseded by an underwriting agreement entered into in connection with
the underwritten public offering, the obligations of the Company and the Holders under this
Section 2.8 shall survive the completion of any offering of Registrable Securities in a
registration under this Section 2, and otherwise shall survive the termination of this
Agreement.

          2.9 Reports Under Exchange Act. With a view to making available to the Investors the
benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit
the Investors to sell securities of the Company to the public without registration or pursuant to a
registration on Form S 3, the Company shall:

               (a) make and keep available adequate current public information, as those terms are understood
and defined in SEC Rule 144, at all times after the effective date of the registration statement
filed by the Company for the IPO;

               (b) use commercially reasonable efforts to file with the SEC in a timely manner all reports
and other documents required of the Company under the Securities Act and the Exchange Act (at any
time after the Company has become subject to such reporting

-11-

 

requirements); and

               (c) furnish to the Investors, so long as the Investors own any Registrable Securities,
forthwith upon request (i) to the extent accurate, a written statement by the Company that it has
complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after
the effective date of the registration statement filed by the Company for the IPO), the Securities
Act, and the Exchange Act (at any time after the Company has become subject to such reporting
requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form
S 3 (at any time after the Company so qualifies); (ii) a copy of the most recent annual or
quarterly report of the Company and such other reports and documents so filed by the Company; and
(iii) such other information as may be reasonably requested in availing the Investors of any rule
or regulation of the SEC that permits the selling of any such securities without registration (at
any time after the Company has become subject to the reporting requirements under the Exchange Act)
or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). So long as
the Company is filing such reports and documents electronically, it shall be entitled to furnish
such documents by electronic delivery or by reference to the website maintained by the SEC on which
the reports and documents are filed.

          2.10 Limitations on Subsequent Registration Rights. From and after the date of this
Agreement, the Company shall not, without the prior written consent of the a Majority in Interest
of the Investors, enter into any agreement with any holder or prospective holder of any securities
of the Company that allow such holder or prospective holder (i) to include such securities in any
registration unless, under the terms of such agreement, such holder or prospective holder may
include such securities in any such registration only to the extent that the inclusion of such
securities will not reduce the number of the Registrable Securities of the Investors that are
included, or (ii) allow such holder or prospective holder to initiate a demand for registration of
any securities held by such holder or prospective holder.

          2.11 “Market Stand off” Agreement. Each Holder hereby agrees that he, she or it will
not, without the prior written consent of the managing underwriter, during the period commencing on
the date of the final prospectus relating to the registration by the Company for its own behalf of
shares of its Common Stock or any other equity securities under the Securities Act on a
registration statement on Form S-1, and ending on the date specified by the Company and the
managing underwriter (such period not to exceed one hundred eighty (180) days (or such longer
period, not to exceed 34 days after the expiration of such 180-day period, if requested by the
Company or an underwriter in order to comply with National Association of Securities Dealers Rule
2711)), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase;
purchase any option or contract to sell; grant any option, right, or warrant to purchase; or
otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any
securities convertible into or exercisable or exchangeable (directly or indirectly) for Common
Stock held immediately before the effective date of the registration statement for such offering or
(ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any
of the economic consequences of ownership of such securities, whether any such transaction
described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other
securities, in cash, or otherwise; provided, however, notwithstanding the foregoing or anything
else to the contrary contained in this Agreement, each Holder shall be entitled to make a bona fide
pledge (including a right of foreclosure) of Common Stock, or any securities convertible

-12-

 

into or exercisable or exchangeable (directly or indirectly) for Common Stock, to a bank,
financial institution or like entity. The foregoing provisions of this Section 2.11 shall
apply only to the IPO, shall not apply to the sale of any shares to an underwriter pursuant to an
underwriting agreement, and shall be applicable to the Holders only if all officers, directors and
stockholders holding more than one percent (1%) of the Company’s outstanding Common Stock (after
giving effect to the conversion into Common Stock of all outstanding Preferred Stock) are subject
to the same restrictions. The underwriters in connection with such registration are intended third
party beneficiaries of this Section 2.11 and shall have the right, power, and authority to
enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to
execute such agreements as may be reasonably requested by the underwriters in connection with such
registration that are consistent with this Section 2.11 or that are necessary to give
further effect thereto.

          2.12 Termination of Registration Rights. The right of the Holders to request
registration or inclusion of Registrable Securities in any registration pursuant to
Section 2.1 or Section 2.2 shall terminate upon the earliest to occur of:

               (a) the closing of a Deemed Liquidation Event, as such term is defined in the Company’s
Certificate of Incorporation;

               (b) such time at which all Registrable Securities held by such Holder (and any affiliate of
such Holder with whom such Holder must aggregate its sales under Rule 144) can be sold in a single
market sale on a single day without registration in compliance with Rule 144 of the Act.

     3. Information and Observer Rights.

          3.1 Delivery of Financial Statements. The Company shall deliver to the Investors:

               (a) as soon as practicable, but in any event within one hundred twenty (120) days after the
end of each fiscal year of the Company, (i) a balance sheet as of the end of such year, (ii)
statements of income and of cash flows for such year, and a comparison between (x) the actual
amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and as
included in the Budget (as defined in below) for such year, with an explanation of any material
differences between such amounts and a schedule as to the sources and applications of funds for
such year, and (iii) a statement of stockholders’ equity as of the end of such year, all such
financial statements audited and certified by PMB Helin Donovan, LLP or any other independent
public accountants of nationally or regionally recognized standing selected by the audit committee
of the Company’s Board of Directors in accordance with its charter;

               (b) as soon as practicable, but in any event within forty five (45) days after the end of each
of the first three (3) quarters of each fiscal year of the Company, unaudited statements of income
and of cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of
stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance with GAAP
(except that such financial statements may (i) be subject to normal year-end audit adjustments and
(ii) not contain all notes thereto that may be required in accordance

-13-

 

with GAAP);

               (c) upon the reasonable request of any Investor, a statement showing the number of shares of
each class and series of capital stock and securities convertible into or exercisable for shares of
capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or
exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange
ratio or exercise price applicable thereto, and the number of shares of issued stock options and
stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to
permit the Investor to calculate its percentage equity ownership in the Company, and certified by
the chief financial officer and chief executive officer of the Company as being true, complete, and
correct;

               (d) as soon as practicable, but in any event within thirty (30) days of the end of each month,
an unaudited income statement and statement of cash flows for such month, and an unaudited balance
sheet and statement of stockholders’ equity as of the end of such month, all prepared in accordance
with GAAP (except that such financial statements may (i) be subject to normal year-end audit
adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP);

               (e) with respect to the financial statements called for in Section 3.1(a),
Section 3.1(b) and Section 3.1(d), an instrument executed by the chief financial
officer and chief executive officer of the Company certifying that such financial statements were
prepared in accordance with GAAP consistently applied with prior practice for earlier periods
(except as otherwise set forth in Section 3.1(b) and Section 3.1(d)) and fairly
present the financial condition of the Company and its results of operation for the periods
specified therein; and

               (f) such other information relating to the financial condition, business, prospects, or
corporate affairs of the Company as the Investors may from time to time reasonably request;
provided, however, that the Company shall not be obligated under this
Section 3.1 to provide information (i) that the Company reasonably determines in good faith
to be a trade secret or confidential information (unless covered by an enforceable confidentiality
agreement, in form acceptable to the Company) or (ii) the disclosure of which would adversely
affect the attorney-client privilege between the Company and its counsel.

If, for any period, the Company has any subsidiary whose accounts are consolidated with those of
the Company, then in respect of such period the financial statements delivered pursuant to the
foregoing Sections shall be the consolidated and consolidating financial statements of the Company
and all such consolidated subsidiaries.

Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease
providing the information set forth in this Section 3.1 during the period starting with the
date thirty (30) days before the Company’s good-faith estimate of the date of filing of a
registration statement if it reasonably concludes it must do so to comply with the SEC rules
applicable to such registration statement and related offering; provided that the Company’s
covenants under this Section 3.1 shall be reinstated at such time as the Company is no
longer actively employing its commercially reasonable efforts to cause such registration statement
to become effective.

-14-

 

          3.2 Inspection. The Company shall permit the Investors to visit and inspect the
Company’s properties; examine its books of account and records; and discuss the Company’s affairs,
finances, and accounts with its officers, during normal business hours of the Company as may be
reasonably requested by the Investors; provided, however, that the Company shall not be
obligated pursuant to this Section 3.2 to provide access to any information that it
reasonably and in good faith considers to be a trade secret or confidential information (unless
covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the
disclosure of which would adversely affect the attorney-client privilege between the Company and
its counsel.

          3.3 Termination of Information Rights. The covenants set forth in Section 3.1
and Section 3.2 shall terminate and be of no further force or effect (i) immediately before
the consummation of the IPO, or (ii) when the Company first becomes subject to the periodic
reporting requirements of Section 12(g) or 15(d) of the Exchange Act, whichever event occurs first.

     4. Rights to Future Stock Issuances.

          4.1 Right of First Offer. Subject to the terms and conditions of this
Section 4.1 and applicable securities laws, if the Company proposes to offer or sell any
New Securities, the Company shall first offer to the Investors and each Common Holder identified on
Schedule B-1 hereto (the Investors and Common Holders set forth on Schedule B-1 are
collectively referred to as the “Major Holders” and individually, as a “Major Holder”)) such Major
Holder’s Pro Rata Share (as defined below) of such New Securities. Each Major Holder shall be
entitled to apportion the right of first offer hereby granted to it among itself and its Affiliates
in such proportions as it deems appropriate. A Major Holder’s “Pro Rata Share” for purposes of
this right of first offer is the ratio of (x) the number of shares of Fully-Diluted Common Stock
(as defined below) of the Company held by such Major Holder to (y) the total number of shares of
Fully-Diluted Common Stock of the Company then held by all Major Holders. “Fully-Diluted Common
Stock” for purposes of this right of first offer shall mean, at any time, the then outstanding
shares of Common Stock plus (without duplication) all shares of Common Stock issuable (at the time
or upon passage of time or the occurrence of future events), upon the exercise, conversion or
exchange of all then outstanding rights, warrants, options, convertible securities or other rights
or securities convertible into, directly or indirectly, Common Stock, including all Common Stock
issuable upon the conversion of the shares of Series A-1 Preferred Stock.

               (a) The Company shall give notice (the “Offer Notice”) to each Major Holder, stating (i) its
bona fide intention to offer such New Securities, (ii) the number of such New Securities to be
offered, and (iii) the price and terms, if any, upon which it proposes to offer such New
Securities.

               (b) By notification to the Company within twenty (20) days after the Offer Notice is given,
each Major Holder may elect to purchase or otherwise acquire, at the price and on the terms
specified in the Offer Notice, up to such Major Holder’s Pro Rata Share of New Securities. At the
expiration of such twenty (20) day period, the Company shall promptly notify each Major Holder that
elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Holder”) of
any other Major Holder’s failure to do likewise. During the ten (10) day

-15-

 

period commencing after the Company has given such notice, each Fully Exercising Holder may,
by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares
specified above, up to that portion of the New Securities for which Major Holders were entitled to
subscribe but that were not subscribed for by the Major Holders which is equal to the ratio of (y)
the number of shares of Fully-Diluted Common Stock of the Company then held by such Fully
Exercising Holder, to (y) the total number of shares of Fully-Diluted Common Stock of the Company
then held by all Fully Exercising Holders who wish to purchase such unsubscribed shares. The
closing of any sale pursuant to this Section 4.1(b) shall occur within the later of ninety
(90) days of the date that the Offer Notice is given and the date of initial sale of New Securities
pursuant to Section 4.1(c).

               (c) If the New Securities referred to in the Offer Notice are not elected to be purchased or
acquired as provided in Section 4.1(b), the Company may, during the ninety (90) day period
following the expiration of the periods provided in Section 4.1(b), offer and sell the
remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less
than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice.
If the Company does not enter into an agreement for the sale of the New Securities within such
period, the right provided hereunder shall be deemed to be revived and such New Securities shall
not be offered unless first reoffered to the Major Holders in accordance with this
Section 4.1.

               (d) The right of first offer in this Section 4.1 shall not be applicable to (i) shares
of Common Stock issued or issuable upon conversion of outstanding shares of Series A-1 Preferred
Stock; (ii) shares of Common Stock (or options or rights for Common Stock) granted pursuant to the
Company’s 2007 Long Term Incentive Plan (the “Plan”), or any other written stock option, stock
purchase, stock incentive or stock appreciation plan or arrangement, and any increase in the number
of shares of Common Stock reserved for issuance pursuant to any of the foregoing; provided,
that any increase in the number of shares of Common Stock reserved for issuance pursuant to the
Plan or adoption of any other plan or arrangement is approved by a majority of the members of the
Board of Directors, including the Series A-1 Director Approval and by the holders of a majority of
the outstanding shares of Series A-1 Preferred Stock pursuant to the terms of the Series A-1
Preferred Stock; (iii) shares of the Company’s Common Stock or preferred stock (and/or options,
rights or warrants for Common Stock or preferred stock) issued or issuable in connection with an
acquisition transaction, building or equipment lease transaction, bank loan transaction, strategic
alliance or partnering arrangement that is not primarily for equity financing purposes and that is
approved by a majority of the members of the Board of Directors, including the Series A-1 Director
Approval; (iv) shares of the Company’s Common Stock or preferred stock issued in connection with
any stock split or stock dividend; and (v) shares of Common Stock issued in the IPO. For purposes
of this Agreement, the “Series A-1 Director Approval” shall mean the written approval of the Series
A-1 Director of resolutions distributed pursuant to an action by prior written consent of the Board
of Directors or in advance of any meeting of the Board of Directors in which action is taken by the
Board of Directors with respect to such resolutions together with any changes made to such
resolutions after such distribution approved in writing by the Series A-1 Director.

-16-

 

          4.2 Termination of Covenants. The covenants set forth in Section 4.1 shall
terminate and be of no further force or effect immediately upon the conversion of the last
outstanding share of Series A-1 Preferred Stock into Common Stock.

     5. Additional Covenants.

          5.1 Insurance. The Company shall use its commercially reasonable efforts to obtain,
within ninety (90) days of the date hereof, from financially sound and reputable insurers Directors
and Officers liability insurance in an amount and on terms and conditions satisfactory to the Board
of Directors, and will use commercially reasonable efforts to cause such insurance policy to be
maintained until such time as the Board of Directors determines that such insurance should be
discontinued. The Directors and Officers liability insurance shall not be cancelable by the
Company without prior written approval by the Investors.

          5.2 Employee Agreements. The Company will cause (i) each Key Employee to enter into a
Confidential Information, Invention Assignment and Non-Competition Agreement, substantially in the
form attached hereto as Exhibit A and (ii) each other employee now or hereafter employed by
it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent
contractor) to enter into a Confidential Information and Invention Assignment Agreement,
substantially in the form attached hereto as Exhibit B.

          5.3 Employee Stock. Unless otherwise approved by a majority of the members of the
Board of Directors, including the Series A-1 Director Approval, all future employees and
consultants of the Company who purchase, receive options to purchase, or receive awards of shares
of the Company’s capital stock after the date hereof shall be required to execute restricted stock
or option agreements, as applicable, providing for (i) vesting of shares over a five (5) year
period, with the first twenty percent (20%) of such shares vesting following twelve (12) months of
continued employment or service, and the remaining shares vesting in equal monthly installments
over the following forty-eight (48) months, and (ii) a market stand-off provision substantially
similar to that in Section 2.11. In addition, unless otherwise approved by a majority of
the members of the Board of Directors, including the Series A-1 Director Approval, the Company
shall retain a “right of first refusal” on employee transfers until the Company’s IPO and shall
have the right to repurchase unvested shares at cost upon termination of employment of a holder of
restricted stock.

          5.4 Matters Requiring Board Approval. The Company hereby covenants and agrees that it
shall not, without the approval of a majority of the members of the Board of Directors, including
the Series A-1 Director Approval:

               (a) make, or permit any subsidiary to make, any loan or advance to, or own any stock or other
securities of, any subsidiary or other corporation, partnership, or other entity unless it is
wholly owned by the Company;

               (b) create or hold capital stock in any subsidiary that is not wholly owned (either directly
or through one or more other subsidiaries) by the Company, or sell, transfer or otherwise dispose
of any capital stock of any direct or indirect subsidiary of the Company, or permit any direct or
indirect subsidiary to sell, lease, transfer, exclusively license or

-17-

 

otherwise dispose (in a single transaction or related transactions) of all or substantially
all of the assets of such subsidiary;

               (c) make, or permit any subsidiary to make, any loan or advance to any Person, including,
without limitation, any employee or director of the Company or any subsidiary, except advances and
similar expenditures in the ordinary course of business or under the terms of the Plan or any other
employee stock or option plan approved by a majority of the members of the Board of Directors,
including the Series A-1 Director Approval;

               (d) guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or
indirectly, any indebtedness for borrowed money, except for trade accounts of the Company or any
subsidiary arising in the ordinary course of business, or guarantee, create or authorize the
creation of, or issue, or authorize the issuance of any debt security in excess of $250,000 in the
aggregate that has not previously been approved by a majority of the members of the Board of
Directors, including the Series A-1 Director Approval, other than trade credit incurred in the
ordinary course of business, or permit any subsidiary to take any such action with respect to any
such debt security;

               (e) make any investment inconsistent with any investment policy approved by a majority of the
members of the Board of Directors, including the Series A-1 Director Approval;

               (f) incur any aggregate indebtedness for borrowed money in excess of $250,000 in the aggregate
that has not previously been approved by a majority of the members of the Board of Directors,
including the Series A-1 Director Approval, other than trade credit incurred in the ordinary course
of business;

               (g) otherwise enter into or be a party to any transaction with any director, officer, or
employee of the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange
Act) of any such Person, except for transactions contemplated by or described in this Agreement,
and the Purchase Agreement, or transactions made in the ordinary course of business and pursuant to
reasonable requirements of the Company’s business and upon fair and reasonable terms that are
approved by a majority of the members of the Board of Directors, including the Series A-1 Director
Approval;

               (h) hire, terminate, or change the compensation of the executive officers, including approving
any option grants or stock awards to executive officers;

               (i) sell, assign, license, pledge, or encumber any material technology or intellectual
property of the Company, other than licenses granted in the ordinary course of business;

               (j) enter into a corporate strategic relationship, joint venture, partnership or like
transaction with any Person involving the payment, contribution, or assignment by the Company or to
the Company of money or assets greater than $250,000;

               (k) file any registration statement under the 1933 Act, as amended or under the 1934 Act, or
otherwise offer shares of the Company’s capital stock to the public;

-18-

 

               (l) acquire (by merger, consolidation, or acquisition of stock or assets) any company,
corporation, partnership or other business organization or division thereof, or any material
assets;

               (m) divest the Company of any subsidiary, any line of business or any material assets;

               (n) materially change the general nature of the Company’s business;

               (o) make any change in the Company’s auditors; or

               (p) (i) amend any of the agreements referenced in Section 5.2 to carveout any
intellectual property from the assignment of newly-created intellectual property under such
agreement or to modify the nondisclosure, nonsolicitation or noncompetition obligations under such
agreement or (ii) amend, modify, terminate, waive, or otherwise alter, in whole or in part, any
employment agreement between the Company and any employee.

          5.5 Board Matters.

               (a) Meetings. Unless otherwise determined by the vote of a majority of the directors
then in office, the Board of Directors shall meet at least quarterly in accordance with an
agreed-upon schedule. The Company shall reimburse the nonemployee directors for all reasonable
out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection
with attending meetings of the Board of Directors. The Company shall cause to be established, as
soon as practicable, and will maintain, an audit and compensation committee, each of which shall
include the Series A-1 Director. The approval of the compensation committee shall be required for
the issuance of any stock, stock options, stock awards or other securities to, and all compensation
arrangements with, any employee or consultant of the Company. Any and all action taken by the
audit and compensation committees shall require the Series A-1 Director Approval.

               (b) Budget. As soon as practicable, but in any event thirty (30) days before the end
of each fiscal year, the Company shall deliver to the Board of Directors for approval a budget and
business plan for the next fiscal year (collectively, the “Budget”) prepared on a monthly basis,
including balance sheets, income statements, and statements of cash flow for such months and,
promptly after prepared, any other budgets or revised budgets prepared by the Company.

          5.6 Successor Indemnification. If the Company or any of its successors or assignees
consolidates with or merges into any other Person and is not the continuing or surviving
corporation or entity of such consolidation or merger, then to the extent necessary, proper
provision shall be made so that the successors and assignees of the Company assume the obligations
of the Company with respect to indemnification of members of the Board of Directors as in effect
immediately before such transaction, whether such obligations are contained in the Company’s
Bylaws, its Certificate of Incorporation, or elsewhere, as the case may be.

-19-

 

          5.7 Termination of Covenants. The covenants set forth in this Section 5,
except for Section 5.6, shall terminate and be of no further force or effect (i)
immediately before the consummation of the IPO or (ii) when the Company first becomes subject to
the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act.

     6. Voting Provisions.

          6.1 Voting Provisions Regarding Board of Directors.

               (a) Size of the Board. Each Stockholder agrees to vote, or cause to be voted, all
Shares (as defined below) owned by such Stockholder, or over which such Stockholder has voting
control, from time to time and at all times, in whatever manner as shall be necessary to ensure
that the size of the Board of Directors shall be set and remain at three (3) directors and may be
increased only with the written consent of a Majority in Interest of the Investors. For purposes
of this Section 6, the term “Shares” shall mean and include any securities of the Company
the holders of which are entitled to vote for members of the Board of Directors, including without
limitation, all shares of Common Stock and Series A-1 Preferred Stock, by whatever name called, now
owned or subsequently acquired by a Stockholder, however acquired, whether through stock splits,
stock dividends, reclassifications, recapitalizations, similar events or otherwise.

               (b) Board Composition. Each Stockholder agrees to vote, or cause to be voted, all
Shares owned by such Stockholder, or over which such Stockholder has voting control, from time to
time and at all times, in whatever manner as shall be necessary to ensure that at each annual or
special meeting of stockholders at which an election of directors is held or pursuant to any
written consent of the stockholders, the following persons shall be elected to the Board of
Directors:

                    (i) One candidate designated by the holders of a Majority in Interest of the Investors, who
initially shall be Matt Zell (the “Series A-1 Director”);

                    (ii) One candidate designated by the holders of a majority of the outstanding shares of Common
Stock (excluding any shares issued or issuable upon conversion of the Preferred Stock), who
initially shall be Mark Chandler; and

                    (iii) The Chief Executive Officer of the Company, who shall initially be T. Craig Benson.

In the event that the number of directors constituting the Board of Directors is increased above
the number provided in this Section 6, this Agreement shall continue with respect to three
of the total number of directors, with the remaining directors being elected in such manner as may
be provided by law or in the Restated Certificate of Incorporation or Bylaws of the Company or
pursuant to any agreement entered into in connection with such increase.

               (c) Failure to Designate Board Member. In the absence of any designation from the
Persons or groups with the right to designate a director as specified above, the director
previously designated by them and then serving shall be reelected if still eligible to serve as
provided herein; provided, however, notwithstanding the foregoing, a party or group

-20-

 

entitled to designate a director pursuant to Section 6.1(b) may determine not to make
any designation and to leave vacant such board seat at any time (including after the initial or any
successor director may have held such board seat) and such failure to designate a replacement
designee shall not result in the loss or waiver of such parties’ rights under this
Section 6.1(b) to designate a new candidate at anytime thereafter and to enforce all of its
rights under this Section 6.1.

               (d) Removal of Board Members. Each Stockholder also agrees to vote, or cause to be
voted, all Shares owned by such Stockholder, or over which such Stockholder has voting control,
from time to time and at all times, in whatever manner as shall be necessary to ensure that:

                    (i) no director elected pursuant to Sections 6.1(b) or 6.1(c) of this
Agreement may be removed from office other than for cause unless such removal is directed or
approved by the affirmative vote of the Person, or of the holders of at least a majority of
the shares of stock, entitled under Section 6.1(b) to designate that director;
provided, however, that notwithstanding the foregoing, any director designated under
Section 6.1(b)(iii) may be removed with the approval of the holders of a majority of
the outstanding shares of capital stock on an as-converted basis;

                    (ii) any vacancies created by the resignation, removal or death of a director elected
pursuant to Sections 6.1(b) or 6.1(c) shall be filled pursuant to the
provisions of this Section 6.1; and

                    (iii) upon the request of any party entitled to designate a director as provided in
Section 6.1(b)(i) to remove such director, such director shall be removed; and

                    (iv) in the event any director designated under Section 6.1(b)(iii) ceases to
be the Chief Executive Officer of the Company, such director shall be removed and replaced
by the new Chief Executive Officer of the Company.

All Stockholders agree to execute any written consents required to perform the obligations of this
Agreement, and the Company agrees at the request of any party entitled to designate directors to
call a special meeting of stockholders for the purpose of electing directors.

               (e) No Liability for Election of Recommended Directors. No Stockholder, nor any
Affiliate of any Stockholder, shall have any liability as a result of designating a person for
election as a director for any act or omission by such designated person in his or her capacity as
a director of the Company, nor shall any Stockholder have any liability as a result of voting for
any such designee in accordance with the provisions of this Agreement.

          6.2 Vote to Increase Authorized Common Stock. Each Stockholder agrees to vote or
cause to be voted all Shares owned by such Stockholder, or over which such Stockholder has voting
control, from time to time and at all times, in whatever manner as shall be necessary to increase
the number of authorized shares of Common Stock from time to time to ensure that there will be
sufficient shares of Common Stock available for conversion of all of the shares of Preferred Stock
outstanding at any given time.

-21-

 

          6.3 Drag Along Rights.

               (a) Definitions. For purposes of this Section 6.3, a “Sale of the Company”
shall mean either: (a) a transaction or series of related transactions in which a Person, or a
group of related Persons, acquires from stockholders of the Company shares representing more than
fifty percent (50%) of the outstanding voting power of the Company (a “Stock Sale”); or (b) a
transaction that qualifies as a “Deemed Liquidation Event” as defined in the Restated Certificate.

               (b) Actions to Be Taken. In the event that (i) a Majority in Interest of the
Investors, and (ii) the Board of Directors, approve a Sale of the Company, then each Stockholder
hereby agrees:

                    (i) if such transaction requires stockholder approval, with respect to all Shares that
such Stockholder owns or over which such Stockholder otherwise exercises voting power, to
vote (in person, by proxy or by action by written consent, as applicable) all Shares in
favor of, and adopt, such Sale of the Company (together with any related amendment to the
Restated Certificate required in order to implement such Sale of the Company) and to vote in
opposition to any and all other proposals that could reasonably be expected to delay or
impair the ability of the Company to consummate such Sale of the Company;

                    (ii) if such transaction is a Stock Sale, to sell the same proportion of shares of
capital stock of the Company beneficially held by such Stockholder as is being sold by the
Investors to the Person to whom the Investors propose to sell their Shares, and, except as
permitted in Section 6.3(c) below, on the same terms and conditions as the
Investors;

                    (iii) to execute and deliver all related documentation and take such other action in
support of the Sale of the Company as shall reasonably be requested by the Company or the a
Majority in Interest of the Investors in order to carry out the terms and provision of this
Section 6.3, including without limitation executing and delivering instruments of
conveyance and transfer, and any purchase agreement, merger agreement, indemnity agreement,
escrow agreement, consent, waiver, governmental filing, share certificates duly endorsed for
transfer (free and clear of impermissible liens, claims and encumbrances) and any similar or
related documents;

                    (iv) not to deposit, and to cause their Affiliates not to deposit, except as provided
in this Agreement, any Shares of the Company owned by such party or Affiliate in a voting
trust or subject any Shares to any arrangement or agreement with respect to the voting of
such Shares, unless specifically requested to do so by the acquiror in connection with the
Sale of the Company;

                    (v) to refrain from exercising any dissenters’ rights or rights of appraisal under
applicable law at any time with respect to such Sale of the Company; and

                    (vi) if the consideration to be paid in exchange for the Shares pursuant to this
Section 6.3 includes any securities and due receipt thereof by any

-22-

 

Stockholder would require under applicable law (x) the registration or qualification of
such securities or of any person as a broker or dealer or agent with respect to such
securities or (y) the provision to any Stockholder of any information other than such
information as a prudent issuer would generally furnish in an offering made solely to
“accredited investors” as defined in Regulation D promulgated under the Securities Act of
1933, as amended, the Company may cause to be paid to any such Stockholder in lieu thereof,
against surrender of the Shares which would have otherwise been sold by such Stockholder, an
amount in cash equal to the fair value (as determined in good faith by the Company) of the
securities which such Stockholder would otherwise receive as of the date of the issuance of
such securities in exchange for the Shares.

               (c) Exceptions. Notwithstanding the foregoing, a Stockholder will not be required to
comply with Section 6.3(b) above in connection with any proposed Sale of the Company (the
“Proposed Sale”) unless:

                    (i) any representations and warranties to be made by such Stockholder in connection
with the Proposed Sale are limited to representations and warranties related to authority,
ownership and the ability to convey title to such Shares, including but not limited to
representations and warranties that (A) the Stockholder holds all right, title and interest
in and to the Shares such Stockholder purports to hold, free and clear of all liens and
encumbrances, (B) the obligations of the Stockholder in connection with the transaction have
been duly authorized, if applicable, (C) the documents to be entered into by the Stockholder
have been duly executed by the Stockholder and delivered to the acquirer and are enforceable
against the Stockholder in accordance with their respective terms and (D) neither the
execution and delivery of documents to be entered into in connection with the transaction,
nor the performance of the Stockholder’s obligations thereunder, will cause a breach or
violation of the terms of any agreement, law or judgment, order or decree of any court or
governmental agency;

                    (ii) the Stockholder shall not be liable for the inaccuracy of any representation or
warranty made by any other Person in connection with the Proposed Sale, other than the
Company (except to the extent that funds may be paid out of an escrow established to cover
breach of representations, warranties and covenants of the Company as well as breach by any
stockholder of any of identical representations, warranties and covenants provided by all
stockholders);

                    (iii) the liability for indemnification, if any, of such Stockholder in the Proposed
Sale and for the inaccuracy of any representations and warranties made by the Company in
connection with such Proposed Sale, is several and not joint with any other Person (except
to the extent that funds may be paid out of an escrow established to cover breach of
representations, warranties and covenants of the Company as well as breach by any
stockholder of any of identical representations, warranties and covenants provided by all
stockholders), and is pro rata in proportion to the amount of consideration paid to such
Stockholder in connection with such Proposed Sale (in accordance with the provisions of the
Restated Certificate);

-23-

 

                    (iv) liability shall be limited to such Stockholder’s applicable share (determined
based on the respective proceeds payable to each Stockholder in connection with such
Proposed Sale in accordance with the provisions of the Restated Certificate) of a negotiated
aggregate indemnification amount that applies equally to all Stockholders but that in no
event exceeds the amount of consideration otherwise payable to such Stockholder in
connection with such Proposed Sale, except with respect to claims related to fraud by such
Stockholder, the liability for which need not be limited as to such Stockholder;

                    (v) upon the consummation of the Proposed Sale, (A) each holder of each class or series
of the Company’s stock will receive the same form of consideration for their shares of such
class or series as is received by other holders in respect of their shares of such same
class or series of stock, (B) each holder of a series of Preferred Stock will receive the
same amount of consideration per share of such series of Preferred Stock as is received by
other holders in respect of their shares of such same series, (C) each holder of Common
Stock will receive the same amount of consideration per share of Common Stock as is received
by other holders in respect of their shares of Common Stock, and (D) unless the holders of
at least a Majority in Interest of the Series A-1 Preferred Stock elect otherwise by written
notice given to the Company at least ten (10) days prior to the effective date of any such
Proposed Sale, the aggregate consideration receivable by all holders of the Preferred Stock
and Common Stock shall be allocated among the holders of Preferred Stock and Common Stock on
the basis of the relative liquidation preferences to which the holders of each respective
series of Preferred Stock and the holders of Common Stock are entitled in a Deemed
Liquidation Event (assuming for this purpose that the Proposed Sale is a Deemed Liquidation
Event) in accordance with the Company’s Certificate of Incorporation in effect immediately
prior to the Proposed Sale; and

                    (vi) subject to clause (v) above, requiring the same form of consideration to be
available to the holders of any single class or series of capital stock, if any holders of
any capital stock of the Company are given an option as to the form and amount of
consideration to be received as a result of the Proposed Sale, all holders of such capital
stock will be given the same option.

               (d) Restrictions on Sales of Control of the Company. No Stockholder shall be a party
to any Stock Sale unless all holders of Series A-1 Preferred Stock are allowed to participate in
such transaction and the consideration received pursuant to such transaction is allocated among the
parties thereto in the manner specified in the Company’s Certificate of Incorporation in effect
immediately prior to the Stock Sale (as if such transaction were a Deemed Liquidation Event),
unless a Majority in Interest of the Investors elects otherwise by written notice given to the
Company at least ten (10) days prior to the effective date of any such transaction or series of
related transactions.

          6.4 Remedies.

          (a) Covenants of the Company. The Company agrees to use its best efforts, within the
requirements of applicable law, to ensure that the rights granted under this Section 6

-24-

 

are effective and that the parties enjoy the benefits of this Agreement. Such actions
include, without limitation, the use of the Company’s best efforts to cause the nomination and
election of the directors as provided in this Agreement.

               (b) Irrevocable Proxy. Each party to this Agreement hereby constitutes and appoints
the President and Treasurer of the Company, and a designee of a Majority in Interest of the
Investors, and each of them, with full power of substitution, as the proxies of the party with
respect to the matters set forth herein, including without limitation, election of persons as
members of the Board of Directors in accordance with Section 6.1 hereto, votes to increase
authorized shares pursuant to Section 6.2 hereof and votes regarding any Sale of the
Company pursuant to Section 6.3 hereof, and hereby authorizes each of them to represent and
to vote, if and only if the party (i) fails to vote or (ii) attempts to vote (whether by proxy, in
person or by written consent), in a manner which is inconsistent with the terms of this Agreement,
all of such party’s Shares in favor of the election of persons as members of the Board of Directors
determined pursuant to and in accordance with the terms and provisions of this Agreement or the
increase of authorized shares or approval of any Sale of the Company pursuant to and in accordance
with the terms and provisions of Sections 6.2 and 6.3, respectively, of this
Agreement. The proxy granted pursuant to the immediately preceding sentence is given in
consideration of the agreements and covenants of the Company and the parties in connection with the
transactions contemplated by this Section 6 and, as such, is coupled with an interest and
shall be irrevocable unless and until the covenants and agreements set forth in this Section
6 terminate or expire pursuant to Section 6.5 hereof. Each party hereto hereby revokes
any and all previous proxies with respect to the Shares and shall not hereafter, unless and until
the covenants and agreements set forth in this Section 6 terminate or expire pursuant to
Section 6.5 hereof, purport to grant any other proxy or power of attorney with respect to
any of the Shares, deposit any of the Shares into a voting trust or enter into any agreement (other
than this Agreement), arrangement or understanding with any person, directly or indirectly, to
vote, grant any proxy or give instructions with respect to the voting of any of the Shares, in each
case, with respect to any of the matters set forth herein.

               6.5 Termination of Covenants. The covenants set forth in Section 6 shall
terminate and be of no further force or effect (i) immediately before the consummation of the IPO,
or (ii) when the Company first becomes subject to the periodic reporting requirements of
Section 12(g) or 15(d) of the Exchange Act, whichever event occurs first.

               6.6 Additional Shares of Stock. In the event additional shares of voting capital
stock of the Company are, at any time during the term of this Agreement, issued to an Investor or a
Common Holder, such additional shares shall automatically become subject to the terms and
provisions of this Agreement and shall be voted in accordance herewith.

     7. Agreement Among the Company, the Investors and the Common Holders

          7.1 Definitions. The following additional definitions shall apply with respect to
this Section 7:

               (a) “Capital Stock” means (a) shares of Common Stock and Preferred Stock (whether now
outstanding or hereafter issued in any context), (b) shares of Common Stock

-25-

 

issued or issuable upon conversion of Preferred Stock and (c) shares of Common Stock issued or
issuable upon exercise or conversion, as applicable, of stock options, warrants or other
convertible securities of the Company, in each case now owned or subsequently acquired by any
Common Holder, any Investor, or their respective successors or permitted transferees or assigns.
For purposes of the number of shares of Capital Stock held by an Investor or a Common Holder (or
any other calculation based thereon), all shares of Preferred Stock shall be deemed to have been
converted into Common Stock at the then applicable conversion ratio.

               (b) “Common Holder Notice” means written notice from a Common Holder notifying the Company and
the selling Common Holder and/or selling Non-Lead Investor, as applicable, that such Common Holder
intends to exercise its Tertiary Refusal Right as to a portion of the Transfer Stock with respect
to any Proposed Transfer.

               (c) “Company Notice” means written notice from the Company notifying the selling Common
Holders and/or selling Non-Lead Investors that the Company intends to exercise its Right of First
Refusal as to some or all of the Transfer Stock with respect to any Proposed Transfer.

               (d) “Investor Notice” means written notice from an Investor notifying the Company and the
selling Common Holder and/or selling Non-Lead Investor, as applicable, that such Investor intends
to exercise its Secondary Refusal Right as to a portion of the Transfer Stock with respect to any
Proposed Transfer.

               (e) “Lead Investor” means EGI-Fund (08-10) Investors, L.L.C.

               (f) “Non-Lead Investors” mean the holders of Preferred Stock or Common Stock issued or
issuable upon conversion of such Preferred Stock, other than the Lead Investor.

               (g) “Proposed Transfer” means any assignment, sale, offer to sell, pledge, mortgage,
hypothecation, encumbrance, disposition of or any other like transfer or encumbering, directly or
indirectly, of any Transfer Stock (or any interest therein) proposed by any of the Common Holders
or Non-Lead Investors.

               (h) “Proposed Transfer Notice” means written notice from a Common Holder or Non-Lead Investor
setting forth the terms and conditions of a Proposed Transfer.

               (i) “Prospective Transferee” means any person to whom a Common Holder or Non-Lead Investor
proposes to make a Proposed Transfer.

               (j) “RBM Holdings” means RBM Holdings LLC.

               (k) “RBM Investment” means RBM Investment LLC.

               (l) “RBM Management” means RBM Management Group LLC.

-26-

 

               (m) “Right of Co-Sale” means the right, but not an obligation, of an Investor to participate
in a Proposed Transfer on the terms and conditions specified in the Proposed Transfer Notice.

               (n) “Right of First Refusal” means the right, but not an obligation, of the Company, or its
permitted transferees or assigns, to purchase some or all of the Transfer Stock with respect to a
Proposed Transfer, on the terms and conditions specified in the Proposed Transfer Notice.

               (o) “Secondary Notice” means written notice from the Company notifying the Investors and the
selling Common Holder or selling Non-Lead Investor, as the case may be, that the Company does not
intend to exercise its Right of First Refusal as to all shares of Transfer Stock with respect to
any Proposed Transfer.

               (p) “Secondary Refusal Right” means the right, but not an obligation, of each Investor to
purchase up to its pro-rata portion (based upon the total number of shares of Capital Stock then
held by all Investors) of any Transfer Stock not purchased pursuant to the Right of First Refusal,
on the terms and conditions specified in the Proposed Transfer Notice.

               (q) “Tertiary Refusal Right” means the right, but not an obligation, of each Common Holder to
purchase up to its pro-rata portion (based upon the total number of shares of Capital Stock then
held by all Common Holders) of any Transfer Stock not purchased pursuant to the Right of First
Refusal, the Secondary Refusal Right or Section 7.2(d), on the terms and conditions
specified in the Proposed Transfer Notice.

               (r) “Transfer Stock” means shares of Capital Stock owned by a Common Holder or Non-Lead
Investor, or issued to a Common Holder or Non-Lead Investor after the date hereof (including,
without limitation, in connection with any stock split, stock dividend, recapitalization,
reorganization, or the like).

               (s) “Undersubscription Notice” means written notice from an Investor notifying the Company and
the selling Common Holder or selling Non-Lead Investor that such Investor intends to exercise its
option to purchase all or any portion of the Transfer Stock not purchased pursuant to the Right of
First Refusal or the Secondary Refusal Right.

          7.2 Right of First Refusal.

               (a) Grant. Subject to the terms of Section 7.5 below, each Common Holder and
each Non-Lead Investor hereby unconditionally and irrevocably grants to the Company a Right of
First Refusal to purchase all or any portion of Transfer Stock that such Common Holder or Non-Lead
Investor may propose to transfer in a Proposed Transfer, at the same price and on the same terms
and conditions as those offered to the Prospective Transferee.

               (b) Notice. Each Common Holder and/or Non-Lead Investor proposing to make a Proposed
Transfer must deliver a Proposed Transfer Notice to the Company and each Investor not later than
forty-five (45) days prior to the consummation of such Proposed Transfer. Such Proposed Transfer
Notice shall contain the material terms and conditions (including price and form of consideration)
of the Proposed Transfer and the identity of the

-27-

 

Prospective Transferee. To exercise its Right of First Refusal under this Section 7,
the Company must deliver a Company Notice to the selling Common Holder or selling Non-Lead
Investor, as the case may be, within twenty (20) days after delivery of the Proposed Transfer
Notice. In the event of a conflict between this Agreement and any other agreement that may have
been entered into by a Common Holder with the Company that contains a preexisting right of first
refusal, the Company and the Common Holder acknowledge and agree that the terms of this Agreement
shall control and the preexisting right of first refusal shall be deemed satisfied by compliance
with Section 7.2(a) and this Section 7.2 (b).

               (c) Grant of Secondary Refusal Right to Investors. Subject to the terms of
Section 7.5 below, each Common Holder and Non-Lead Investor hereby unconditionally and
irrevocably grants to the Investors (other than a selling Non-Lead Investor) a Secondary Refusal
Right to purchase all or any portion of the Transfer Stock not purchased by the Company pursuant to
the Right of First Refusal, as provided in this Section 7.2(c). If the Company does not
intend to exercise its Right of Refusal with respect to all Transfer Stock subject to a Proposed
Transfer, the Company must deliver a Secondary Notice to the selling Common Holder or Non-Lead
Investor, as the case may be, and to each Investor to that effect no later than twenty (20) days
after the selling Common Holder or selling Non-Lead Investor delivers the Proposed Transfer Notice
to the Company. To exercise its Secondary Refusal Right, an Investor must deliver an Investor
Notice to the selling Common Holder or selling Non-Lead Investor, as the case may be, and the
Company within ten (10) days after the Company’s deadline for its delivery of the Secondary Notice
as provided in the preceding sentence.

               (d) Undersubscription of Transfer Stock. If options to purchase have been exercised
by the Company and the Investors with respect to some but not all of the Transfer Stock by the end
of the 10-day period specified in the last sentence of Section 7.2(c) (the “Investor Notice
Period”), then the Company shall, immediately after the expiration of the Investor Notice Period,
send written notice (the “Company Undersubscription Notice”) to those Investors who fully exercised
their Secondary Refusal Right within the Investor Notice Period (the “Exercising Investors”). Each
Exercising Investor shall, subject to the provisions of this Section 7.2(d), have an
additional option to purchase all or any part of the balance of any such remaining unsubscribed
shares of Transfer Stock on the terms and conditions set forth in the Proposed Transfer Notice. To
exercise such option, an Exercising Investor must deliver an Undersubscription Notice to the
selling Common Holder or selling Non-Lead Investor and the Company within ten (10) days after
receiving the Company Undersubscription Notice. In the event there are two or more such Exercising
Investors that choose to exercise the last-mentioned option for a total number of remaining shares
in excess of the number available, the remaining shares available for purchase under this
Section 7.2(d) shall be allocated to such Exercising Investors pro rata based on the number
of shares of Transfer Stock such Exercising Investors have elected to purchase pursuant to the
Secondary Refusal Right (without giving effect to any shares of Transfer Stock that any such
Exercising Investor has elected to purchase pursuant to the Company Undersubscription Notice). If
the options to purchase the remaining shares are exercised in full by the Exercising Investors, the
Company shall immediately notify all of the Exercising Investors and the selling Common Holder or
selling Non-Lead Investor, as applicable, of that fact.

-28-

 

               (e) Grant of Tertiary Refusal Right to Common Holders. If options to purchase have
been exercised by the Company and the Investors with respect to some but not all of the Transfer
Stock by the end of the 10-day period specified in Section 7.2(d) (the “Undersubscription
Notice Period”), then the Company shall, immediately after the expiration of the Undersubscription
Notice Period, send written notice (the “Common Holder Undersubscription Notice”) to each Common
Holder. Subject to the terms of Section 7.5 below, each Common Holder and Non-Lead
Investor hereby unconditionally and irrevocably grants to the Common Holders (other than a selling
Common Holder) a Tertiary Refusal Right to purchase all or any portion of the Transfer Stock not
purchased by the Company pursuant to the Right of First Refusal and not purchased by the Investors
pursuant to the Secondary Refusal Right or Section 7.2(d), as provided in this
Section 7.2(e). To exercise its Tertiary Refusal Right, a Common Holder must deliver a
Common Holder Notice to the selling Common Holder or selling Non-Lead Investor, as the case may be,
and the Company within ten (10) days after receiving the Common Holder Undersubscription Notice.
In the event there are two or more such Common Holders that choose to exercise the last-mentioned
option for a total number of remaining shares in excess of the number available, the remaining
shares available for purchase under this Section 7.2(e) shall be allocated to such Common
Holders pro rata based on the number of shares of Transfer Stock such Common Holders have elected
to purchase pursuant to the Tertiary Refusal Right (without giving effect to any shares of Transfer
Stock that any such Common Holder has elected to purchase pursuant to the Common Holder
Undersubscription Notice). If the options to purchase the remaining shares are exercised in full
by the Common Holders, the Company shall immediately notify all of the Common Holders and the
selling Common Holder or selling Non-Lead Investor, as applicable, of that fact.

               (f) Consideration; Closing. If the consideration proposed to be paid for the Transfer
Stock is in property, services or other non-cash consideration, the fair market value of the
consideration shall be as determined in good faith by the Company’s Board of Directors and as set
forth in the Company Notice. If the Company, any Investor or any Common Holder cannot for any
reason pay for the Transfer Stock in the same form of non-cash consideration, the Company, such
Investor or such Common Holder may pay the cash value equivalent thereof, as determined in good
faith by the Board of Directors and as set forth in the Company Notice. The closing of the
purchase of Transfer Stock by the Company, the Investors and the Common Holders, as applicable,
shall take place, and all payments from the Company, the Investors and the Common Holders, as
applicable, shall have been delivered to the selling Common Holder or selling Non-Lead Investor by
the later of (i) the date specified in the Proposed Transfer Notice as the intended date of the
Proposed Transfer and (ii) seventy (70) days after delivery of the Proposed Transfer Notice.

               (g) Application to Interest in Partnerships, LLCs, and Other Entities.
Notwithstanding anything to the contrary contained herein, in the event that a Common Holder is a
corporation, partnership, limited partnership, limited liability or other entity (a “Common Holder
Entity”), each such Common Holder Entity and RBM Investment (collectively, a “Covered Entity”)
hereby agrees that it shall not permit the assignment, sale, offer to sell, pledge, mortgage,
hypothecation, encumbrance, disposal of or completion of any other like transfer or encumbrance
(collectively, a “Transfer”), other than a repurchase by a Common Holder Entity of Interests in
such Common Holder Entity, of any partnership, LLC or like interest (an “Interest”) in such Covered
Entity to a third party (i.e. non shareholder, partner,

-29-

 

member or existing beneficial owner of such Covered Entity), but rather that it shall first
distribute any Transfer Stock held by such Covered Entity directly to such shareholder, partner,
member or other beneficial owner (collectively, the “Beneficial Owner”) and obtain such Beneficial
Owner’s written agreement to execute and be bound by the provisions of this Agreement, including
without limitation this Section 7 in order to ensure that the Transfer Stock will be
subject to the restrictions set forth herein and that the Beneficial Owner thereof shall not make
any Transfer of such Transfer Stock without first complying with the terms and conditions of this
Section 7. Each existing and future Covered Entity covenants and agrees to comply with the
terms and conditions of this Section 7 prior to making any Transfer of any Interest in such
Covered Entity to any third party. Transfers of an Interest in a Covered Entity by a Beneficial
Owner to another Beneficial Owner of the same Covered Entity shall be permissible so long as the
Company and Investors holding a majority of the outstanding shares of Series A-1 Preferred Stock
consent in writing to such Transfer or, with respect to Transfers not relating to the termination
of employment of a Beneficial Owner with the Company, such Transfers (i) do not exceed more than
15% (in the aggregate through one or more Transfers) of the total Interests in such Covered Entity,
and (ii) do not result in a change of control with respect to such Covered Entity such that the
Beneficial Owners holdings more than 50% of the voting Interests in such Covered Entity prior to
such Transfer hold less than 50% of the voting Interests in such Covered Entity following the
Transfer. For the avoidance of doubt, the term “Covered Entity” shall mean and include RBM
Holdings, RBM Management and RBM Investment.

          7.3 Right of Co-Sale.

               (a) Exercise of Right. If any Transfer Stock subject to a Proposed Transfer is not
purchased pursuant to Section 7.2 above and thereafter is to be sold to a Prospective
Transferee, each Investor (who is not a selling Non-Lead Investor in such Proposed Transfer) may
elect to exercise its Right of Co-Sale and participate on a pro rata basis in the Proposed Transfer
as set forth in Section 7.3(b) below and otherwise on the same terms and conditions
specified in the Proposed Transfer Notice (provided that if an Investor wishes to sell Preferred
Stock, the price set forth in the Proposed Transfer Notice shall be appropriately adjusted based on
the conversion ratio of the Preferred Stock into Common Stock). Each Investor who desires to
exercise its Right of Co-Sale, must give the selling Common Holder or selling Non-Lead Investor, as
applicable, written notice to that effect within twenty (20) days after the deadline for delivery
of the Secondary Notice described above, and upon giving such notice such Investor shall be deemed
to have effectively exercised the Right of Co-Sale.

               (b) Shares Includable. To the extent that an Investor (who is not a selling Non-Lead
Investor in such Proposed Transfer) timely exercises such Investor’s Right of Co-Sale by delivering
the written notice provided for above in Section 7.3(a), such Investor may include in the
Proposed Transfer all or any part of such Investor’s Capital Stock equal to the product obtained by
multiplying (i) the aggregate number of shares of Transfer Stock subject to the Proposed Transfer
(excluding shares purchased by the Company or the Investors pursuant to the Right of First Refusal
or the Secondary Refusal Right) by (ii) a fraction, the numerator of which is the number of shares
of Capital Stock owned by such Investor immediately before consummation of the Proposed Transfer
(including any shares that such Investor has agreed to purchase pursuant to the Secondary Refusal
Right) and the denominator of which is the total number of shares of Capital Stock owned, in the
aggregate, by all Investors (other than a selling

-30-

 

Non-Lead Investor in such Proposed Transaction, if applicable) immediately prior to the
consummation of the Proposed Transfer (including any shares that such Investor has agreed to
purchase pursuant to the Secondary Refusal Right), plus the number of shares of Transfer
Stock held by the selling Common Holder or selling Non-Lead Investor, as applicable. To the extent
one or more Investors exercise such right of participation in accordance with the terms and
conditions set forth herein, the number of shares of Transfer Stock that the selling Common Holder
or selling Non-Lead Investor, as applicable, may sell in the Proposed Transfer shall be
correspondingly reduced.

               (c) Delivery of Certificates. Each Investor shall effect its participation in the
Proposed Transfer by delivering to the transferring Common Holder or Non-Lead Investor, as
applicable, no later than ten (10) days after such Investor’s exercise of the Right of Co-Sale, one
or more stock certificates, properly endorsed for transfer to the Prospective Transferee,
representing:

                    (i) the number of shares of Common Stock that such Investor elects to include in the Proposed
Transfer; or

                    (ii) the number of shares of Preferred Stock that is at such time convertible into the number
of shares of Common Stock that such Investor elects to include in the Proposed Transfer;
provided, however, that if the Prospective Transferee objects to the delivery of
convertible Preferred Stock in lieu of Common Stock, such Investor shall first convert the
Preferred Stock into Common Stock and deliver Common Stock as provided above. The Company agrees
to make any such conversion concurrent with and contingent upon the actual transfer of such shares
to the Prospective Transferee.

               (d) Purchase Agreement. The parties hereby agree that the terms and conditions of any
sale pursuant to this Section 7.3 will be memorialized in, and governed by, a written
purchase and sale agreement with customary terms and provisions for such a transaction and the
parties further covenant and agree to enter into such an agreement as a condition precedent to any
sale or other transfer pursuant to this Section 7.3.

               (e) Deliveries. Each stock certificate an Investor delivers to the selling Common
Holder or selling Non-Lead Investor pursuant to Section 7.3(c) above will be transferred to
the Prospective Transferee against payment therefor in consummation of the sale of the Transfer
Stock pursuant to the terms and conditions specified in the Proposed Transfer Notice and the
purchase and sale agreement, and the selling Common Holder or selling Non-Lead Investor, as the
case may be, shall concurrently therewith remit or direct payment to each Investor the portion of
the sale proceeds to which such Investor is entitled by reason of its participation in such sale.
If any Prospective Transferee or Transferees refuse(s) to purchase securities subject to the Right
of Co-Sale from any Investor exercising its Right of Co-Sale hereunder, no Common Holder or
Non-Lead Investor may sell any Transfer Stock to such Prospective Transferee or Transferees unless
and until, simultaneously with such sale, such Common Holder or Non-Lead Investor purchases all
securities subject to the Right of Co-Sale from such Investor on the same terms and conditions
(including the proposed purchase price) as set forth in the Proposed Transfer Notice.

-31-

 

               (f) Additional Compliance. If any Proposed Transfer is not consummated within sixty
days (60) days after receipt of the Proposed Transfer Notice by the Company, the Common Holders or
Non-Lead Investors proposing the Proposed Transfer may not sell any Transfer Stock unless they
first comply in full with each provision of this Section 7. The exercise or election not
to exercise any right by an Investor hereunder shall not adversely affect its right to participate
in any other sales of Transfer Stock subject to this Section 7.3.

          7.4 Effect of Failure to Comply.

               (a) Transfer Void; Equitable Relief. Any Proposed Transfer not made in compliance
with the requirements of this Section 7 shall be null and void ab initio, shall not be
recorded on the books of the Company or its transfer agent and shall not be recognized by the
Company. Each party hereto acknowledges and agrees that any breach of this Section 7 would
result in substantial harm to the other parties hereto for which monetary damages alone could not
adequately compensate. Therefore, the parties hereto unconditionally and irrevocably agree that
any non-breaching party hereto shall be entitled to seek protective orders, injunctive relief and
other remedies available at law or in equity (including, without limitation, seeking specific
performance or the rescission of purchases, sales and other transfers of Transfer Stock not made in
strict compliance with this Section 7).

               (b) Violation of First Refusal Right. If any Common Holder or Non-Lead Investor
becomes obligated to sell any Transfer Stock to the Company, an Investor or a Common Stockholder
under this Section 7 and fails to deliver such Transfer Stock in accordance with the terms
of this Section 7, the Company, such Investor and/or such Common Holder may, at its option,
in addition to all other remedies it may have, send to such Common Holder or Non-Lead Investor the
purchase price for such Transfer Stock as is herein specified and transfer to the name of the
Company or such Investor (or request that the Company effect such transfer in the name of an
Investor) on the Company’s books the certificate or certificates representing the Transfer Stock to
be sold.

               (c) Violation of Co-Sale Right. If any Common Holder or Non-Lead Investor purports to
sell any Transfer Stock in contravention of the Right of Co-Sale (a “Prohibited Transfer”), each
Investor (other than a selling Non-Lead Investor in a Proposed Transfer), to the extent it desires
to exercise its Right of Co-Sale under Section 7.3 may, in addition to such remedies as may
be available by law, in equity or hereunder, require such Common Holder or Non-Lead Investor, as
applicable, to purchase from such Investor the type and number of shares of Capital Stock that such
Investor would have been entitled to sell to the Prospective Transferee under Section 7.3
had the Prohibited Transfer been effected pursuant to and in compliance with the terms of
Section 7.3. The sale will be made on the same terms and subject to the same conditions as
would have applied had the Common Holder or Non-Lead Investor, as applicable, not made the
Prohibited Transfer, except that the sale (including, without limitation, the delivery of the
purchase price) must be made within ninety (90) days after the Investor learns of the Prohibited
Transfer, as opposed to the timeframe proscribed in Section 7.3. Such Common Holder or
Non-Lead Investor shall also reimburse each Investor for any and all reasonable and documented
out-of-pocket fees and expenses, including reasonable legal fees and expenses, incurred pursuant to
the exercise or the attempted exercise of the Investor’s rights under Section 7.3.

-32-

 

          7.5 Exempt Transfers.

               (a) Exempted Transfers. Notwithstanding the foregoing or anything to the contrary
herein, the provisions of Sections 7.2 and 7.3 shall not apply: (i) to a repurchase
of Transfer Stock from a Common Holder by the Company at a price no greater than that originally
paid by such Common Holder for such Transfer Stock and pursuant to an agreement containing vesting
and/or repurchase provisions approved by a majority of the Board of Directors, (ii) in the case of
a Common Holder or Non-Lead Investor that is a natural person, upon a transfer of Transfer Stock by
such Common Holder or Non-Lead Investor made for bona fide estate planning purposes, either during
his or her lifetime or on death by will or intestacy to his or her spouse, child (natural or
adopted), or any other direct lineal descendant of such Common Holder or Non-Lead Investor (or his
or her spouse) (all of the foregoing collectively referred to as “family members”), or any other
relative approved by unanimous consent of the Board of Directors of the Company, or any custodian
or trustee of any trust, partnership or limited liability company for the benefit of, or the
ownership interests of which are owned wholly by, such Common Holder or Non-Lead Investor or any
such family members, or (iii) subject to compliance with the terms and conditions of Section
7.2(g), any transfer of Transfer Stock by a Common Holder or Non-Lead Investor to (A) any
Person who controls, is controlled by or is under common control with such Common Holder or
Non-Lead Investor, as applicable, (within the meaning of the Securities Act of 1933); (B) its
general or limited partners, members, stockholders or beneficiaries; or (C) to an entity owned or
organized for the benefit of the general or limited partners, members, stockholders, officers,
directors, employees or beneficiaries of such Common Holder or Non-Lead Investor; provided that in
the case of clause (ii) and (iii), the Common Holder and/or Non-Lead Investor shall deliver prior
written notice to the Investors of such gift or transfer and such shares of Transfer Stock shall at
all times remain subject to the terms and restrictions set forth in this Agreement and such
transferee shall, as a condition to such issuance, deliver a counterpart signature page to this
Agreement as confirmation that such transferee shall be bound by all the terms and conditions of
this Agreement as a Common Holder or Non-Lead Investor, as applicable, (but only with respect to
the securities so transferred to the transferee), including the obligations of a Common Holder or
Non-Lead Investor with respect to Proposed Transfers of such Transfer Stock pursuant to
Section 7; and provided, further, in the case of any transfer pursuant to clause (ii) and
(iii) above, that such transfer is made pursuant to a transaction in which there is no
consideration actually paid for such transfer.

               (b) Exempted Offerings. Notwithstanding the foregoing or anything to the contrary
herein, the provisions of Section 7 shall not apply to the sale of any Transfer Stock (i)
to the public in an offering pursuant to an effective registration statement under the Securities
Act of 1933, as amended (a “Public Offering”) or (ii) pursuant to a Deemed Liquidation Event (as
defined in the Company’s Certificate of Incorporation).

               (c) Prohibited Transferees. Notwithstanding the foregoing, no Common Holder or
Non-Lead Investor shall transfer any Transfer Stock to (a) any entity which, in the determination
of the Company’s Board of Directors, directly or indirectly competes with the Company or (b) any
customer, distributor or supplier of the Company, if the Company’s Board of Directors should
determine that such transfer would result in such customer, distributor

-33-

 

or supplier receiving information that would place the Company at a competitive disadvantage
with respect to such customer, distributor or supplier.

          7.6 Agreement to be Bound. Any successor or permitted assignee of any Common Holder
or Non-Lead Investor, including as noted above any Prospective Transferee who purchases shares of
Transfer Stock in accordance with the terms hereof, shall deliver to the Company and the Investors,
as a condition to any transfer or assignment, a counterpart signature page hereto pursuant to
which such successor or permitted assignee shall confirm their agreement to be subject to and bound
by all of the provisions set forth in this Agreement that were applicable to the predecessor or
assignor of such successor or permitted assignee.

          7.7 Stop Transfer Instructions. Each Common Holder and Non-Lead Investor agrees that
the Company may instruct its transfer agent to impose transfer restrictions on the shares held by
the Common Holders and Non-Lead Investors to enforce the provisions of this Section 7, and
the Company agrees to promptly do so.

          7.8 Termination of Covenants. The covenants set forth in this Section 7 shall
automatically terminate upon the earlier of (a) immediately prior to the consummation of a
Qualified Offering, as defined in Article Fourth, Part B, Section 4.3.1 of the Company’s
Certificate of Incorporation, as may be amended from time to time, and (b) the consummation of a
Deemed Liquidation Event (as defined in the Company’s Certificate of Incorporation).

          7.9 Ownership. Each Common Holder represents and warrants that such Common Holder is
the sole legal and beneficial owner of the shares of Transfer Stock subject to this Section
7 and that no other person or entity has any interest in such shares (other than a community
property interest as to which the holder thereof has acknowledged and agreed in writing to the
restrictions and obligations hereunder).

     8. Exercise of Guarantee for RBM Management Group, L.L.C. In the event that the
Company is required, under that certain letter agreement by and among the Company, RBM Management
Group, L.L.C (“RBM Management”), RBM Holdings LLC (“RBM Holdings”) and Dr. Manfred Schmolz dated on
or about September 24, 2007, as amended (the “Guarantee”), to issue any portion of the Put
Consideration (as such term is defined in the Put Right Letter Agreement) to Dr. Manfred Schmolz in
connection with his exercise of the Put Right under that certain letter agreement dated September
24, 2007 by and among the Company, RBM Management and Dr. Manfred Schmolz (the “Put Right Letter
Agreement”), then, contemporaneous with the payment of Put Consideration made by the Company under
the Guarantee (a) the Company shall make an additional payment in the aggregate amount of $423,100
to the Investors (“Investors Payment”), to be allocated among such Investors on a pro rata basis
based on the number of shares of Series A-1 Preferred Stock held by each such Investor; and (b) RBM
Management shall transfer, sell and assign 239,500 shares of Common Stock of the Company (the
“Forfeited Shares”) to the Company, together with a stock certificates representing the Forfeited
Shares, for cancellation as payment for the Company’s satisfaction of the payment of such Put
Consideration pursuant to the Guarantee; provided, however, that such Investors Payment and the
number of Forfeited Shares shall be reduced pro rata in proportion to the portion of such Put
Consideration that the Company is not required to issue. The payment by the Company of the Put
Consideration shall be effective to automatically

-34-

 

transfer the Forfeited Shares to the Company without any action required of RBM Management or
any other party and RBM Management shall have no further right, title or interest in such Forfeited
Shares. Notwithstanding the foregoing, RBM Management agrees to execute any instruments or
documents reasonably requested by the Company in order to further effectuate the transfer of the
Forfeited Shares to the Company; provided, however, the Company shall be entitled to recognize the
transfer of the Forfeited Shares in its records without any action of any other party, including
RBM Management. Without limiting the generality of the foregoing, RBM Management hereby appoints
the Company its attorney-in-fact to execute on its behalf any instruments or documents necessary to
effectuate the transfer of the Forfeited Shares to the Company. Upon payment of the Put
Consideration by the Company, the Company shall promptly cancel the Forfeited Shares.

     9. Miscellaneous.

          9.1 Legends. Each certificate evidencing any of the Shares shall bear a legend
substantially as follows:

     “THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A
CERTAIN INVESTORS’ RIGHTS AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, AND MAY NOT BE SOLD,
TRANSFERRED, ENCUMBERED OR VOTED EXCEPT IN ACCORDANCE WITH THE TERMS AND PROVISIONS OF SAID
AGREEMENT, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL EXECUTIVE OFFICE OF THE COMPANY AND WILL BE
FURNISHED TO THE HOLDER OF THIS CERTIFICATE UPON REQUEST AND WITHOUT CHARGE.”

Each Stockholder agrees that the Company may instruct its transfer agent to impose transfer
restrictions on the shares represented by certificates bearing the legend referred to in this
Section 9.1 above to enforce the provisions of this Agreement, and the Company agrees to
promptly do so. The legend shall be removed upon termination of this Agreement at the request of
the holder.

          9.2 Successors and Assigns. The rights under this Agreement may be assigned (but only
with all related obligations) by an Investor to a transferee of Capital Stock that (i) is an
Affiliate of such Investor; (ii) is a direct or indirect partner, limited partner or retired
partner of such Investor, (iii) is a direct or indirect member or retired member of such Investor,
(iv) is a spouse, bona fide domestic partner, sibling, lineal descendant or ancestor of any of the
Persons identified in clause (i), (ii) and (iii), (v) is an affiliated venture capital fund or
investment fund; provided, however, that (x) the Company is, within a reasonable
time after such transfer, furnished with written notice of the name and address of such transferee
and the Capital Stock with respect to which such rights are being transferred; and (y) such
transferee agrees in a written instrument delivered to the Company to be bound by and subject to
the terms and conditions of this Agreement, including the provisions of Section 2.11. The
terms and conditions of this Agreement inure to the benefit of and are binding upon the respective
successors and permitted assignees of the parties. Nothing in this Agreement, express or implied,
is intended to confer upon any party other than the parties hereto or their respective successors
and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this
Agreement, except as expressly provided herein.

-35-

 

          9.3 Governing Law. This Agreement shall be governed by, and construed in accordance
with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under
applicable principles of conflicts of law.

          9.4 Counterparts; Facsimile. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument. This Agreement may also be executed and delivered by facsimile
signature and in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument.

          9.5 Titles and Subtitles. The titles and subtitles used in this Agreement are for
convenience only and are not to be considered in construing or interpreting this Agreement.

          9.6 Notices. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual
receipt or: (i) personal delivery to the party to be notified; (ii) when sent, if sent by
electronic mail or facsimile during the recipient’s normal business hours, and if not sent during
normal business hours, then on the recipient’s next business day; (iii) five (5) days after having
been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one
(1) business day after the business day of deposit with a nationally recognized overnight courier,
freight prepaid, specifying next-day delivery, with written verification of receipt. All
communications shall be sent to the respective parties at their addresses as set forth on the
signature pages hereto, or to the principal office of the Company and to the attention of the Chief
Executive Officer, in the case of the Company, or to such email address, facsimile number, or
address as subsequently modified by written notice given in accordance with this
Section 9.6. If notice is given to the Company, a copy shall also be given to Vinson &
Elkins L.L.P., Attention: J. Nixon Fox, III, 2801 Via Fortuna, Suite 100, Austin, Texas 78746;
Facsimile: (512) 236-3216. If notice is given to EGI Fund (08-10) Investors, L.L.C., a copy shall
also be given to Perkins Coie LLP, Attention: James Cruger, 131 South Dearborn Street, Suite 1700,
Chicago, Illinois 60603-5559; Facsimile: (312) 324-9400.

          9.7 Amendments and Waivers. Any term of this Agreement may be amended and the
observance of any term of this Agreement may be waived (either generally or in a particular
instance, and either retroactively or prospectively) only with the written consent of the Company,
a Majority in Interest of the Investors and the holders of a majority of the Common Stock;
provided that any provision hereof may be waived by any waiving party on such party’s own
behalf, without the consent of any other party; provided further that any amendment to
Section 2.11 shall require the written consent of Cross Creek Capital, L.P. except to the
extent such amendment is required by an underwriter. The Company shall give prompt notice of any
amendment or termination hereof or waiver hereunder to any party hereto that did not consent in
writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected
in accordance with this Section 9.7 shall be binding on all parties hereto, regardless of
whether any such party has consented thereto. No waivers of or exceptions to any term, condition,
or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as
a further or continuing waiver of any such term, condition, or provision.

-36-

 

          9.8 Severability. In case any one or more of the provisions contained in this
Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such
invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement,
and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it
will be valid, legal, and enforceable to the maximum extent permitted by law.

          9.9 Aggregation of Stock. All shares of Capital Stock held or acquired by Affiliates
shall be aggregated together for the purpose of determining the availability of any rights under
this Agreement and such Affiliated persons may apportion such rights as among themselves in any
manner they deem appropriate.

          9.10 Entire Agreement. This Agreement (including any Schedules and Exhibits hereto)
constitutes the full and entire understanding and agreement among the parties with respect to the
subject matter hereof, and any other written or oral agreement relating to the subject matter
hereof existing between the parties is expressly canceled.

          9.11 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally
submit to the jurisdiction of the federal and state courts located within the geographic boundaries
of the United States District Court for the Northern District of Illinois for the purpose of any
suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to
commence any suit, action or other proceeding arising out of or based upon this Agreement except in
the federal and state courts located within the geographic boundaries of the United States District
Court for the Northern District of Illinois, and (c) hereby waive, and agree not to assert, by way
of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is
not subject personally to the jurisdiction of the above-named courts, that its property is exempt
or immune from attachment or execution, that the suit, action or proceeding is brought in an
inconvenient forum, that the venue of the suit, action or proceeding is improper or that this
Agreement or the subject matter hereof may not be enforced in or by such court.

          9.12 Specific Performance. In addition to any and all other remedies that may be
available at law in the event of any breach of this Agreement, each Investor shall be entitled to
specific performance of the agreements and obligations of the Company and the Common Holders under
Sections 6 and 7 and to such other injunction or other equitable relief as may be
granted by a court of competent jurisdiction.

          9.13 Delays or Omissions. No delay or omission to exercise any right, power, or
remedy accruing to any party under this Agreement, upon any breach or default of any other party
under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or
nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach
or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any
single breach or default be deemed a waiver of any other breach or default theretofore or
thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded
to any party, shall be cumulative and not alternative.

          9.14 Acknowledgment. The Company acknowledges that the Investors are in the business
of venture capital investing and therefore review the business plans and related proprietary
information of many enterprises, including enterprises which may have products or

-37-

 

services which compete directly or indirectly with those of the Company. Nothing in this
Agreement shall preclude or in any way restrict the Investors from investing or participating in
any particular enterprise whether or not such enterprise has products or services which compete
with those of the Company. No Investor shall be liable to the Company or to any other Investor for
any claim arising out of, or based upon, (i) the investment by Investor in any entity competitive
to the Company, or (ii) actions taken by any partner, officer or other representative of any
Investor to assist any such competitive company, whether or not such action was taken as a board
member of such competitive company, or otherwise, and whether or not such action has a detrimental
effect on the Company.

          9.15 Additional Parties. In the event that after the date of this Agreement, the
Company issues shares of Common Stock, or options, warrants or other instruments that are
convertible into or exercisable for Common Stock, to any Person (including without limitation, any
employee or consultant of the Company), the Company shall, as a condition to such issuance, cause
such Person to execute a counterpart signature page hereto as a Common Holder, and such Person
shall thereby be bound by, and subject to, all the terms and provisions of this Agreement
applicable to a Common Holder, as applicable.

          9.16 Stock Split. All references to numbers of shares in this Agreement shall be
appropriately adjusted to reflect any stock dividend, split, combination or other recapitalization
affecting the Capital Stock (as defined in Section 7) occurring after the date of this
Agreement.

          9.17 Liquidation Examples. The parties agree that the liquidation examples set forth
on Exhibit C attached hereto shall evidence the understanding of the parties hereto with
respect to the operation of the provisions set forth in Article Fourth, Part B, Sections 2.1, 2.2,
2.3, 4.3 and 4.4 of the Restated Certificate. These liquidation examples are provided solely for
the purpose of providing examples in the liquidation context and are based on a particular set of
assumptions which may or may not ultimately be applicable in an actual liquidation. Accordingly,
the outcomes under an actual liquidation can and likely will vary from the examples set forth
therein.

[Remainder of Page Intentionally Left Blank]

-38-

 

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above.

	 	 	 	 	 
	 	 	RULES-BASED MEDICINE, INC.
	 
	 	 	 	 
	 

	 	By:	 	/s/  T. Craig Benson 
	 

	 	 	 	 
	 	 	Name: T. Craig Benson
	 	 	Title: President and Chief Executive Officer

Signature Page to

Investors’ Rights Agreement

 

 

	 	 	 	 	 
	 	 	INVESTORS:
	 
	 	 	 	 
	 	 	EGI-FUND (08-10) INVESTORS, L.L.C.
	 
	 	 	 	 
	 

	 	By:	 	/s/ Phillip Tinkler 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	Name:	 	Phillip Tinkler 
	 

	 	 	 	 
	 

	 	 	 	(print)
	 
	 	 	 	 
	 

	 	Title:	 	Vice President 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	Address:
	 	Two North Riverside Plaza, Suite 600
	 
	 	 	 	 
	 

	 	 	 	Chicago, Illinois 60606

Signature Page to

Investors’ Rights Agreement

 

 

	 	 	 	 	 
	 	 	INVESTORS (cont’d):
	 
	 	 	 	 
	 	 	CROSS CREEK CAPITAL, L.P.
	 
	 	 	 	 
	 

	 	By:
	 	Cross Creek Capital GP, L.P., its Sole
	 

	 	 	 	General Partner
	 
	 	 	 	 
	 

	 	By:
	 	Cross Creek Capital, LLC, its Sole
	 

	 	 	 	General Partner
	 
	 	 	 	 
	 

	 	By:
	 	Wasatch Advisors, Inc., its Sole
	 

	 	 	 	Member
	 
	 	 	 	 
	 

	 	By:	 	/s/  Daniel Thurber 
	 

	 	 	 	 
	 	 	Name: Daniel Thurber
	 	 	Title: Vice President
	 
	 	 	 	 
	 	 	Address: 150 Social Hall Avenue, 4th Floor
	 
	 	 	 	 
	 

	 	 	 	Salt Lake City, Utah 84111
	 
	 	 	 	 
	 	 	CROSS CREEK CAPITAL EMPLOYEES FUND, L.P.
	 
	 	 	 	 
	 

	 	By:
	 	Cross Creek Capital GP, L.P., its Sole
	 

	 	 	 	General Partner
	 
	 	 	 	 
	 

	 	By:
	 	Cross Creek Capital, LLC, its Sole
	 

	 	 	 	General Partner
	 
	 	 	 	 
	 

	 	By:
	 	Wasatch Advisors, Inc., its Sole
	 

	 	 	 	Member
	 
	 	 	 	 
	 

	 	By:	 	/s/ Daniel Thurber 
	 

	 	 	 	 
	 	 	Name: Daniel Thurber
	 	 	Title: Vice President
	 
	 	 	 	 
	 

	 	Address:
	 	 150 Social Hall Avenue, 4th Floor
	 
	 	 	 	 
	 

	 	 	 	Salt Lake City, Utah 84111

Signature Page to

Investors’ Rights Agreement

 

 

	 	 	 	 	 
	 	 	INVESTORS (cont’d):
	 
	 	 	 	 
	 	 	RBM INVESTMENT LLC
	 
	 	 	 	 
	 

	 	By:
	 	Stephens Capital Partners LLC, its manager
	 
	 	 	 	 
	 

	 	By:	 	/s/ Jackson Farrow, Jr. 
	 

	 	 	 	 
	 	 	Name: Jackson Farrow, Jr.
	 	 	Title: Managing Director
	 
	 	 	 	 
	 	 	Address: 111 Center Street, Suite 2500
	 
	 	 	 	 
	 

	 	 	 	        Little Rock, Arkansas 72201

Signature Page to

Investors’ Rights Agreement

 

 

	 	 	 	 	 
	 	 	COMMON HOLDERS:
	 
	 	 	 	 
	 	 	RBM HOLDINGS LLC
	 
	 	 	 	 
	 

	 	By:	 	/s/  Mark Chandler 
	 

	 	 	 	 
	 	 	Name: Mark Chandler, Ph.D.
	 	 	Title: Manager
	 
	 	 	 	 
	 	 	RBM MANAGEMENT GROUP LLC
	 
	 	 	 	 
	 

	 	By:	 	/s/ Mark Chandler 
	 

	 	 	 	 
	 	 	Name: Mark Chandler, Ph.D.
	 	 	Title: Manager

Signature Page to

Investors’ Rights Agreement

 

 

SCHEDULE A

SCHEDULE OF INVESTORS

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	Number of	 	 	 	 
	 	 	 	 	Shares of Series	 	Price per	 	Total Purchase
	Name	 	Address	 	A-1 Preferred	 	Share	 	Price
	 
	EGI-Fund (08-10)Investors, L.L.C.
	 	Two North Riverside Plaza,	 	 	6,437,299	 	 	$	3.339910285	 	 	$	21,500,001.14	 
	 
	 	Suite 600 Chicago, Illinois  60606	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Attn:  Joseph M. Paolucci	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	         Chief Legal Officer	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Cross Creek Capital, L.P.
	 	150 Social Hall Avenue, 4th Floor	 	 	545,235	 	 	$	3.339910285	 	 	$	1,821,035.98	 
	 
	 	Salt Lake City, Utah  84111	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Cross Creek Capital
	 	150 Social Hall Avenue, 4th Floor	 	 	53,583	 	 	$	3.339910285	 	 	$	178,962.41	 
	Employees Fund, L.P.
	 	Salt Lake City, Utah  84111	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	RBM Investment LLC
	 	111 Center Street, Suite 2500	 	 	449,114	 	 	$	3.339910285	 	 	$	1,500,000.47	 
	 
	 	Little Rock, Arkansas  72201	 	 	 	 	 	 	 	 	 	 	 	 
	 
	TOTAL
	 	 	 	 	7,485,231	 	 	 	 	 	 	$	25,000,000.00	 

 

 

SCHEDULE B

COMMON HOLDERS

RBM Holdings, LLC

3300 Duval Road

Austin, TX 78759

Phone: 512-835-8026

Fax: 512-835-4687

Email: cbenson@rbmmaps.com

RBM Management Group, LLC

3300 Duval Road

Austin, TX 78759

Phone: 512-835-8026

Fax: 512-835-4687

Email: cbenson@rbmmaps.com

 

 

SCHEDULE B-1

COMMON HOLDERS WITH RIGHTS UNDER SECTION 4

RBM Holdings, LLC

3300 Duval Road

Austin, TX 78759

Phone: 512-835-8026

Fax: 512-835-4687

Email: cbenson@rbmmaps.com

RBM Management Group, LLC

3300 Duval Road

Austin, TX 78759

Phone: 512-835-8026

Fax: 512-835-4687

Email: cbenson@rbmmaps.com

 

 

EXHIBIT A

CONFIDENTIAL INFORMATION, INVENTION ASSIGNMENT

AND NON-COMPETITION AGREEMENT

[See Attached]

 

 

RULES-BASED MEDICINE, INC.

CONFIDENTIAL INFORMATION, INVENTION

ASSIGNMENT AND NON-COMPETITION AGREEMENT

     As a condition of my commencing my relationship, as an employee, consultant, independent
contractor or otherwise (or my employment or other relationship being continued, as applicable),
with Rules-Based Medicine, Inc., a Delaware corporation, or any of its present or future
subsidiaries, parent companies, affiliates, successors or assigns (collectively, the “Company”),
and in consideration of (i) my relationship as an employee, independent contractor, consultant or
otherwise of the Company, (ii) my receipt of an ownership interest in RBM Management Group, LLC
(“RBM Management Interest”), a Delaware limited liability company owning stock of the Company, and
(iii) the compensation now and hereafter paid to me by Company (the receipt and sufficiency of
which is hereby acknowledged), I agree to the following:

     1. Employment, Consulting or Other Relationship. I understand and acknowledge that
this Confidential Information, Invention Assignment and Non-Competition Agreement (this
“Agreement”) does not expand upon any rights I may have to continue in the employ of, or in a
consulting or other relationship with, or the duration of my relationship with the Company as an
employee, independent contractor, consultant or otherwise, under any other agreements between the
Company and me or under applicable law. (Any employment or other relationship between the Company
and me, whether commenced prior to or upon the date of this Agreement, shall be referred to herein
as the “Relationship.”)

     2. Agreement Regarding RBM Management Interest. Upon receipt of my RBM Management
Interest, I agree to execute and deliver to the Company an agreement setting forth the terms and
restrictions applicable to my RBM Management Interest, and any further agreement requested by the
Company from time to time related to my RBM Management Interest.

     3. At-Will Relationship. I understand and acknowledge that my Relationship with the
Company constitutes an at-will relationship under applicable law, meaning that either I or the
Company may terminate the Relationship at any time, with or without good cause or for any or no
cause, with or without prior notice. This Agreement shall supersede and does hereby terminate any
Employment Agreement, Consulting Agreement or similar agreement between me and Luminex Corporation,
notwithstanding the assumption of any such agreement by the Company; provided, however, that any
confidentiality, non-solicitation or non-competition provision in any such agreement, not
inconsistent with the provisions of this Agreement, shall survive the termination of such agreement
hereunder.

     4. Confidential Information.

     (a) Company Information. The Company agrees, in consideration for my agreement
to the various terms of this Agreement, to provide me with Confidential Customer
Information belonging to the Company as well as names of the Company’s

1

 

customers. I agree at all times, during the term of the Relationship and thereafter, to hold in
strictest confidence, and not to use, except for the benefit of the Company, or to disclose to any
person, firm, corporation or other entity without written authorization of the President of the
Company or such other person as appointed by the President of the Company, any Confidential
Information of the Company. I further agree not to make copies of such Confidential Information
except as authorized in writing by the Company or required for the performance of my
responsibilities under the Relationship. Any such copies made pursuant to the preceding sentence
shall be available to, and shall remain the sole property of, the Company at all times. I
understand that “Confidential Information” means any Company proprietary information, technical
data, trade secrets or know-how, including, but not limited to, (i) information derived from
reports, investigations, experiments, research and work in progress, (ii) methods of operation,
(iii) market data, (iv) technology, hardware, proprietary computer programs and code (in object
code and source code format), (v) drawings, designs, plans and proposals, (vi) marketing and sales
programs, (vii) customer, licensee and supplier lists and any other information about the Company’s
relationships with others, (viii) historical financial information and financial projections, (ix)
network and system architecture, (x) all other formulate, patterns, devices or compilations,
concepts, ideas, materials and information prepared or performed for or by the Company, (xi) all
information related to the business plan, business, products, purchases or sales of the Company or
any of its suppliers and customers, other than information that is publicly available, (xii)
software or applications of software, developments, inventions, models, samples, flowcharts,
statistical data and compilations, (xiii) computer programs, disks, diskettes, tapes, and (xiv) all
other proprietary information disclosed to me by the Company either directly or indirectly in
writing, orally or by drawings or observation, or created by me during the period of the
Relationship, using Company time and/or materials or equipment. I understand that Confidential
Information includes, but is not limited to, information pertaining to any aspects of the Company’s
business which is either information not known by actual or potential competitors of the Company,
or proprietary information of the Company or its customers or suppliers or other third parties with
which it has business relationships, whether of a technical or financial nature, or otherwise. I
further understand that Confidential Information does not include any of the foregoing items which
shall become publicly known and made generally available through no wrongful act of mine or of
others who were under confidentiality obligations as to the item or items involved.

     (b) Former Employer Information. I represent and warrant that my performance of this
Agreement or the Relationship has not breached, and will not breach, any agreement or trust
relationship between myself and any former, concurrent, or subsequent employer or other third
party (collectively, “Other Party”), including, without limitation, any agreement with respect to
such Other Party’s inventions, unpublished documents or confidential or proprietary information. I
agree that I will not disclose to the Company, bring on the Company’s premises, or induce the
Company to use any Other Party’s inventions, unpublished documents, or confidential or proprietary
information without such Other Party’s prior written consent, a copy of which I also shall provide
to the Company.

2

 

     (c) Third Party Information. I recognize that the Company has received and in the
future will receive from third parties their confidential or proprietary information subject to a
duty on the Company’s part to maintain the confidentiality of such information and to use it only
for certain limited purposes. I agree to hold all such confidential or proprietary information in
the strictest confidence and not to disclose it to any person, firm or corporation or to use it
except as necessary in carrying out my work for the Company consistent with the terms of this
Agreement.

     5. Inventions.

     (a) Inventions Retained and Licensed. I have attached hereto, as Exhibit A a list
describing all ideas, discoveries, inventions, original works of authorship, developments,
designs, work products, innovations, concepts, know-how, and trade secrets which were made by me
prior to my Relationship with the Company (collectively referred to as “Prior Inventions”), which
belong to me, which relate to the Company’s current or proposed business, products or research and
development, whether or not specifically within my duties or responsibilities with the Company,
whether or not patentable or registrable under copyright or similar laws and whether or not
reduced to writing, and which are not assigned to the Company hereunder; or, if no such list is
attached, I represent that there are no such Prior Inventions. If, in the course of my
Relationship with the Company, I incorporate into a Company product, process, program, software or
machine a Prior Invention owned by me or in which I have an interest, the Company is hereby
granted and shall have a nonexclusive, royalty-free, transferable, irrevocable, perpetual,
worldwide license to make, have made, modify, use, reproduce, distribute, create derivative works
from, publicly perform, publicly display and sell such Prior Invention as part of, or in
connection with such product, process, program, software, work or machine. I agree that I will
not, without the prior approval of the Company, incorporate in any Company product, process,
program, software, work or machine any photographs, video or film, music, computer programs or
other materials obtained from a third party (via the Internet or otherwise) for which the Company
has not been granted an express license for such incorporation.

     (b)
Assignment of Inventions. I agree that I will promptly make full written
disclosure to the Company of any and all ideas, discoveries, inventions, original works of
authorship, developments, designs, work products, innovations, concepts, know-how, and trade
secrets which relate to the Company’s current or proposed business, products or research and
development, whether or not specifically within my duties or responsibilities with the Company and
whether or not patentable or registrable under copyright or similar laws and whether or not reduced
to writing, which I may solely or jointly conceive or develop or reduce to practice, or cause to be
conceived or developed or reduced to practice, during the period of time I have a Relationship with
the Company, whether or not during working hours or by the use of the facilities of the Company
(collectively referred to as “Inventions”). I further agree that I will hold in trust for the sole
right and benefit of the Company, and hereby assign to the Company, or its designee, all my right,
title, and interest in and to any and all such Inventions which I may solely or jointly conceive or
develop or reduce to practice, or cause to be conceived or developed or reduced to practice, using
the Company’s time and/or materials or equipment. I further

3

 

acknowledge that all of the above-described Inventions made during the period of my Relationship
with the Company are “works made for hire”, as that term is defined in the United States Copyright
Act, to the greatest extent permitted by applicable law, and are compensated by my salary (if I am
an employee) or by such other amount paid to me under any applicable consulting, independent
contractor or other agreement or arrangement (if I am not an employee). All Inventions or other
work product created by me or on my behalf or by my affiliates pursuant to this Agreement shall be
free and clear of all encumbrances, including without limitation, security interest(s), licenses,
liens or other restrictions other than as expressly provided for in this Agreement. I hereby
appoint the Company as my attorney-in-fact to execute on my behalf any assignments or other
documents deemed necessary by the Company to protect or perfect its rights to any Inventions.

     (c)
Inventions Assigned to the United States. I agree to assign to the United States
government all my right, title, and interest in and to any and all Inventions whenever such full
title is required to be in the United States by a contract between the Company and the United
States or any of its agencies.

     (d)
Maintenance of Records. I agree to create and maintain adequate and current
written records of all Inventions made by me (solely or jointly with others), and assigned to the
Company under Section 5(b) above, during the term of my Relationship with the Company. The records
will be in the form of notes, sketches, drawings, and any other format that may be specified by
the Company. The records will be available to and remain the sole property of the Company at all
times. I agree not to remove such records from the Company’s place of business except as expressly
permitted by the Company policy, which may, from time to time, be revised at the sole discretion
of the Company.

     (e)
Patent and Copyright Registrations. I agree to reasonably assist the Company, or
its designee, at the Company’s expense, in every proper way to secure the Company’s rights in the
Inventions and any copyrights, patents, mask work rights, moral rights, or other intellectual
property rights relating thereto in any and all countries, including the disclosure to the Company
of all pertinent information and data with respect thereto, the execution of all applications,
specifications, oaths, assignments and all other instruments which the Company shall reasonably
deem necessary in order to apply for and obtain such rights and in order to assign and convey to
the Company, its successors, assigns, and nominees the sole and exclusive rights, title and
interest in and to such Inventions, and any copyrights, patents, mask work rights, moral rights or
other intellectual property rights relating thereto. I further agree that my obligation to execute
or cause to be executed, when it is in my power to do so, any such instrument or papers shall
continue after the termination of this Agreement. If the Company is unable because of my mental or
physical incapacity, unavailability, or for any other reason to secure my signature to apply for or
to pursue any application for any United States or foreign patents or copyright registrations
covering Inventions or original works of authorship assigned to the Company as above, then I hereby
irrevocably designate and appoint the Company and its duly authorized officers and agents as my
agent and attorney in fact, to act for and in my behalf and stead to execute and file any such
applications and to do all other lawfully permitted acts to further the prosecution and issuance of
letters patent,

4

 

copyright registrations or enforcement of other intellectual property rights thereon with
the same legal force and effect as if executed by me.

     6. Conflicting
Employment. I agree that, during the term of my Relationship with the
Company, I will not engage in any other employment, occupation, consulting or other business
activity directly related to the business in which the Company is now involved or becomes involved
during the term of the Relationship, nor will I engage in any other activities that conflict with
my obligations to the Company.

     7. Returning
Company Documents. I agree that, at the time of termination of my
Relationship with the Company, I will deliver to the Company (and will not keep in my possession,
copy, reproduce, recreate or deliver to anyone else) any and all devices, records, data, notes,
reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches,
materials, equipment, other documents or property, or reproductions of any of the aforementioned
items developed by me pursuant to my Relationship with the Company or otherwise belonging to the
Company, its successors or assigns. I further agree that any property situated on the Company’s
premises or on the Company’s computers or servers, including disks and other storage media, email,
and filing cabinets and other work areas, is subject to inspection by Company personnel at any
time with or without notice. In the event of the termination of the Relationship, I agree to sign
and deliver the “Termination Certification” attached hereto as Exhibit B.

     8. Notification
of New Employer. Upon termination of my Relationship with the
Company, I hereby grant consent to notification by the Company to my new employer or any other
party with which I may enter into a new relationship with respect to my obligations under this
Agreement.

     9. Certain
Covenants.

     (a)
Solicitation of Employees, Consultants and Customers. 
In consideration of the Company’s obligations under this Agreement and the other consideration recited
above, I agree that during the Relationship and for a period of twenty-four (24) months immediately
following the termination of my Relationship with the Company, whether with or without cause, I
shall not, either directly or indirectly, either alone or in concert with others, solicit, induce,
recruit, encourage or entice, or attempt to solicit, induce, recruit, encourage or entice, any
employee of or consultant to the Company to leave the Company or work for anyone in competition
with the Company. Also, during the Relationship and for a period of twenty-four (24) months
immediately following the termination of my Relationship with the Company, I will not directly or
indirectly, either for myself or for any other person, firm or corporation, divert or take away or
attempt to divert or take away, call on or solicit or attempt to call on or solicit, any licensee
or customer of the Company, including but not limited to those on whom I called or whom I solicited
or with whom I became acquainted while engaged as an employee of or a consultant to the Company’s
business. During the Relationship, I agree not to plan or otherwise take any steps, preliminary or
otherwise, either alone or in concert with others, to set up or engage in any business enterprise
that would be in competition with the Company. In the event of the termination of the Relationship,
I will not accept or engage in any activities, where the loyal and complete fulfillment of the
duties of the activities would inherently call upon me to

5

 

reveal Confidential Information to which I have access or of which I have learned during or as a
result of the Relationship.

     (b) Noncompetition.

     (i) I agree that for the term of the Relationship and for a period of twelve
(12) months thereafter I will not, directly or indirectly, engage or invest in,
own, manage, operate, finance, control, or participate in the ownership,
management, operation, financing, or control of, be employed by, associated with,
or in any manner connected with, or render services or advice to, any business
similar to or competitive with the business of the Company (“RBM Business”),
anywhere in North America or in any other geographical area in or with respect to
which I have any duties or responsibilities during the Relationship.

     (ii) Notwithstanding the provisions of this Section 9, my non-competition
obligations hereunder shall not preclude me from owning less than one percent (1%)
of any class of securities of any enterprise conducting business in the RBM
Business (but without otherwise participating in the activities of such enterprise)
if such securities are listed on any national or regional securities exchange or
have been registered under Section 12(g) of the Securities Exchange Act of 1934.

     (iii) I agree that the time periods and the geographic scope within this
Section 9 are reasonable in order for the Company to be protected from unfair
competition, and are ancillary to and designed to ensure my compliance with the
confidentiality provisions of this Agreement. I specifically recognize and
acknowledge that the work of the Company is so specialized and unique that only
such geographic scope can protect the Company from unfair competition.

     (c) Breach. In the event of my breach of any covenant set forth in this Section
9, the term of such covenant will be extended by the period of the duration of such breach.

     (d) Severability. If at any time the provisions of this Section 9 are
determined to be invalid or unenforceable by reason of being vague or unreasonable as to
area, duration or scope of activity, this Section 9 shall be considered divisible and shall
be immediately amended to only such area, duration or scope of activity as shall be
determined to be reasonable and enforceable by the court or other body having jurisdiction
over the matter; and I agree that this Section 9 as so amended shall be valid and binding
as though any invalid or unenforceable provision had not been included herein.

     10. Conflict of Interest Guidelines. I agree to diligently adhere to the Conflict of
Interest Guidelines attached as Exhibit C hereto.

6

 

     11. Representations. I agree to execute any proper oath or verify any proper document
required to carry out the terms of this Agreement. I have not entered into, and I agree I will not
enter into, any oral or written agreement in conflict herewith.

     12. General Provisions.

     (a) Governing Law; Consent to Personal Jurisdiction. This Agreement will be
governed by the laws of the State of Texas. I hereby expressly consent to the personal
jurisdiction of the state and federal courts located in Texas for any lawsuit filed there
against me by the Company arising from or relating to this Agreement.

     (b) Entire Agreement. This Agreement sets forth the entire agreement and
understanding between the Company and me relating to the subject matter herein and merges
all prior discussions between us. No modification of or amendment to this Agreement, nor
any waiver of any rights under this Agreement, will be effective unless in writing signed
by the party to be charged. Any subsequent change or changes in my duties, salary or other
compensation will not affect the validity or scope of this Agreement.

     (c) Severability. If one or more of the provisions in this Agreement are
deemed void by law, then the remaining provisions will continue in full force and effect.

     (d) Successors and Assigns. This Agreement will be binding upon my heirs,
executors, administrators and other legal representatives and will be for the benefit of
the Company, its successors, and its assigns.

     (e) Survival. The provisions of this Agreement shall survive the termination
of the Relationship and the assignment of this Agreement by the Company to any successor in
interest or other assignee.

     (f) Supervised Employees. I agree to cause any employee engaged by me, or
otherwise introduced to the Company by me, to agree to be bound by the terms of this
Agreement, as if the terms of this Agreement applied directly to such employee, unless
such employee executes an agreement directly with the Company substantially similar to
this Agreement.

     (g) ADVICE OF COUNSEL. I ACKNOWLEDGE THAT, IN EXECUTING THIS AGREEMENT, I
HAVE HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND I HAVE READ
AND UNDERSTAND ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. I HEREBY REPRESENT THAT
I EITHER HAVE SOUGHT INDEPENDENT LEGAL COUNSEL OR HAVE ELECTED FREELY NOT TO DO SO. THIS
AGREEMENT SHALL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR
PREPARATION HEREOF.

7

 

Date:                                         

	 	 	 	 	 
	 
	 

	 	 	 	 
	 

	 	Signature
	 	 
	 
	 	 	 	 
	 
	 

	 	 	 	 
	 

	 	Name of Individual (typed or printed)	 	 

	 	 	 	 	 
	Acknowledged and agreed: 

RULES-BASED MEDICINE, INC.

 	 	 
	By:  	 	 	 
	 	Name:  	Patrick S. McClain  	 	 
	 	Title:  	Chief Financial Officer 	 	 

8

 

EXHIBIT A

LIST OF PRIOR INVENTIONS

AND ORIGINAL WORKS OF AUTHORSHIP

	 	 	 	 	 
	 	 	 	 	Identifying Number
	Title	 	Date	 	or Brief Description
	 

	 	 
	 	 

                     No inventions or improvements

                     Additional Sheets Attached

Signature of Individual:
                                           

Print Name of Individual:                                         

Date:                                         

9

 

EXHIBIT B

TERMINATION CERTIFICATION

     This is to certify that I do not have in my possession, nor have I failed to return, any
devices, records, data, notes, reports, proposals, lists, correspondence, specifications,
drawings, blueprints, sketches, materials, equipment, Confidential Information (as such term is
defined in the Company’s Confidential Information and Invention Assignment Agreement (the
“Agreement”)), other documents or property, or reproductions of any aforementioned items belonging
to the Company.

     I further certify that I have complied with all the terms of Agreement, including the
reporting of any Inventions (as defined in the Agreement), conceived or made by me (solely or
jointly with others) covered by the Agreement.

     I further agree that, in compliance with the Agreement, I will hereafter preserve as
confidential all Confidential Information.

     I further agree that for twenty-four (24) months from this date, I will be bound by the
provisions of Section 9 of the Agreement.

Date:                                         

	 	 	 	 	 
	 

	 	 	 	 
	 

	 	(Individual’s Signature)
	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 

	 	(Type/Print Individual’s Name)	 	 

10

 

EXHIBIT C

COMPANY

CONFLICT OF INTEREST GUIDELINES

     It is the policy of the Company to conduct its affairs in strict compliance with the letter
and spirit of the law and to adhere to the highest principles of business ethics. Accordingly, all
officers, employees, independent contractors, consultants and other agents, must avoid activities
which are in conflict, or give the appearance of being in conflict, with these principles and with
the interests of the Company. The following are potentially compromising situations which must be
avoided. Any exceptions must be reported to the President, and written approval for continuation
must be obtained.

     1. Revealing confidential information to outsiders or misusing confidential information.
Unauthorized divulgence of information is a violation of this policy whether or not for personal
gain and whether or not harm to the Company is intended or occurs. (The Confidential Information,
Invention Assignment and Non-Competition Agreement elaborates on this principle and is a binding
agreement.)

     2. Accepting or offering substantial gifts, excessive entertainment, favors or payments which
may be deemed to constitute undue influence or which may otherwise be improper or embarrassing to
the Company.

     3. Participating in civic or professional organizations that might involve divulging
confidential information of the Company.

     4. Initiating or approving personnel actions affecting reward or punishment of employees or
applicants where there is a family relationship or is, or appears to be, a personal or social
involvement.

     5. Initiating or approving any form of personal or social harassment of employees.

     6. Investing or holding outside directorship in suppliers, customers, or competing companies,
including financial speculations, where such investment or directorship might influence in any
manner a decision or course of action of the Company.

     7. Borrowing from or lending to customers or suppliers. Except in the case of banking related
customers where the terms of the lending or deposit relationship is not more favorable what those
granted to other bank customers under common underwriting guidelines and is consistent with the
bank’s normal lending practices.

     8. Acquiring real estate of interest to the Company.

     9. Improperly using or disclosing to the Company any proprietary information or trade secrets
of any former or concurrent employer or other person or entity with whom obligations of
confidentiality exist.

     10. Unlawfully discussing prices, costs, customers, sales or markets with competing companies
or their employees.

     11. Making any unlawful agreement with distributors with respect to prices.

     12.
Improperly using or authorizing the use of any inventions which are the subject
of patent claims of any other person or entity.

11

 

     Each officer, employee and independent contractor must take every necessary action to ensure
compliance with these guidelines and to bring problem areas or questions to the attention of higher
management for review. Violations of this conflict of interest policy may result in termination of
employment or any contractual relationship with the Company without warning.

12

 

EXHIBIT B

CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT

AGREEMENT

[See Attached]

 

 

RULES-BASED MEDICINE, INC.

CONFIDENTIAL INFORMATION AND INVENTION

ASSIGNMENT AGREEMENT

     As a condition of my commencing my relationship, as an employee, consultant, independent
contractor or otherwise (or my employment or other relationship being continued, as applicable),
with Rules-Based Medicine, Inc., a Delaware corporation, or any of its present or future
subsidiaries, parent companies, affiliates, successors or assigns (collectively, the “Company”),
and in consideration of (i) my relationship as an employee, independent contractor, consultant or
otherwise of the Company, (ii) my receipt of confidential company information such as customer
lists, proprietary testing procedures and know-how, and (iii) the compensation now and hereafter
paid to me by Company (the receipt and sufficiency of which is hereby acknowledged), I agree to
the following:

     1. Employment, Consulting or Other Relationship. I understand and acknowledge that
this Confidential Information and Invention Assignment (this “Agreement”) does not expand upon any
rights I may have to continue in the employ of, or in a consulting or other relationship with, or
the duration of my relationship with the Company as an employee, independent contractor,
consultant or otherwise, under any other agreements between the Company and me or under applicable
law. (Any employment or other relationship between the Company and me, whether commenced prior to
or upon the date of this Agreement, shall be referred to herein as the “Relationship.”)

     2. At-Will Relationship. I understand and acknowledge that my Relationship with the
Company constitutes an at-will relationship under applicable law, meaning that either I or the
Company may terminate the Relationship at any time, with or without good cause or for any or no
cause, with or without prior notice. This Agreement shall supersede and does hereby terminate any
Employment Agreement, Consulting Agreement or similar agreement between me and Luminex
Corporation, notwithstanding the assumption of any such agreement by the Company; provided,
however, that any confidentiality, non-solicitation or non-competition provision in any such
agreement, not inconsistent with the provisions of this Agreement, shall survive the termination
of such agreement hereunder.

     3. Confidential Information.

     (a) Company Information. The Company agrees, in consideration for my agreement
to the various terms of this Agreement, to provide me with Confidential Customer
Information belonging to the Company as well as names of the Company’s customers. I agree
at all times, during the term of the Relationship and thereafter, to hold in strictest
confidence, and not to use, except for the benefit of the Company, or to disclose to any
person, firm, corporation or other entity without written authorization of the President of
the Company or such other person as appointed by the President of the Company, any
Confidential Information of the Company. I further agree not to make copies of such
Confidential Information except as authorized in writing by the Company or required for the
performance of my responsibilities under the Relationship. Any such

1

 

copies made pursuant to the preceding sentence shall be available to, and shall remain the sole
property of, the Company at all times. I understand that “Confidential Information” means any
Company proprietary information, technical data, trade secrets or know-how, including, but not
limited to, (i) information derived from reports, investigations, experiments, research and work in
progress, (ii) methods of operation, (iii) market data, (iv) technology, hardware, proprietary
computer programs and code (in object code and source code format), (v) drawings, designs, plans
and proposals, (vi) marketing and sales programs, (vii) customer, licensee and supplier lists and
any other information about the Company’s relationships with others, (viii) historical financial
information and financial projections, (ix) network and system architecture, (x) all other
formulate, patterns, devices or compilations, concepts, ideas, materials and information prepared
or performed for or by the Company, (xi) all information related to the business plan, business,
products, purchases or sales of the Company or any of its suppliers and customers, other than
information that is publicly available, (xii) software or applications of software, developments,
inventions, models, samples, flowcharts, statistical data and compilations, (xiii) computer
programs, disks, diskettes, tapes, and (xiv) all other proprietary information disclosed to me by
the Company either directly or indirectly in writing, orally or by drawings or observation, or
created by me during the period of the Relationship, using Company time and/or materials or
equipment. I understand that Confidential Information includes, but is not limited to,
information pertaining to any aspects of the Company’s business which is either information not
known by actual or potential competitors of the Company, or proprietary information of the Company
or its customers or suppliers or other third parties with which it has business relationships,
whether of a technical or financial nature, or otherwise. I further understand that Confidential
Information does not include any of the foregoing items which shall become publicly known and made
generally available through no wrongful act of mine or of others who were under confidentiality
obligations as to the item or items involved.

     (b) Former Employer Information. I represent and warrant that my performance of this
Agreement or the Relationship has not breached, and will not breach, any agreement or trust
relationship between myself and any former, concurrent, or subsequent employer or other third
party (collectively, “Other Party”), including, without limitation, any agreement with respect to
such Other Party’s inventions, unpublished documents or confidential or proprietary information. I
agree that I will not disclose to the Company, bring on the Company’s premises, or induce the
Company to use any Other Party’s inventions, unpublished documents, or confidential or proprietary
information without such Other Party’s prior written consent, a copy of which I also shall provide
to the Company.

     (c) Third Party Information. I recognize that the Company has received and in the
future will receive from third parties their confidential or proprietary information subject to a
duty on the Company’s part to maintain the confidentiality of such information and to use it only
for certain limited purposes. I agree to hold all such confidential or proprietary information in
the strictest confidence and not to disclose it to any person, firm or corporation or to use it
except as necessary in carrying out my work for the Company consistent with the terms of this
Agreement.

2

 

     4. Inventions.

     (a) Inventions Retained and Licensed. I have attached hereto, as Exhibit A a list
describing all ideas, discoveries, inventions, original works of authorship, developments,
designs, work products, innovations, concepts, know-how, and trade secrets which were made by me
prior to my Relationship with the Company (collectively referred to as “Prior Inventions”), which
belong to me, which relate to the Company’s current or proposed business, products or research and
development, whether or not specifically within my duties or responsibilities with the Company,
whether or not patentable or registrable under copyright or similar laws and whether or not
reduced to writing, and which are not assigned to the Company hereunder; or, if no such list is
attached, I represent that there are no such Prior Inventions. If, in the course of my
Relationship with the Company, I incorporate into a Company product, process, program, software or
machine a Prior Invention owned by me or in which I have an interest, the Company is hereby
granted and shall have a nonexclusive, royalty-free, transferable, irrevocable, perpetual,
worldwide license to make, have made, modify, use, reproduce, distribute, create derivative works
from, publicly perform, publicly display and sell such Prior Invention as part of, or in
connection with such product, process, program, software, work or machine. I agree that I will
not, without the prior approval of the Company, incorporate in any Company product, process,
program, software, work or machine any photographs, video or film, music, computer programs or
other materials obtained from a third party (via the Internet or otherwise) for which the Company
has not been granted an express license for such incorporation.

     (b) Assignment of Inventions. I agree that I will promptly make full written
disclosure to the Company of any and all ideas, discoveries, inventions, original works of
authorship, developments, designs, work products, innovations, concepts, know-how, and trade
secrets which relate to the Company’s current or proposed business, products or research and
development, whether or not specifically within my duties or responsibilities with the Company and
whether or not patentable or registrable under copyright or similar laws and whether or not reduced
to writing, which I may solely or jointly conceive or develop or reduce to practice, or cause to be
conceived or developed or reduced to practice, during the period of time I have a Relationship with
the Company, whether or not during working hours or by the use of the facilities of the Company
(collectively referred to as “Inventions”). I further agree that I will hold in trust for the sole
right and benefit of the Company, and hereby assign to the Company, or its designee, all my right,
title, and interest in and to any and all such Inventions which I may solely or jointly conceive or
develop or reduce to practice, or cause to be conceived or developed or reduced to practice, using
the Company’s time and/or materials or equipment. I further acknowledge that all of the
above-described Inventions made during the period of my Relationship with the Company are “works
made for hire”, as that term is defined in the United States Copyright Act, to the greatest extent
permitted by applicable law, and are compensated by my salary (if I am an employee) or by such
other amount paid to me under any applicable consulting, independent contractor or other agreement
or arrangement (if I am not an employee). All Inventions or other work product created by me or on
my behalf or by my affiliates pursuant to this Agreement shall be free and clear of all
encumbrances, including without limitation, security interest(s), licenses, liens or

3

 

other restrictions other than as expressly provided for in this Agreement. I hereby appoint
the Company as my attorney-in-fact to execute on my behalf any assignments or other
documents deemed necessary by the Company to protect or perfect its rights to any
Inventions.

     (c) Inventions Assigned to the United States. I agree to assign to the United
States government all my right, title, and interest in and to any and all Inventions
whenever such full title is required to be in the United States by a contract between the
Company and the United States or any of its agencies.

     (d) Maintenance of Records. I agree to create and maintain adequate and
current written records of all Inventions made by me (solely or jointly with others), and
assigned to the Company under Section 5(b) above, during the term of my Relationship with
the Company. The records will be in the form of notes, sketches, drawings, and any other
format that may be specified by the Company. The records will be available to and remain
the sole property of the Company at all times. I agree not to remove such records from the
Company’s place of business except as expressly permitted by the Company policy, which may,
from time to time, be revised at the sole discretion of the Company.

     (e) Patent and Copyright Registrations. I agree to reasonably assist the
Company, or its designee, at the Company’s expense, in every proper way to secure the
Company’s rights in the Inventions and any copyrights, patents, mask work rights, moral
rights, or other intellectual property rights relating thereto in any and all countries,
including the disclosure to the Company of all pertinent information and data with respect
thereto, the execution of all applications, specifications, oaths, assignments and all
other instruments which the Company shall reasonably deem necessary in order to apply for
and obtain such rights and in order to assign and convey to the Company, its successors,
assigns, and nominees the sole and exclusive rights, title and interest in and to such
Inventions, and any copyrights, patents, mask work rights, moral rights or other
intellectual property rights relating thereto. I further agree that my obligation to
execute or cause to be executed, when it is in my power to do so, any such instrument or
papers shall continue after the termination of this Agreement. If the Company is unable
because of my mental or physical incapacity, unavailability, or for any other reason to
secure my signature to apply for or to pursue any application for any United States or
foreign patents or copyright registrations covering Inventions or original works of
authorship assigned to the Company as above, then I hereby irrevocably designate and
appoint the Company and its duly authorized officers and agents as my agent and attorney in
fact, to act for and in my behalf and stead to execute and file any such applications and
to do all other lawfully permitted acts to further the prosecution and issuance of letters
patent, copyright registrations or enforcement of other intellectual property rights
thereon with the same legal force and effect as if executed by me.

     5. Conflicting Employment. I agree that, during the term of my Relationship with the
Company, I will not engage in any other employment, occupation, consulting or other business
activity directly related to the business in which the Company is now involved or becomes involved
during the term of the Relationship, nor will I engage in any other activities that conflict with
my obligations to the Company.

4

 

     6. Returning Company Documents. I agree that, at the time of termination of my
Relationship with the Company, I will deliver to the Company (and will not keep in my possession,
copy, reproduce, recreate or deliver to anyone else) any and all devices, records, data, notes,
reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches,
materials, equipment, other documents or property, or reproductions of any of the aforementioned
items developed by me pursuant to my Relationship with the Company or otherwise belonging to the
Company, its successors or assigns. I further agree that any property situated on the Company’s
premises or on the Company’s computers or servers, including disks and other storage media, email,
and filing cabinets and other work areas, is subject to inspection by Company personnel at any
time with or without notice. In the event of the termination of the Relationship, I agree to sign
and deliver the “Termination Certification” attached hereto as Exhibit B.

     7. Notification of New Employer. Upon termination of my Relationship with the
Company, I hereby grant consent to notification by the Company to my new employer or any other
party with which I may enter into a new relationship with respect to my obligations under this
Agreement.

     8. Certain Covenants.

          (a) Solicitation of Employees, Consultants and Customers. In
consideration of the Company’s obligations under this Agreement and the other consideration
recited above, I agree that during the Relationship and for a period of twenty-four (24) months
immediately following the termination of my Relationship with the Company, whether with or without
cause, I shall not, either directly or indirectly, either alone or in concert with others,
solicit, induce, recruit, encourage or entice, or attempt to solicit, induce, recruit, encourage
or entice, any employee of or consultant to the Company to leave the Company or work for anyone in
competition with the Company. Also, during the Relationship and for a period of twenty-four (24)
months immediately following the termination of my Relationship with the Company, I will not
directly or indirectly, either for myself or for any other person, firm or corporation, divert or
take away or attempt to divert or take away, call on or solicit or attempt to call on or solicit,
any licensee or customer of the Company, including but not limited to those on whom I called or
whom I solicited or with whom I became acquainted while engaged as an employee of or a consultant
to the Company’s business. During the Relationship, I agree not to plan or otherwise take any
steps, preliminary or otherwise, either alone or in concert with others, to set up or engage in
any business enterprise that would be in competition with the Company. In the event of the
termination of the Relationship, I will not accept or engage in any activities, where the loyal
and complete fulfillment of the duties of the activities would inherently call upon me to reveal
Confidential Information to which I have access or of which I have learned during or as a result
of the Relationship.

     9. Conflict of Interest Guidelines. I agree to diligently adhere to the Conflict of
Interest Guidelines attached as Exhibit C hereto.

5

 

     10. Representations. I agree to execute any proper oath or verify any proper document
required to carry out the terms of this Agreement. I have not entered into, and I agree I will not
enter into, any oral or written agreement in conflict herewith.

     11. General Provisions.

          (a)
Governing Law; Consent to Personal Jurisdiction. This
Agreement will be
governed by the laws of the State of Texas. I hereby expressly consent to the personal
jurisdiction of the state and federal courts located in Texas for any lawsuit filed there
against me by the Company arising from or relating to this Agreement.

     (b) Entire Agreement. This Agreement sets forth the entire agreement and
understanding between the Company and me relating to the subject matter herein and merges
all prior discussions between us. No modification of or amendment to this Agreement, nor
any waiver of any rights under this Agreement, will be effective unless in writing signed
by the party to be charged. Any subsequent change or changes in my duties, salary or other
compensation will not affect the validity or scope of this Agreement.

     (c) Severability. If one or more of the provisions in this Agreement are
deemed void by law, then the remaining provisions will continue in full force and effect.

     (d) Successors and Assigns. This Agreement will be binding upon my heirs,
executors, administrators and other legal representatives and will be for the benefit of
the Company, its successors, and its assigns.

     (e) Survival. The provisions of this Agreement shall survive the termination
of the Relationship and the assignment of this Agreement by the Company to any successor in
interest or other assignee.

     (f) Supervised Employees. I agree to cause any employee engaged by me, or
otherwise introduced to the Company by me, to agree to be bound by the terms of this
Agreement, as if the terms of this Agreement applied directly to such employee, unless
such employee executes an agreement directly with the Company substantially similar to
this Agreement.

     (g) ADVICE OF COUNSEL. I ACKNOWLEDGE THAT, IN EXECUTING THIS AGREEMENT, I HAVE
HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND I HAVE READ AND
UNDERSTAND ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. I HEREBY REPRESENT THAT I
EITHER HAVE SOUGHT INDEPENDENT LEGAL COUNSEL OR HAVE ELECTED FREELY NOT TO DO SO. THIS
AGREEMENT SHALL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION
HEREOF.

6

 

Date:

	 	 	 	 	 
	 

	 	 	 	 
	 

	 	Signature
	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 

	 	Name of Individual (typed or printed)	 	 

	 	 	 	 	 
	Acknowledged and agreed: 

RULES-BASED MEDICINE, INC.

 	 	 
	By:  	 	 	 
	 	Name:  	Patrick S. McClain  	 	 
	 	Title:  	Chief Financial Officer 	 	 

7

 

	 	 	 	 	 

EXHIBIT A

LIST OF PRIOR INVENTIONS

AND ORIGINAL WORKS OF AUTHORSHIP

	 	 	 	 	 
	 	 	 	 	Identifying Number
	Title	 	Date	 	or Brief Description
	 

	 	 
	 	 

                     No inventions or improvements

                     Additional Sheets Attached

Signature of Individual:                                         

Print Name of Individual:                                         

Date:                     

8

 

EXHIBIT C 

LIQUIDATION EXAMPLES

[See Attached]

 

 

Rules-Based Medicine, Inc.

Investor Rights Agreement: Schedule C — Liquidation Examples

			
	 	 	 
	Returns Analysis — On or Prior to October 12, 2009
	 	No Options Issued

Waterfall of Distribution of Assets on or prior to October 12, 2009

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total Assets of the Company Available for Distribution	 	$25,000,000	 	$50,000,000	 	$75,000,000	 	$125,000,000	 	$175,000,000	 	$225,000,000	 	$275,000,000	 	$300,000,000
	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 1 — Section 2.1.1 of Certificate of Incorporation,
Accrued but unpaid cash dividends
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-l Preferred Stock
	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 2 — Section 2.1.2 of Certificate of Incorporation — up
to Series A-1 Original Issue Price
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-l Preferred Stock
	 	 	24,500,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of Common Stock
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	24,500,000	 	 	 	49,500,000	 	 	 	99,500,000	 	 	 	149,500,000	 	 	 	199,500,000	 	 	 	249,500,000	 	 	 	274,500,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 3 — Section 2.1.3 of Certificate of Incorporation
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-l Preferred Stock
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of Common Stock
	 	 	—	 	 	 	24,500,000	 	 	 	27,083,332	 	 	 	27,083,332	 	 	 	27,083,332	 	 	 	27,083,332	 	 	 	27,083,332	 	 	 	27,083,332	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	—	 	 	 	22,416,668	 	 	 	72,416,668	 	 	 	122,416,468	 	 	 	172,416,668	 	 	 	222,416,668	 	 	 	247,416,668	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 4 — Section 2.1.4 of Certificate of Incorporation
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-l Preferred Stock
	 	 	—	 	 	 	—	 	 	 	10,760,001	 	 	 	34,760,001	 	 	 	50,000,000	 	 	 	50,000,000	 	 	 	50,000,000	 	 	 	50,000,000	 
	Distribution to holders of Common Stock
	 	 	—	 	 	 	—	 	 	 	11,656,667	 	 	 	37,656,667	 	 	 	54,166,665	 	 	 	54,166,665	 	 	 	54,166,665	 	 	 	54,166,665	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	18,250,003	 	 	 	68,250,003	 	 	 	118,250,003	 	 	 	143,250,003	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 5 — Section 2.1.5 of Certificate of Incorporation
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-1 Preferred Stock
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	1,825,000	 	 	 	6,825,000	 	 	 	10,763,889	 	 	 	10,763,889	 
	Distribution to holders of Common Stock
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	16,425,002	 	 	 	61,425,002	 	 	 	96,874,998	 	 	 	96,874,998	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	10,611,116	 	 	 	35,611,116	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 6
— Section 2.1.6 of Certificate of Incorporation
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-1 Preferred Stock
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	3,448,613	 	 	 	11,573,613	 
	Distribution to holders of Common Stock
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	7,162,503	 	 	 	24,037,503	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total Distribution to holders of A-l Preferred Stock
	 	 	25,000,000	 	 	 	25,500,000	 	 	 	36,260,001	 	 	 	60,260,001	 	 	 	77,325,000	 	 	 	82,325,000	 	 	 	89,712,501	 	 	 	97,837,502	 
	 
	Total Distribution to holders of Common Stock
	 	 	—	 	 	 	24,500,000	 	 	 	38,739,999	 	 	 	64,739,999	 	 	 	97,675,000	 	 	 	142,675,000	 	 	 	185,287,499	 	 	 	202,162,498	 
	 

Investor Rights Certificate — Exhibit C

Page 1 of 13

 

Rules-Based
Medicine, Inc.

Investor Rights Agreement: Schedule C — Liquidation Examples

			
	 	 	 
	Returns Analysis — On or Prior
to October 12, 2009
	 	No Options Issued

Adjusted Preferred Ownership Percentage (“APO”) Calculation

	 	 	 	 	 
	A-1 Preferred Shares
	 	 	7,485,231	 
	+ Adjustment For Diluting Shares
	 	 	—	 
	Numerator
	 	 	7,485,231	 
	 
	 	 	 	 
	A-1 Preferred Shares
	 	 	7,485,231	 
	+ Adjustment For Diluting Shares
	 	 	—	 
	Total A-1 Preferred Shares
	 	 	7,485,231	 
	+ Original Common Outstanding
	 	 	8,109,000	 
	+ Common Issued for Options for owners of >2.5%
	 	 	—	 
	+ Common Issued for Options for owners of <2.5%
	 	 	—	 
	Denominator
	 	 	15,594,231	 
	APO
	 	 	48.0	%

Adjustment for Diluting Shares

	 	 	 	 	 
	Series A-1 Preferred Shares
	 	 	7,485,231	 
	divided by Outstanding Common
	 	 	8,109,000	 
	Equals
	 	 	92	%
	 
	 	 	 	 
	Multiplied by
	 	 	 	 
	Common Issued for Options for owners of >2.5%
	 	 	—	 
	Adjustment for Diluting Shares
	 	 	—	 

Step 3
— Section 2 1.3 of Certificate of Incorporation

			
	 	 	 
	Total distribution due to
Common Holders in this step $25,000,000 * ((1-APO)/APO) = $25,000,000 * (0 52/0 48) =
	 	$27,083,332

Step 4 — Section 2.1.4 of Certificate of Incorporation

			
	 	 	 
	Maximum distribution in this step ($75,000,000-distribution in Step 2)/APO =
	 	$104,166,665
	Maximum
distribution to Preferred Holders:

	 	$  50,000,000
	Maximum
distribution to Common Holders

	 	$  54,166,665

Step 5 — Section 2.1.5 of Certificate of Incorporation

Pre-2012 Permitted Dilution Factor

Shares of capital issued since Oct 12, 2007/then outstanding shares of capital stock (excluding Diluting Shares)

Pre-2012 Permitted Dilution Factor 0%

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Cash Payout to	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	A-1 Pref	 	 	Common	 
	Preferred distribution. 10%*(1-Pre-2012 Permitted Dilution Factor)
	 	 	 	 	 	 	10 0	%	 	Step 2	 	 	25,000000	 	 	 	0	 
	Common distribution. (1-Preferred Distribution)
	 	 	 	 	 	 	90 0	%	 	Step 3	 	 	0	 	 	 	27,083,332	 
	 
	 	 	 	 	 	 	 	 	 	Step 4	 	 	50 000,000	 	 	 	54,166,665	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	Total	 	 	75 000,000	 	 	 	81,249 997	 
	Maximum incremental total distribution in Step 5
	 	$	107,638,886	 	 	 	 	 	 	Step 5	 	 	10,763,889	 	 	 	96,874,998	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	Total	 	 	85,763,889	 	 	 	178,124,995	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Max Preferred distribution in Steps 2, 4 and 5 32.5%*APO/48% =
	 	 	 	 	 	 	32.5	%	 	 	%	 	 	 	32.5	%	 	 	67.5	%

Step 6 — Section 2.1.6 of Certificate of Incorporation

			
	 	 	 
	Residual Preferred Percentage 32.5% * APO/48% =
	 	32 5%
	Common distribution 100% — Residual Preferred Percentage =
	 	67 5%

Investor Rights Certificate — Exhibit C

Page 2 of 13

 

Rules-Based Medicine, Inc.

Investor Rights Agreement: Schedule C — Liquidation Examples

			
	 	 	 
	Returns Analysis — On or Prior to October 12, 2009
	 	 Options issued to those who own >2.5%

Waterfall of Distribution of Assets on or prior to October 12, 2009

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total Assets of the Company Available for Distribution	 	$25,000,000	 	$50,000,000	 	$75,000,000	 	$125,000,000	 	$175,000,000	 	$225,000,000	 	$275,000,000	 	$300,000,000
	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 1
— Section 2.1.1 of Certificate of Incorporation:
Accrued but unpaid cash dividends
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-l Preferred Stock
	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 2 — Section 2.1.2 of Certificate of Incorporation — up
to Series A-1 Original Issue Price
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-l Preferred Stock
	 	 	24,500,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of Common Stock
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	24,500,000	 	 	 	49,500,000	 	 	 	99,500,000	 	 	 	149,500,000	 	 	 	199,500,000	 	 	 	249,500,000	 	 	 	274,500,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 3 — Section 2.1.3 of Certificate of Incorporation
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-l Preferred Stock
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of Common Stock
	 	 	—	 	 	 	24,500,000	 	 	 	27,083,332	 	 	 	27,083,332	 	 	 	27,083,332	 	 	 	27,083,332	 	 	 	27,083,332	 	 	 	27,083,332	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	—	 	 	 	22,416,668	 	 	 	72,416,668	 	 	 	122,416,668	 	 	 	172,416,668	 	 	 	222,416,668	 	 	 	247,416,668	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 4 — Section 2.1.4 of Certificate of Incorporation
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-l Preferred Stock
	 	 	—	 	 	 	—	 	 	 	10,760,001	 	 	 	34,760,001	 	 	 	50,000,000	 	 	 	50,000,000	 	 	 	50,000,000	 	 	 	50,000,000	 
	Distribution to holders of Common Stock
	 	 	—	 	 	 	—	 	 	 	11,656,667	 	 	 	37,656,667	 	 	 	54,166,665	 	 	 	54,166,665	 	 	 	54,166,665	 	 	 	54,166,665	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	18,250,003	 	 	 	68,250,003	 	 	 	118,250,003	 	 	 	143,250,003	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 5 — Section 2.1.5 of Certificate of Incorporation
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-1 Preferred Stock
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	1,825,000	 	 	 	6,825,000	 	 	 	10,763,889	 	 	 	10,763,889	 
	Distribution to holders of Common Stock
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	16,425,002	 	 	 	61,425,002	 	 	 	96,874,998	 	 	 	96,874,998	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	10,611,116	 	 	 	35,611,116	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 6
— Section 2.1.6 of Certificate of Incorporation
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-1 Preferred Stock
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	3,448,613	 	 	 	11,573,613	 
	Distribution to holders of Common Stock
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	7,162,503	 	 	 	24,037,503	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total Distribution to holders of A-l Preferred Stock
	 	 	25,000,000	 	 	 	25,500,000	 	 	 	36,260,001	 	 	 	60,260,001	 	 	 	77,325,000	 	 	 	82,325,000	 	 	 	89,712,501	 	 	 	97,837,502	 
	 
	
          Total Distribution
            to holders of Common Stock

        	 	 	—	 	 	 	24,500,000	 	 	 	38,739,999	 	 	 	64,739,999	 	 	 	97,675,000	 	 	 	142,675,000	 	 	 	185,287,499	 	 	 	202,162,498	 
	 

Investor Rights Certificate — Exhibit C

    Page 3 of 13 

 

Rules-Based
Medicine, Inc.

Investor Rights Agreement: Schedule C — Liquidation Examples

			
	 	 	 
	Returns Analysis — On or Prior
to October 12, 2009
	 	Options issued to those who own
>2.5%

Adjusted Preferred Ownership Percentage (“APO”) Calculation

	 	 	 	 	 
	A-1 Preferred Shares
	 	 	7,485,231	 
	+ Adjustment For Diluting Shares
	 	 	757,614	 
	Numerator
	 	 	8,242,845	 
	 
	 	 	 	 
	A-1 Preferred Shares
	 	 	7,485,231	 
	+ Adjustment For Diluting Shares
	 	 	757,614	 
	Total A-1 Preferred Shares
	 	 	8,242,845	 
	+ Original Common Outstanding
	 	 	8,109,000	 
	+ Common Issued for Options for owners of >2.5%
	 	 	820,749	 
	+ Common Issued for Options for owners of <2.5%
	 	 	—	 
	Denominator
	 	 	17,172,594	 
	APO
	 	 	48.0	%

Adjustment for Diluting Shares

	 	 	 	 	 
	Series A-1 Preferred Shares
	 	 	7,485,231	 
	divided
by Outstanding Common
	 	 	8,109,000	 
	Equals
	 	 	92	%
	 
	 	 	 	 
	Multiplied by
	 	 	 	 
	Common Issued for Options for owners of >2.5%
	 	 	820,749	 
	Adjustment for Diluting Shares
	 	 	757,614	 

Step 3
— Section 2.1.3 of Certificate of Incorporation

			
	 	 	 
	Total distribution due to
Common Holders in this step $25,000,000 * ((1-APO)/APO) = $25,000,000 * (0 52/0 48) =
	 	$27,083,332

Step 4 — Section 2.1.4 of Certificate of Incorporation

			
	 	 	 
	Maximum distribution in this step ($75,000,000-distribution in Step 2)/APO =
	 	$104,166,665
	Maximum distribution to Preferred
Holders.
	 	$  50,000,000
	Maximum distribution to Common
Holders.
	 	$  54,166,665

Step 5 — Section 2.1.5 of Certificate of Incorporation

Pre-2012 Permitted Dilution Factor

Shares of capital issued since Oct 12, 2007/then outstanding shares of capital stock (excluding Diluting Shares)

Pre-2012 Permitted Dilution Factor 0%

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Cash Payout to	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	A 1 Pref	 	 	Common	 
	Preferred distribution 10%*(1-Pre-2012 Permitted Dilution Factor)
	 	 	 	 	 	 	10.0	%	 	Step 2	 	 	25,000,000	 	 	 	0	 
	Common
distribution (1-Preferred Distribution).
	 	 	 	 	 	 	90.0	%	 	Step 3	 	 	0	 	 	 	27 083,332	 
	 
	 	 	 	 	 	 	 	 	 	Step 4	 	 	50,000,000	 	 	 	54,166,665	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	Total	 	 	75,000,000	 	 	 	81,249 997	 
	Maximum incremental total distribution in Step 5
	 	$	107,638,886	 	 	 	 	 	 	Step 5	 	 	10,763,889	 	 	 	96,874,998	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	Total	 	 	85,763,889	 	 	 	178,124,995	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Max Preferred distribution in Steps 2, 4 and 5 32.5%*APO/48% =
	 	 	 	 	 	 	32.5	%	 	 	%	 	 	 	32.5	%	 	 	67.5	%

Step 6 — Section 2.1.6 of Certificate of Incorporation

			
	 	 	 
	Residual Preferred Percentage 32.5% * APO/48% =
	 	32.5%
	Common distribution 100% — Residual Preferred Percentage =
	 	67.5%

Investor Rights Certificate — Exhibit C

Page 4 of 13

 

Rules-Based Medicine, Inc.

Investor Rights Agreement: Schedule C — Liquidation Examples

			
	 	 	 
	Returns Analysis — On or Prior to October 12, 2009
	 	 Options issued to those who own <2.5%

Waterfall of Distribution of Assets on or prior to October 12, 2009

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total Assets of the Company Available for Distribution	 	$25,000,000	 	$50,000,000	 	$75,000,000	 	$125,000,000	 	$175,000,000	 	$225,000,000	 	$275,000,000	 	$300,000,000
	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 1 — Section 2.1.1 of Certificate of Incorporation:
Accrued but unpaid cash dividends
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-l Preferred Stock
	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 2 — Section 2.1.2 of Certificate of Incorporation — up
to Series A-1 Original Issue Price
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-l Preferred Stock
	 	 	24,500,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of Common Stock
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	24,500,000	 	 	 	49,500,000	 	 	 	99,500,000	 	 	 	149,500,000	 	 	 	199,500,000	 	 	 	249,500,000	 	 	 	274,500,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 3 — Section 2.1.3 of Certificate of Incorporation
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-l Preferred Stock
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of Common Stock
	 	 	—	 	 	 	24,500,000	 	 	 	29,824,561	 	 	 	29,824,561	 	 	 	29,824,561	 	 	 	29,824,561	 	 	 	29,824,561	 	 	 	29,824,561	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	—	 	 	 	19,675,439	 	 	 	69,675,439	 	 	 	119,675,439	 	 	 	169,675,439	 	 	 	219,675,439	 	 	 	244,675,439	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 4 — Section 2.1.4 of Certificate of Incorporation
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-l Preferred Stock
	 	 	—	 	 	 	—	 	 	 	8,972,001	 	 	 	31,772,001	 	 	 	50,000,000	 	 	 	50,000,000	 	 	 	50,000,000	 	 	 	50,000,000	 
	Distribution to holders of Common Stock
	 	 	—	 	 	 	—	 	 	 	10,703,439	 	 	 	37,903,439	 	 	 	59,649,121	 	 	 	59,649,121	 	 	 	59,649,121	 	 	 	59,649,121	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	10,026,318	 	 	 	60,026,318	 	 	 	110,026,318	 	 	 	135,026,318	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 5 — Section 2.1.5 of Certificate of Incorporation
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-1 Preferred Stock
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	952,500	 	 	 	5,702,500	 	 	 	10,452,500	 	 	 	10,763,889	 
	Distribution to holders of Common Stock
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	9,073,818	 	 	 	54,323,818	 	 	 	99,573,818	 	 	 	102,540,202	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	21,722,227	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 6 — Section 2.1.6 of Certificate of Incorporation
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-1 Preferred Stock
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	6,706,738	 
	Distribution to holders of Common Stock
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	15,015,490	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total Distribution to holders of A-l Preferred Stock
	 	 	25,000,000	 	 	 	25,500,000	 	 	 	34,472,001	 	 	 	57,272,001	 	 	 	76,452,300	 	 	 	81,202,500	 	 	 	85,952,500	 	 	 	92,970,626	 
	 
	
          Total Distribution
            to holders of Common Stock

        	 	 	—	 	 	 	24,500,000	 	 	 	40,527,999	 	 	 	67,727,999	 	 	 	98,547,500	 	 	 	143,797,500	 	 	 	189,047,500	 	 	 	207,029,374	 
	 

Investor Rights Certificate — Exhibit C

    Page 5 of 13 

 

Rules-Based
Medicine, Inc.

Investor Rights Agreement: Schedule C — Liquidation Examples

			
	 	 	 
	Returns Analysis — On or Prior
to October 12, 2009
	 	Options issued to those who own
<2.5%

Adjusted Preferred Ownership Percentage (“APO”) Calculation

	 	 	 	 	 
	A-1 Preferred Shares
	 	 	7,485,231	 
	+ Adjustment For Diluting Shares
	 	 	—	 
	Numerator
	 	 	7,485,231	 
	 
	 	 	 	 
	A-1 Preferred Shares
	 	 	7,485,231	 
	+ Adjustment For Diluting Shares
	 	 	—	 
	Total A-1 Preferred Shares
	 	 	7,485,231	 
	+ Original Common Outstanding
	 	 	8,109,000	 
	+ Common Issued for Options for owners of >2.5%
	 	 	—	 
	+ Common Issued for Options for owners of <2.5%
	 	 	820,749	 
	Denominator
	 	 	16,414,980	 
	APO
	 	 	45.6	%

Adjustment for Diluting Shares

	 	 	 	 	 
	Series A-1 Preferred Shares
	 	 	7,485,231	 
	divided by Outstanding Common
	 	 	8,109,000	 
	Equals
	 	 	92	%
	 
	 	 	 	 
	Multiplied by
	 	 	 	 
	Common Issued for Options for owners of >2.5%
	 	 	—	 
	Adjustment for Diluting Shares
	 	 	—	 

Step 3
— Section 2.1.3 of Certificate of Incorporation

			
	 	 	 
	Total distribution due to
Common Holders in this step $25,000,000 * ((1-APO)/APO) = $25,000,000 *
(0.54/0 46) =
	 	$29,824,561

Step 4 — Section 2.1.4 of Certificate of Incorporation

			
	 	 	 
	Maximum distribution in this step ($75,000,000-distribution in Step 2)/APO =
	 	$109,649,121
	Maximum
distribution to Preferred Holders

	 	$  50,000,000
	Maximum
distribution to Common Holders

	 	$  59,649,121

Step 5 — Section 2.1.5 of Certificate of Incorporation

Pre-2012 Permitted Dilution Factor

Shares of capital issued since Oct 12, 2007/then outstanding shares of capital stock (excluding Diluting Shares)

Pre-2012
Permitted Dilution factor 5%

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Cash Payout to	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	A-1 Pref	 	 	Common	 
	Preferred distribution. 10%*(1-Pre-2012 Permitted Dilution Factor)
	 	 	 	 	 	 	9.5	%	 	Step 2	 	 	25,000,000	 	 	 	0	 
	Common distribution (1-Preferred Distribution)
	 	 	 	 	 	 	90 5	%	 	Step 3	 	 	0	 	 	 	29,824,561	 
	 
	 	 	 	 	 	 	 	 	 	Step 4	 	 	50,000,000	 	 	 	59,649,121	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	Total	 	 	75,000,000	 	 	 	89,473,682	 
	Maximum incremental total distribution in Step 5
	 	$	113,304,091	 	 	 	 	 	 	Step 5	 	 	10,763,889	 	 	 	102,540,202	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	Total	 	 	85,763,889	 	 	 	192,013,884	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Max Preferred distribution in Steps 2, 4 and 5 32.5%*APO/48% =
	 	 	 	 	 	 	30 9	%	 	 	%	 	 	 	30 9	%	 	 	69 1	%

Step 6 — Section 2.1.6 of Certificate of Incorporation

			
	 	 	 
	Residual Preferred Percentage 32.5% * APO/48% =
	 	30 9%
	Common distribution 100% — Residual Preferred Percentage =
	 	69 1%

Investor Rights Certificate — Exhibit C

Page 6 of 13

 

Rules-Based Medicine, Inc.

Investor Rights Agreement: Schedule C — Liquidation Examples

			
	 	 	 
	Returns Analysis — October 13,
          2009 to December 31, 2011 	 	 No Options Issued

  Waterfall of Distribution
    of Assets October 13, 2009 — December 31, 2011

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total Assets of the Company Available for Distribution	 	$25,000,000	 	$50,000,000	 	$75,000,000	 	$125,000,000	 	$175,000,000	 	$225,000,000	 	$275,000,000	 	$300,000,000
	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
          Step 1 — Section 2.1.1
            of Certificate of Incorporation, Accrued but unpaid cash dividends

        	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-l Preferred Stock
	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 2 — Section 2.1.2 of Certificate of Incorporation — up
to Series A-1 Original Issue Price
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-l Preferred Stock
	 	 	24,500,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of Common Stock
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	
Remaining Assets Available for Distribution
	 	 	—	 	 	 	24,500,000	 	 	 	49,500,000	 	 	 	99,500,000	 	 	 	149,500,000	 	 	 	199,500,000	 	 	 	249,500,000	 	 	 	274,500,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
          Step 3 —Section 2.1.3
            of Certificate of Incorporation

        	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-l Preferred Stock
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of Common Stock
	 	 	—	 	 	 	24,500,000	 	 	 	27,083,332	 	 	 	27,083,332	 	 	 	27,083,332	 	 	 	27,083,332	 	 	 	27,083,332	 	 	 	27,083,332	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	—	 	 	 	22,416,668	 	 	 	72,416,668	 	 	 	122,416,668	 	 	 	172,416,668	 	 	 	222,416,668	 	 	 	247,416,668	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 4 — Section 2.1.4 of Certificate of Incorporation
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-l Preferred Stock
	 	 	—	 	 	 	—	 	 	 	10,760,001	 	 	 	34,760,001	 	 	 	50,000,000	 	 	 	50,000,000	 	 	 	50,000,000	 	 	 	50,000,000	 
	Distribution to holders of Common Stock
	 	 	—	 	 	 	—	 	 	 	11,656,667	 	 	 	37,656,667	 	 	 	54,166,665	 	 	 	54,166,665	 	 	 	54,166,665	 	 	 	54,166,665	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	18,250,003	 	 	 	68,250,003	 	 	 	118,250,003	 	 	 	143,250,003	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
          Step 5 — Section 2.1.5
            of Certificate of Incorporation

        	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-1 Preferred Stock
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	3,650,001	 	 	 	13,650,001	 	 	 	23,650,001	 	 	 	28,650,001	 
	Distribution to holders of Common Stock
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	14,600,002	 	 	 	54,600,002	 	 	 	94,600,002	 	 	 	114,600,002	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 6 — Section 2.1.6 of Certificate of Incorporation
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-1 Preferred Stock
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 
	Distribution to holders of Common Stock
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total Distribution to holders of A-l Preferred Stock
	 	 	25,000,000	 	 	 	25,500,000	 	 	 	36,260,001	 	 	 	60,260,001	 	 	 	79,150,001	 	 	 	89,150,001	 	 	 	99,130,001	 	 	 	104,150,001	 
	 
	
          Total Distribution
            to holders of Common Stock

        	 	 	—	 	 	 	24,500,000	 	 	 	38,739,999	 	 	 	64,739,999	 	 	 	95,849,999	 	 	 	135,849,999	 	 	 	175,849,999	 	 	 	195,849,999	 
	 

Investor Rights Certificate — Exhibit C

    Page 7 of 13 

 

Rules-Based
Medicine, Inc.

Investor Rights Agreement: Schedule C — Liquidation Examples

			
	 	 	 
	Returns Analysis —
October 13, 2009 to December 31, 2011
	 	No Options Issued

Adjusted Preferred Ownership Percentage (“APO”) Calculation

	 	 	 	 	 
	A-1 Preferred Shares
	 	 	7,485,231	 
	+ Adjustment For Diluting Shares
	 	 	—	 
	Numerator
	 	 	7,485,231	 
	 
	 	 	 	 
	A-1 Preferred Shares
	 	 	7,485,231	 
	+ Adjustment For Diluting Shares
	 	 	—	 
	Total A-1 Preferred Shares
	 	 	7,485,231	 
	+ Original Common Outstanding
	 	 	8,109,000	 
	+ Common Issued for Options for owners of >2.5%
	 	 	
 	 
	+ Common Issued for Options for owners of <2.5%
	 	 	—	 
	Denominator
	 	 	15,594,231	 
	APO
	 	 	48.0	%

Adjustment for Diluting Shares

	 	 	 	 	 
	Series A-1 Preferred Shares
	 	 	7,485,231	 
	divided by Outstanding Common
	 	 	8,109,000	 
	Equals
	 	 	92	%
	 
	 	 	 	 
	Multiplied by
	 	 	 	 
	Common Issued for Options for owners of >2.5%
	 	 	—	 
	Adjustment for Diluting Shares
	 	 	—	 

Step 3
— Section 2.1.3 of Certificate of Incorporation

			
	 	 	 
	Total distribution due to
Common Holders in this step $25,000,000 * ((1 APO)/APO) = $25,000,000 * (0.52/0 48) =
	 	$27,083,332

Step 4 — Section 2.1.4 of Certificate of Incorporation

			
	 	 	 
	Maximum distribution in this step ($75,000,000-distribution in Step 2)/APO =
	 	$104,166 665
	Maximum distribution to Preferred Holders.

	 	$  50,000,000
	Maximum distribution to Common Holders

	 	$  54,166,665

Step 5 — Section 2.1.5 of Certificate of Incorporation

Pre-2012 Permitted Dilution Factor

Shares of capital issued since Oct 12, 2007/then outstanding shares of capital stock (excluding Diluting Shares)

Pre-2012 Permitted Dilution Factor 0%

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Cash Payout to	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	A-1 Pref	 	 	Common	 
	Preferred distribution 10%*(1-Pre-2012 Permitted Dilution Factor)
	 	 	 	 	 	 	20 0	%	 	Step 2	 	 	25 000 000	 	 	 	0	 
	Common
distribution (1 Preferred Distribution)
	 	 	 	 	 	 	80 0	%	 	Step 3	 	 	0	 	 	 	27,083,332	 
	 
	 	 	 	 	 	 	 	 	 	Step 4	 	 	50,000,000	 	 	 	54 166,665	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	Total	 	 	75,000,000	 	 	 	81,249,997	 
	Maximum incremental total distribution in Step 5
	 	$	193,749,992	 	 	 	 	 	 	Step 5	 	 	38,749,998	 	 	 	154,999,994	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	Total	 	 	113,749,998	 	 	 	236,249,991	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Max Preferred distribution in Steps 2, 4 and 5 32.5%*APO/48% =
	 	 	 	 	 	 	32.5	%	 	 	%	 	 	 	32.5	%	 	 	67.5	%

Step 6 — Section 2.1.6 of Certificate of Incorporation

			
	 	 	 
	Residual Preferred Percentage 32.5% * APO/48% =
	 	32.5%
	Common distribution 100% — Residual Preferred Percentage =
	 	67.5%

Investor Rights Certificate — Exhibit C

Page 8 of 13

 

Rules-Based Medicine, Inc.

Investor Rights Agreement: Schedule C — Liquidation Examples

			
	 	 	 
	Returns Analysis — October 13,
          2009 to December 31, 2011 	 	 Options issued to those who own >2.5%

  Waterfall of Distribution
    of Assets October 13, 2009 — December 31, 2011

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total Assets of the Company Available for Distribution	 	$25,000,000	 	$50,000,000	 	$75,000,000	 	$125,000,000	 	$175,000,000	 	$225,000,000	 	$275,000,000	 	$300,000,000
	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
          Step 1 — Section 2.1.1
            of Certificate of Incorporation Accrued but unpaid cash dividends

        	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-l Preferred Stock
	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 	 	 	500,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 2 — Section 2.1.2 of Certificate of Incorporation — up
to Series A-1 Original Issue Price
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-l Preferred Stock
	 	 	24,500,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 	 	 	25,000,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of Common Stock
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	
Remaining Assets Available for Distribution
	 	 	—	 	 	 	24,500,000	 	 	 	49,500,000	 	 	 	99,500,000	 	 	 	149,500,000	 	 	 	199,500,000	 	 	 	249,500,000	 	 	 	274,500,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
          Step 3
— Section 2.1.3
            of Certificate of Incorporation

        	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-l Preferred Stock
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of Common Stock
	 	 	—	 	 	 	24,500,000	 	 	 	27,083,332	 	 	 	27,083,332	 	 	 	27,083,332	 	 	 	27,083,332	 	 	 	27,083,332	 	 	 	27,083,332	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	—	 	 	 	22,416,668	 	 	 	72,416,668	 	 	 	122,416,668	 	 	 	172,416,668	 	 	 	222,416,668	 	 	 	247,416,668	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 4 — Section 2.1.4 of Certificate of Incorporation
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-l Preferred Stock
	 	 	—	 	 	 	—	 	 	 	10,760,001	 	 	 	34,760,001	 	 	 	50,000,000	 	 	 	50,000,000	 	 	 	50,000,000	 	 	 	50,000,000	 
	Distribution to holders of Common Stock
	 	 	—	 	 	 	—	 	 	 	11,656,667	 	 	 	37,656,667	 	 	 	54,166,665	 	 	 	54,166,665	 	 	 	54,166,665	 	 	 	54,166,665	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	18,250,003	 	 	 	68,250,003	 	 	 	118,250,003	 	 	 	143,250,003	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
          Step 5 — Section 2.1.5
            of Certificate of Incorporation

        	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-1 Preferred Stock
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	3,650,001	 	 	 	13,650,001	 	 	 	23,650,001	 	 	 	28,650,001	 
	Distribution to holders of Common Stock
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	14,600,002	 	 	 	54,600,002	 	 	 	94,600,002	 	 	 	114,600,002	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 		 	 	 	—	 	 	 	—	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Step 6 Section 2.1.6 of Certificate of Incorporation
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Distribution to holders of A-1 Preferred Stock
	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 
	Distribution to holders of Common Stock
	 	 		 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 
	 
	Remaining Assets Available for Distribution
	 	 	—	 	 	 		 	 	 	—	 	 	 	—	 	 	 	—	 	 	 		 	 	 	—	 	 	 	—	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total Distribution to holders of A-l Preferred Stock
	 	 	25,000,000	 	 	 	25,500,000	 	 	 	36,260,001	 	 	 	60,260,001	 	 	 	79,150,001	 	 	 	89,150,001	 	 	 	99,150,001	 	 	 	104,150,001	 
	 
	
          Total Distribution
            to holders of Common Stock

        	 	 	—	 	 	 	24,500,000	 	 	 	38,739,999	 	 	 	64,739,999	 	 	 	95,849,999	 	 	 	135,849,999	 	 	 	175,849,999	 	 	 	195,849,999	 
	 

Investor Rights Certificate — Exhibit C

    Page 9 of 13 

 

Rules-Based Medicine, Inc.

Investor Rights Agreement: Schedule C — Liquidation Examples

			
	 	 	 
	Returns Analysis —
October 13, 2009 to December 31, 2011
	 	Options Issued to those who own
> 2.5%

Adjusted Preferred Ownership Percentage (“APO”) Calculation

	 	 	 	 	 
	A-1 Preferred Shares
	 	 	7,485,231	 
	+ Adjustment For Diluting Shares
	 	 	757,614	 
	Numerator
	 	 	8,242,845	 
	 
	 	 	 	 
	A 1 Preferred Shares
	 	 	7,485,231	 
	+ Adjustment For Diluting Shares
	 	 	757,614	 
	Total A-1 Preferred Shares
	 	 	8,242,845	 
	+ Original Common Outstanding
	 	 	8,109,000	 
	+ Common Issued for Options for owners of > 2.5%
	 	 	820,749	 
	+ Common Issued for Options for owners of < 2.5%
	 	 	—	 
	Denominator
	 	 	17,172,594	 
	APO
	 	 	48.0	%

Adjustment for Diluting Shares

	 	 	 	 	 
	Series A-1 Preferred Shares
	 	 	7,485,231	 
	divided by Outstanding Common
	 	 	8,109,000	 
	Equals
	 	 	92	%
	 
	 	 	 	 
	Multiplied by
	 	 	 	 
	Common Issued for Options for owners of >2.5%
	 	 	820,749	 
	Adjustment for Diluting Shares
	 	 	757,614	 

Step 3 — Section 21.3 of Certificate of Incorporation

			
	 	 	 
	Total distribution due to Common Holders in this step $25,000,000* ((1-APO)/APO) = $25,000,000* (0 52/0 48) =
	 	$27,083,332

Step 4 — Section 2.1.4 of Certificate of Incorporation

			
	 	 	 
	Maximum distribution in this step ($75,000,000-distribution in Step 2)/APO =
	 	$104,166,665
	Maximum
distribution to Preferred Holders:

	 	$  50,000,000
	Maximum
distribution to Common Holders.

	 	$  54,166,665

Step 5 — Section 2.1.5 of Certificate of Incorporation

Pre-2012 Permitted Dilution Factor

Shares of capital issued since Oct 12, 2007/then outstanding shares of capital stock (excluding Diluting Shares)

Pre-2012 Permitted Dilution Factor 0%

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Cash Payout to	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	A-1 Pref	 	 	Common	 
	Preferred distribution 10%*(1-Pre-2012 Permitted Dilution Factor)
	 	 	 	 	 	 	20.0	%	 	Step 2	 	 	25,000,000	 	 	 	0	 
	Common distribution (1-Preferred Distribution)
	 	 	 	 	 	 	80.0	%	 	Step 3	 	 	0	 	 	 	27,083,332	 
	 
	 	 	 	 	 	 	 	 	 	Step 4	 	 	50,000,000	 	 	 	54,166,665	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	Total	 	 	75,000,000	 	 	 	81,249,997	 
	Maximum incremental total distribution in Step 5.
	 	$	193,749,992	 	 	 	 	 	 	Step 5	 	 	38,749,998	 	 	 	154,999,994	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	Total	 	 	113,749,998	 	 	 	236,249,991	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Max Preferred distribution in Steps 2, 4 and 5 32.5%*APO/48% =
	 	 	 	 	 	 	32.5	%	 	 	%	 	 	 	32.5	%	 	 	67.5	%

Step 6 — Section 2.1.6 of Certificate of Incorporation

			
	 	 	 
	Residual Preferred Percentage 32.5% * APO/48% =
	 	32.5%
	Common distribution: 100% — Residual Preferred Percentage =
	 	67.5%

Investor Rights Certificate — Exhibit C

Page 10 of 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}]]